**Clinical Investigation Program RCS MED-300(RI)**  
Department of Clinical Investigation  
Walter Reed Army Medical Center

**COL Maria H. Sjogren, MC**  
Chief, Department of Clinical Investigation

**Department of Clinical Investigation**  
Walter Reed Army Medical Center  
Washington, DC 20307-5001

**Clinical Investigation Regulatory Office**  
U.S. Army Medical Department Center and School  
Ft. Sam Houston, TX 78234-6060

The findings in this report are not to be considered as an official Department of the Army position unless so designated by other authorized documents.

**Approved for public release: Distribution unlimited.**

This report identifies approved clinical research activities conducted at Walter Reed Army Medical Center through protocols approved by the Clinical Investigation Committee (CIC), the Human Use Committee/Institutional Review Board (HUC/IRB), and the Institutional Laboratory Animal Care and Use Committee (IACUC), as appropriate. This report includes a Detail Summary Sheet outlining the progress of each protocol during Fiscal Year 94. Also included is a list of all known presentations and publications related to approved studies, as well as an addendum listing presentations and publications not related to approved clinical investigations. All research was conducted under the provisions of AR 40-38 (Clinical Investigation Program), AR 40-7 (Use of Investigational Drugs in Humans and the Use of Schedule I Controlled Drug Substances), AR 70-25 (Use of Volunteers as Subjects of Research), HSC Regulation 40-23 (Management of Clinical Investigations, Protocols, and Reports), and AR 70-18 (The Use of Animals in DOD Programs).
FORWARD

The Annual Progress Report (APR) documents the continuing review during FY-94 of research approved by the Clinical Investigation Committee (CIC), the Institutional Laboratory Animal Care and Use Committee (IACUC), and the Human Use Committee/Institutional Review Board (HUC/IRB) of Walter Reed Army Medical Center (WRAMC). The review of each research protocol is initiated by the Department of Clinical Investigation (DCI) on the anniversary month of its approval. At that time, a request is sent to the principal investigator for submission of a progress report. The completed report consists of a detail summary sheet, a copy of the approved consent form, and a questionnaire regarding the continuing review of human subject participation or animal use. Members of the HUC/IRB or IACUC review the progress reports throughout the year, and one of the following recommendations is made: 1) approval, 2) request additional information, or 3) request termination of the protocol. The members' recommendations are presented monthly to the HUC/IRB or IACUC for final approval. The approved detail summary sheets of 556 protocols are included in this document.

The FY-94 APR process at WRAMC was administered by the Editorial Office, Research Administration Service, Department of Clinical Investigation.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>I. UNIT SUMMARY</th>
<th>VOL#</th>
<th>PAGE#</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Objective</td>
<td>I</td>
<td>3</td>
</tr>
<tr>
<td>B. Technical Approach</td>
<td>I</td>
<td>3</td>
</tr>
<tr>
<td>C. Organization Scheme</td>
<td>I</td>
<td>3</td>
</tr>
<tr>
<td>D. DCI Staff</td>
<td>I</td>
<td>4</td>
</tr>
<tr>
<td>E. DCI Financial Support</td>
<td>I</td>
<td>9</td>
</tr>
<tr>
<td>F. Research Activity</td>
<td>I</td>
<td>10</td>
</tr>
</tbody>
</table>

| II. PROTOCOL EXPENSES BY DEPARTMENT | I    | 23    |
| III. PROTOCOL LIST BY DEPARTMENT   | I    | 32    |
| IV. LIST OF PUBLICATIONS, PRESENTATIONS, AND ABSTRACTS BY DEPARTMENT | I    | 84    |
| V. AUTHOR INDEX                    | I    | 203   |
| VI. INVESTIGATOR INDEX              | I    | 239   |
| VII. SUBJECT INDEX                  | I    | 248   |
| VIII. DETAIL SUMMARY SHEETS         | II   | 1-556 |

2
I. UNIT SUMMARY

A. OBJECTIVE

To implement and manage the clinical investigation program at Walter Reed Army Medical Center (WRAMC) by promoting, supporting, coordinating, planning, conducting, and publishing ethical, scientific inquiry into clinical health problems of beneficiaries of the military health care system, to include studies in humans and animals.

B. TECHNICAL APPROACH

The clinical investigation program at WRAMC is conducted in accordance with the following:

AR 40-7 Use of Investigational Drugs in Humans and the Use of Schedule I Controlled Drug Substances

AR 40-38 Clinical Investigation Program

AR 70-18 The Use of Animals in DOD Programs

TB MED 525 Control of Hazards to Health from Ionizing Radiation Used by the Army Medical Department

HSC 40-23 Management of Clinical Investigation Protocols and Reports

WRAMC 70-1 Clinical Investigation Program, WRAMC Research Activities

45 CFR 46 Protection of Human Subjects

21 CFR A,D,& F Food and Drug Administration

C. ORGANIZATION SCHEME

[Diagram of the organizational structure of the office of the chief, with departments such as Research Review Service, Research Administration Service, Research Operations Service, and Clinical Studies Service, and sections like Institutional Oversight Biometrics Section, Logistics, Financial/Grant Management, Extramural Funding, Computer Operations, Lab Animal Facility, Central Support Lab, Specialty Support Labs, KMU Labs, and Specialty Support KMU Nursing.]
D. DCI STAFF [Positions as of 30 September 1994; suffix (G) reflects grant-funded employees]

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>GRADE</th>
<th>MOS</th>
<th>BRANCH</th>
<th>NAME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>OFFICE OF THE CHIEF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>06</td>
<td>60G</td>
<td>MC</td>
<td>Sjogren, MH</td>
<td>DCI</td>
</tr>
<tr>
<td>Secretary</td>
<td>07</td>
<td>0318</td>
<td>GS</td>
<td>Ross, D</td>
<td>DCI</td>
</tr>
<tr>
<td>NCOIC</td>
<td>E7</td>
<td>91K30</td>
<td>NC</td>
<td>Martinez, C</td>
<td>DCI</td>
</tr>
<tr>
<td>RESEARCH REVIEW SERVICE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>05</td>
<td>61D</td>
<td>MC</td>
<td>Tsokos, GC</td>
<td>DCI</td>
</tr>
<tr>
<td>Supv Statistician</td>
<td>14</td>
<td>1530</td>
<td>GS</td>
<td>Chang, AS</td>
<td>DCI</td>
</tr>
<tr>
<td>Statistician</td>
<td>12</td>
<td>1530</td>
<td>GS</td>
<td>Howard, RS</td>
<td>DCI</td>
</tr>
<tr>
<td>Research Coordinator</td>
<td>09</td>
<td>1083</td>
<td>GS</td>
<td>Coleman-Fraser, E</td>
<td>DCI</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>05</td>
<td>1087</td>
<td>GS</td>
<td>Green, IL</td>
<td>DCI</td>
</tr>
<tr>
<td>RESEARCH ADMINISTRATION SERVICE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>12</td>
<td>0501</td>
<td>GS</td>
<td>Burton, ME</td>
<td>DCI</td>
</tr>
<tr>
<td>Asst Administrator</td>
<td>E6</td>
<td>91K30</td>
<td>NC</td>
<td>Floyd, K</td>
<td>DCI</td>
</tr>
<tr>
<td>Computer Spec (Prog)</td>
<td>11</td>
<td>0334</td>
<td>GS</td>
<td>Rose, JG</td>
<td>DCI</td>
</tr>
<tr>
<td>Computer Spec (Prog)</td>
<td>11</td>
<td>0334</td>
<td>GS</td>
<td>Gomez, RJ</td>
<td>DCI</td>
</tr>
<tr>
<td>Tech Pub Editor</td>
<td>09</td>
<td>1083</td>
<td>GS</td>
<td>Walden, JF</td>
<td>DCI</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>07</td>
<td>1087</td>
<td>GS</td>
<td>Vacant</td>
<td>DCI</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>07</td>
<td>1087</td>
<td>GS</td>
<td>Vacant</td>
<td>DCI(G)</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>06/07</td>
<td>1087</td>
<td>GS</td>
<td>Muchui, MJ</td>
<td>DCI</td>
</tr>
<tr>
<td>Supply Technician</td>
<td>06</td>
<td>2005</td>
<td>GS</td>
<td>Thomas, DR</td>
<td>DCI</td>
</tr>
<tr>
<td>Clerk Typist</td>
<td>04</td>
<td>0303</td>
<td>GS</td>
<td>Franklin, AF</td>
<td>DCI</td>
</tr>
<tr>
<td>DESCRIPTION</td>
<td>GRADE</td>
<td>MOS</td>
<td>BRANCH</td>
<td>NAME</td>
<td>ACTIVITY</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>----------------</td>
<td>----------</td>
</tr>
<tr>
<td>RESEARCH OPERATIONS SERVICE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>05</td>
<td>71A67</td>
<td>MS</td>
<td>Kelly, DJ</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Lab NCO</td>
<td>E6</td>
<td>91K30</td>
<td>NC</td>
<td>Floyd, K</td>
<td>DCI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lab Animal Facility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bio Lab Tech</td>
<td>10</td>
<td>0404</td>
<td>GS</td>
<td>Bailey, LR</td>
<td>Animl Resch</td>
</tr>
<tr>
<td>Bio Lab Tech</td>
<td>09</td>
<td>0404</td>
<td>GS</td>
<td>Jackson, D</td>
<td>Animl Resch(G)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central Research Support Lab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief</td>
<td>04</td>
<td>71B67</td>
<td>MS</td>
<td>Borschel, R</td>
<td>DCI</td>
</tr>
<tr>
<td>Chemist</td>
<td>12</td>
<td>1320</td>
<td>GS</td>
<td>Abdel-Rahim, M</td>
<td>DCI</td>
</tr>
<tr>
<td>Chemist</td>
<td>11</td>
<td>1320</td>
<td>GS</td>
<td>Bednarek, J</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Lab NCO</td>
<td>E6</td>
<td>91K30</td>
<td>NC</td>
<td>Hillanbrand, D</td>
<td>DCI</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>91KP9</td>
<td>EN</td>
<td>Taher, M</td>
<td>DCI</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>91KP9</td>
<td>EN</td>
<td>Webster, V</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Lab Spec</td>
<td>E4</td>
<td>91K10</td>
<td>EN</td>
<td>Curtner, D</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Lab Spec</td>
<td>E4</td>
<td>91K10</td>
<td>EN</td>
<td>Allen, R</td>
<td>DCI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialty Support Labs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resch Chemist</td>
<td>13</td>
<td>0644</td>
<td>GS</td>
<td>Salata, KF</td>
<td>Allergy</td>
</tr>
<tr>
<td>Microbiologist</td>
<td>12</td>
<td>0403</td>
<td>GS</td>
<td>Billups, L</td>
<td>Flow Cytom</td>
</tr>
<tr>
<td>Microbiologist</td>
<td>12</td>
<td>0403</td>
<td>GS</td>
<td>Dobek, AS</td>
<td>Inf Disease</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Vacant</td>
<td>Allergy</td>
</tr>
<tr>
<td>Chemist</td>
<td>12</td>
<td>1320</td>
<td>GS</td>
<td>Maydonovitch, CL</td>
<td>GI</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Kapur, JJ</td>
<td>DCI</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Burgess, D</td>
<td>Pediatrics</td>
</tr>
<tr>
<td>DESCRIPTION</td>
<td>GRADE</td>
<td>MOS</td>
<td>BRANCH</td>
<td>NAME</td>
<td>ACTIVITY</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-------</td>
<td>-----</td>
<td>--------</td>
<td>----------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>(Specialty Support Labs cont.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Armstrong, J</td>
<td>Rheum</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>09</td>
<td>0644</td>
<td>GS</td>
<td>Terrell, R</td>
<td>Polyp Prev(G)</td>
</tr>
</tbody>
</table>

**Kyle Metabolic Research Laboratory**

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>GRADE</th>
<th>MOS</th>
<th>BRANCH</th>
<th>NAME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supv Resch Chem</td>
<td>14</td>
<td>1320</td>
<td>GS</td>
<td>Vacant</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Chemist</td>
<td>13</td>
<td>1320</td>
<td>GS</td>
<td>Vacant</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Physiologist</td>
<td>12</td>
<td>0413</td>
<td>GS</td>
<td>Lukes, YD</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Chemist</td>
<td>12</td>
<td>1320</td>
<td>GS</td>
<td>Nicholson, DE</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Chemist</td>
<td>11</td>
<td>1320</td>
<td>GS</td>
<td>Lahiri, S</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Barnes, SG</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>Anderson, JS</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Bio Lab Tech</td>
<td>09</td>
<td>0404</td>
<td>GS</td>
<td>Jenkins, EL</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Editorial Asst</td>
<td>07</td>
<td>1087</td>
<td>GS</td>
<td>Jacobson, A</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Med Technician</td>
<td>05</td>
<td>0645</td>
<td>GS</td>
<td>Martin, JL</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Secretary</td>
<td>05</td>
<td>0318</td>
<td>GS</td>
<td>Phuong, U</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Med Lab NCO</td>
<td>E6</td>
<td>91K30</td>
<td>NC</td>
<td>Arledge, H</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E6</td>
<td>91KP9</td>
<td>NC</td>
<td>Baptiste, V</td>
<td>Endocrine</td>
</tr>
</tbody>
</table>

**CLINICAL STUDIES SERVICE**

**Specialty Support**

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>GRADE</th>
<th>MOS</th>
<th>BRANCH</th>
<th>NAME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>C, Nutrition Care</td>
<td>03</td>
<td>65C00</td>
<td>SP</td>
<td>Patton, B</td>
<td>KMU</td>
</tr>
<tr>
<td>Medical Officer</td>
<td>15</td>
<td>0602</td>
<td>GS</td>
<td>Popovic, NA</td>
<td>Ortho Resch</td>
</tr>
<tr>
<td>Research Nutritionist</td>
<td>13</td>
<td>0630</td>
<td>GS</td>
<td>Mateski, DJ</td>
<td>Polyp Prev(G)</td>
</tr>
<tr>
<td>Resch Audiologist</td>
<td>12</td>
<td>0665</td>
<td>GS</td>
<td>Clay, J</td>
<td>AA&amp;SC(G)</td>
</tr>
<tr>
<td>Gen Health Sci</td>
<td>12</td>
<td>0601</td>
<td>GS</td>
<td>Summers, WV</td>
<td>AA&amp;SC(G)</td>
</tr>
<tr>
<td>Resh Psychologist</td>
<td>12</td>
<td>0180</td>
<td>GS</td>
<td>Hamm, C</td>
<td>Sleep Resch</td>
</tr>
<tr>
<td>DESCRIPTION</td>
<td>GRADE</td>
<td>MOS</td>
<td>BRANCH</td>
<td>NAME</td>
<td>ACTIVITY</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>(Specialty Support cont.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Jamison, J</td>
<td>Hem/Onc(G)</td>
</tr>
<tr>
<td>Resch Asst</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Solomon, BL</td>
<td>KMU</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Myers, DV</td>
<td>Urology(G)</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Abt, MB</td>
<td>Urology</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Vacant</td>
<td>Ortho Resch</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Pangaro, K</td>
<td>Pulmonary(G)</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Argauer, K</td>
<td>Pulmonary(G)</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Kushner, G</td>
<td>Pulmonary(G)</td>
</tr>
<tr>
<td>Dietitian</td>
<td>11</td>
<td>0630</td>
<td>GS</td>
<td>Stoute, E</td>
<td>Polyp Prev(G)</td>
</tr>
<tr>
<td>Dietitian</td>
<td>11</td>
<td>0630</td>
<td>GS</td>
<td>Hancock, S</td>
<td>Polyp Prev(G)</td>
</tr>
<tr>
<td>Dietitian</td>
<td>11</td>
<td>0630</td>
<td>GS</td>
<td>Miskovsky, VJ</td>
<td>Polyp Prev(G)</td>
</tr>
<tr>
<td>Nurse Specialist</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Vacant</td>
<td>Polyp Prev(G)</td>
</tr>
<tr>
<td>Cardiorespir Tech</td>
<td>E6</td>
<td>91B30</td>
<td>NC</td>
<td>Land, R</td>
<td>Sleep Resch</td>
</tr>
<tr>
<td>Secretary</td>
<td>06</td>
<td>0318</td>
<td>GS</td>
<td>Satterwhite, D</td>
<td>Polyp Prev(G)</td>
</tr>
<tr>
<td>Secretary</td>
<td>05</td>
<td>0318</td>
<td>GS</td>
<td>Bryson, DD</td>
<td>Hem/Onc(G)</td>
</tr>
</tbody>
</table>

**Kyle Metabolic Unit Nursing Service**

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>GRADE</th>
<th>MOS</th>
<th>BRANCH</th>
<th>NAME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supv Clin Nurse</td>
<td>12</td>
<td>0610</td>
<td>GS</td>
<td>Parchment, VA</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Bicknell, E</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Andersen, L</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Coleman, A</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Chaudhari, NP</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Saxon, NJ</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Battle, OM</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>11</td>
<td>0610</td>
<td>GS</td>
<td>Vacant</td>
<td>DCI</td>
</tr>
<tr>
<td>Clinical Nurse</td>
<td>10</td>
<td>0610</td>
<td>GS</td>
<td>Burman, MS</td>
<td>DCI</td>
</tr>
</tbody>
</table>
(Kyle Metabolic Unit Nursing Service cont.)

Clinical Nurse  10   0610  GS  Stewart, MO  DCI
Clinical Nurse  9/11  0610  GS  Vacant    DCI
Nurse Asst      05   0620  GS  Keeve, ML  DCI

Because of continuing severe budget constraints, the Department of Clinical Investigation was held to strict limitations on replacing civilian employees when positions were vacated. This resulted in a net decrease of one WRAMC-funded civilian employee, from 46 to 45. Within the administrative sections, the only addition was that of gaining an authorization to hire a Computer Specialist (Programmer) against an established requirement. One loss was replaced, that of the Secretary to the Chief. Grant-funded civilian employees decreased by two, from 17 to 15. The Specialty Support Section of the Clinical Studies Service, which was established during FY-93 as part of a reorganization of the Department's TDA to prepare for the downsizing, saw a reduction from 20 to 19 with the loss of a dietitian supporting the NIH-funded Polyp Prevention Trial. DCI had no gain in officer strength. In July 1994, the Department saw a change in command with the Chief, COL H. Linton Wray, MC, departing to report to the North Atlantic Health Service Support Area Headquarters as Chief of Health Systems Management. Replacing COL Wray as Chief is COL Maria H. Sjogren, MC, formerly a staff gastroenterologist and hepatologist at WRAMC. In May 1994, CPT Matthew Payne, Assistant Chief, Research Operations Service, departed to pursue a civilian career in industry. His replacement, MAJ Richard Borschel, arrived in July from long-term civilian training towards a doctorate in Immunology from Cornell University. The Army Medical Specialist Corps Clinical Investigation Service was transferred to the U.S. Army Research Institute of Environmental Medicine in Natick, Massachusetts. During the year the command reduced the enlisted authorizations from 12 to 6, and all O1H research technician (91KP9) positions were lost. The Department will feel the effect of these losses during late FY-94 and early FY-95. At the end of the fiscal year, the total assigned personnel was at 75, down from the all time high of 78 last year.

More than $658,900 in extramural funding was obtained from the National Institutes of Health to support personnel costs for clinical and laboratory
research being conducted in the Hematology-Oncology Service, the Army Audiology and Speech Center, the Gastroenterology Service, and the Urology Service. These monies were used to fund personnel such as Ph.D.-level researchers, study nurses and coordinators, dietitians, and support staff.

Two civilian staff members received awards for their exceptional contributions to the Clinical Investigation mission. In recognition of his exemplary career, Mr. Mack Burton, Chief of the Research Administration Service, was awarded one of the highest civilian honors, the Meritorious Civilian Service Award. As a result of her many contributions to the Department over the past 6 years, Ms. Robin Howard, Biostatistician, Research Review Service, received the Commander's Award for Civilian Service.

E. DCI FINANCIAL SUPPORT

<table>
<thead>
<tr>
<th></th>
<th>FY-90</th>
<th>FY-91</th>
<th>FY-92</th>
<th>FY-93</th>
<th>FY-94</th>
</tr>
</thead>
<tbody>
<tr>
<td>Civilian Personnel</td>
<td>$1,500,001</td>
<td>$1,922,896</td>
<td>$2,365,661</td>
<td>$2,410,306</td>
<td>$2,285,278</td>
</tr>
<tr>
<td>Consumable Supplies</td>
<td>$708,572</td>
<td>$650,531</td>
<td>$834,703</td>
<td>$818,131</td>
<td>$754,700</td>
</tr>
<tr>
<td>Civilian Contracts</td>
<td>$107,000</td>
<td>$204,385</td>
<td>$123,186</td>
<td>$141,816</td>
<td>$162,000</td>
</tr>
<tr>
<td>TDY</td>
<td>$36,102</td>
<td>$31,399</td>
<td>$54,433</td>
<td>$59,764</td>
<td>$56,833</td>
</tr>
<tr>
<td>Travel</td>
<td></td>
<td></td>
<td>$22,211</td>
<td>$14,802</td>
<td>$46,735</td>
</tr>
<tr>
<td>(non-federal sources)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital Expense</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equipment Program</td>
<td>$30,932</td>
<td>$77,164</td>
<td>$270,374</td>
<td>$270,462</td>
<td>$32,000</td>
</tr>
<tr>
<td>MEDCASE</td>
<td>$572,892</td>
<td>$1,000,076</td>
<td>$1,438,216</td>
<td>$670,110</td>
<td>$763,506</td>
</tr>
<tr>
<td>BLIC-F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$300,000</td>
</tr>
<tr>
<td>Extramural Funding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants (NIH, MRMC, etc)</td>
<td>$528,140</td>
<td>$500,252</td>
<td>$913,851</td>
<td>$1,118,690</td>
<td></td>
</tr>
<tr>
<td>NIH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$658,917</td>
</tr>
<tr>
<td>MRMC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$332,770</td>
</tr>
<tr>
<td>Tri-Svc Nursing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$135,210</td>
</tr>
<tr>
<td>GOG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$81,000</td>
</tr>
<tr>
<td>Military</td>
<td>$392,137</td>
<td>$397,960</td>
<td>$402,488</td>
<td>$451,683</td>
<td>$454,903</td>
</tr>
<tr>
<td>Construction/Renovation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$1,250,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>$3,875,776</td>
<td>$4,784,664</td>
<td>$6,425,123</td>
<td>$5,955,764</td>
<td>$7,313,852</td>
</tr>
</tbody>
</table>
The Clinical Investigation Program maintained a high level of activity during 1994 with a record number of active protocols (764 compared to 717 last year) despite losing personnel, a hiring freeze for civilian personnel, and a decrease in financial support for CEEP requirements.

F. RESEARCH ACTIVITY

1. Accomplished in FY-94

With the mission to empower WRAMC researchers from planning to publication, the Department of Clinical Investigation (DCI) supported a record total of 764 active protocols this year (Table I). Twenty-seven percent (208) of these studies were newly approved during the fiscal year, leaving 556 ongoing for at least one year that are summarized in this report. Medical Corps activities accounted for 81% of the investigations, and less than 1% were conducted at Army Community Hospitals in the Walter Reed Health Service Region.

<table>
<thead>
<tr>
<th>TABLE I. WRAMC Protocol Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROTOCOLS</td>
</tr>
<tr>
<td>ONGOING at the beginning of FY</td>
</tr>
<tr>
<td>NEWLY APPROVED (+)</td>
</tr>
<tr>
<td>TOTAL ACTIVE During FY</td>
</tr>
<tr>
<td>COMPLETED (-)</td>
</tr>
<tr>
<td>TERMINATED (-)</td>
</tr>
<tr>
<td>ONGOING at the end of FY</td>
</tr>
</tbody>
</table>

Human studies accounted for 91% of the investigations, with 37% involving research therapies including investigational drugs or devices and cooperative oncology group studies (Table II). Animal studies accounted for 8%, and laboratory studies accounted for 1%.
TABLE II. WRAMC FY-94 Active Investigations by Subject

<table>
<thead>
<tr>
<th>SUBJECT</th>
<th>ACTIVE STUDIES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>#</td>
</tr>
<tr>
<td>Human</td>
<td></td>
</tr>
<tr>
<td>Investigational New Drug</td>
<td>59</td>
</tr>
<tr>
<td>Investigational Device</td>
<td>4</td>
</tr>
<tr>
<td>Cooperative Oncology Group</td>
<td>206</td>
</tr>
<tr>
<td>Descriptive - Expedited</td>
<td>168</td>
</tr>
<tr>
<td>Greater Risk</td>
<td>259</td>
</tr>
<tr>
<td></td>
<td>696</td>
</tr>
<tr>
<td>Animal</td>
<td></td>
</tr>
<tr>
<td>Laboratory</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>764</td>
</tr>
</tbody>
</table>

Publication and presentation productivity by WRAMC staff included 363 published articles, 225 published abstracts, and 560 conference presentations (Table III).

TABLE III. WRAMC Publications and Presentations

<table>
<thead>
<tr>
<th></th>
<th>FY-90</th>
<th>FY-91</th>
<th>FY-92</th>
<th>FY-93</th>
<th>FY-94</th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Articles*</td>
<td>276*</td>
<td>285*</td>
<td>369*</td>
<td>334*</td>
<td>363*</td>
</tr>
<tr>
<td>Abstracts</td>
<td>67</td>
<td>75</td>
<td>97‡</td>
<td>214‡</td>
<td>225‡</td>
</tr>
<tr>
<td>Presentations</td>
<td>106</td>
<td>110</td>
<td>232</td>
<td>312</td>
<td>560♦</td>
</tr>
</tbody>
</table>

* Fully referenced publications (e.g., journal articles, book chapters)
+ Publications related to approved clinical investigations: FY-90 = 62; FY-91 = 71; FY-92 = 114; FY-93 = 138; FY-94 = 116
‡ Abstracts related to approved clinical investigations: FY-92 = 91; FY-93 = 56; FY-94 = 148
♦ Presentations related to approved clinical investigations: FY-94 = 254
During the past fiscal year, major changes were seen as a result of the DCI Strategic Planning process that was initiated in August 1991. Reorganization of the Department's TDA continues to be implemented and will be completed with the abolition of the Kyle Metabolic Unit Nursing Service during early FY-95. A $1,000,000 contract was awarded, and work began on the renovation of the laboratory animal facility, with an expected completion date of March 1995. The effect of this renovation will elevate the facility's standards to a level eligible for accreditation by the American Association for Accreditation of Laboratory Animal Care (AAALAC). Lastly, execution of the DCI Master Plan is proceeding, with Building 7 designated to house research laboratory space.

Plans continued throughout the year for the relocation of the Department to the Base Realignment and Closure (BRAC) Building (Bldg. 6) currently under construction. The expected move should take place in the spring or early summer of 1995. Over $300,000 was received this year in funds through the Base Realignment Program to purchase equipment and furnishings for the new offices.

Under the auspices of the WRAMC Professional Education and Training Committee, the second WRAMC Research Course was completed in the fall. Attending the 14-hour course were 98 investigators, both physicians in training and WRAMC staff. Course evaluations were extremely favorable, and a third course is being developed for the fall of 1995. Arrangements are being made to move the course to an off-site location to provide attendees with an environment to devote themselves to the entire program.

The prestigious Bailey K. Ashford Clinical Research Award is bestowed annually on a member of the year's graduating class whose research accomplishments excelled during training. Seventeen graduating trainees, representing 13 training programs, were nominated for the 1994 award. A selection committee named five semi-finalists and five finalists. The finalists presented their results at a symposium on 25 May 1994 sponsored by the Department of Clinical Investigation. The 1994 finalists were: MAJ Gregory J. Argyros, Fellow, Pulmonary and Critical Care Medicine Service, Department of Medicine, "The Refractory Period After Eucapnic Voluntary Hyperventilation and its Effect on Challenge Technique"; MAJ John K. Hamelink, Fellow, Vascular Surgery Service, Department of Surgery, "Inhibition of Platelet Accumulation by Hirulog™ and Aspirin in a Carotid
Endarterectomy Model"; MAJ Jose A. Stoute, Fellow, Infectious Disease Service, Department of Medicine, "The Phage Epitope Library: A New Tool for Vaccine Development"; CPT Catherine A. Welch, Resident, Pediatric Endocrinology Service, Department of Pediatrics, "Evidence to Suggest Nitric Oxide is a Previously Unrecognized Regulator of Leydig Cell Steroidogenesis"; and CPT Andrew R. Wiesen, Resident, Internal Medicine Service, Department of Medicine, "Equilibration of Hemoglobin Concentration Following Transfusion of Packed Red Blood Cells." Recipient of the 1994 Bailey K. Ashford Clinical Research Award, MAJ Jose A. Stoute, was announced at graduation in June.

The Research Review Service continued to be busy with an ever-increasing number of protocols being submitted. The Service worked with the Clinical Investigation Regulatory Office to further facilitate the process of approval of protocols and the procedure for requesting and reporting the one-time use of an investigational new drug. To better assist investigators and to expedite their protocols through the approval process, a weekly pre-review meeting was established to review new submissions. Participating in this function are the Chief of the Service, the Protocol Coordinator, and the Biostatisticians. The meeting results in written comments being provided to the investigator to improve the medical/scientific content or to correct administrative deficiencies of the protocol, as needed, before going to committee(s). This method of pre-review has proven to expedite the protocol through the Clinical Investigation Committee, the Institutional Laboratory Animal Care and Use Committee, and/or the Human Use Committee/Institutional Review Board, as applicable. Because of personnel constraints, the Clinical Investigation Recognition Seminars were terminated during the past year; however, plans are being made to sponsor a "Research Day" for presentation of research results.

The Biometrics Section continues to provide a wide range of statistical support to investigators, to include research design, sample size estimation, data analysis, and general troubleshooting. The two Biostatisticians consulted on more than 200 protocols during the past fiscal year. Additionally, they contributed significantly as co-authors or consultants on an increasing number of research manuscripts published in refereed, peer reviewed journals. Both Biostatisticians play key roles in the workshops and research courses sponsored by the Department, as well as offering one-on-one teaching to investigators almost daily. The Section remains vital in facilitating and enhancing the functions and capabilities of data analysis.
Many powerful and user-friendly statistical software tools for data analysis are available to researchers in the DCI Computer Lab or through network connection. Software includes STATISTICS 4.0, SPSS 6.01 WINDOWS, BMDP, and SOLO Power Analysis and Cohen's Power Analysis programs for sample size estimation. Other customized programs include Fisher Exact Test, 95% Confidence Intervals for Proportions, Odds Ratio test, T-Test, and Randomization.

The Research Administration Service provided support for the Department and all WRAMC investigators, managing intra- and extramural monies totalling over $7.3 million. Of this amount, $763,506 was received by the Department in MEDCASE funds, which was a increase of just under $100,000. Extramural funding continued to expand, up $8,200 from 1994, and includes support from the National Institutes of Health (NIH), the U.S. Army Medical Research and Materiel Command (MRMC), and the Tri-Service Military Nursing Research Program.

During the past year, there was continued development of the Extramural Funding Office. All extramural protocols are processed through this office for adherence to guidelines and regulations and for scientific/medical editorial review. For the purposes of this office, extramural is defined as providing support to this institution; be it money, consumable supplies, personnel, equipment, etc., to conduct research. Through the use of e-mail, WRAMC staff members were notified of extramural funding opportunities as they were identified. Investigators submitted 16 proposals to the Defense Women's Health Research [Intramural] Program, implemented by the MRMC, with 10 (62.5%) proposals approved for FY-95 funding. Additionally, there are several collaborative efforts between WRAMC and the private sector that are pending funding through the Defense Women's Health Research [Extramural] Program. During the fiscal year, approval was obtained to begin utilizing the Cooperative Research and Development Agreement (CRDA) to transfer research resources between the government and the private sector. The first CRDA with WRAMC was written late in the fiscal year and is currently being processed for approval. Six others are in the formulative stage. A workshop is being planned for early FY-95 that will offer staff an opportunity to learn more about how to conduct extramurally supported research at WRAMC. Insight will be provided on how DCI can assist investigators with extramural resources, and representatives from the Henry M. Jackson Foundation for the Advancement of Military Medicine and the Facilitators of Applied Clinical
Trials will participate in the program. Due to the loss of two Editorial Assistants, the Editorial Office no longer provides services to investigators/authors in composing research protocols and manuscripts. The compilation of the Annual Progress Report continues to closely monitor the progress of ongoing research projects. All reports are submitted within 30 days of the anniversary date of approval, or the protocol is administratively terminated. Additionally, the Editorial Office continues to update the "Clinical Investigator's Guide," explaining the research review process and research resources at WRAMC and providing checklists, formats, and guidelines. To assist principal investigators further, a program continues whereby the routine forms and instructions required to compile a protocol are available to researchers on user-friendly computer diskettes.

The Computer Operations Section continued expanding and optimizing support applications for staff and investigators in both the computer lab and on the WRAMC-wide research network, DCINET. Improvements included PC and MAC workstation upgrades, incorporation of DDN/INTERNET services, and network server upgrades that allowed expansion and optimization of the centralized database services. The Section worked with the Directorate of Information Management to contract the initiation of a new LAN infrastructure for the WRAMC campus.

During FY-94, MAJ Richard Borschel reported as the new Assistant Chief of the Research Operations Service. Renovation of the laboratory animal facility began in February 1994 and is expected to be completed in March 1995. Construction on the new Infectious Disease Laboratory was completed at a cost of $250,000, and the lab opened in March 1994. As a result of the decreased number of enlisted personnel to support the Service, a number of laboratory consolidations were initiated to reduce duplication of effort and improve laboratory efficiency. Mr. Maged Abdel-Rahim was instrumental in implementing the use of the mass spectrometer in the Analytical Chemistry Laboratory.

The DCI Flow Cytometry Laboratory provided support for 13 fellows and a number of staff from departments around the medical center, including the Allergy-Immunology Service, Rheumatology Service, Pediatric Hematology-Oncology Service, Department of Pathology and Area Laboratories, and Pediatric Endocrinology Service, with 11 protocols initiated and/or supported during the fiscal year. The DCI Immunogenetics Laboratory was instrumental
in the successful application of several grants from industry and federal sources, which will fund approximately $200,000 in research during FY-95. The lab provided support for five fellows and initiated and/or supported eight protocols during the fiscal year. Several of these protocols are studies dealing with Hepatitis B and C. Additionally, the laboratory has established and developed a new method of reverse transcriptase polymerase chain reaction (RT PCR) for Hepatitis C.

The Kyle Metabolic Unit Nursing Service supports 16 beds that are utilized for the evaluation and treatment of endocrine and metabolic disorders. This unit will be abolished in the upcoming fiscal year, and the clinical function will revert to the Department of Medicine. Three clinical nurses will be incorporated into the Specialty Support Section, Clinical Studies Service, DCI, and will provide support for research efforts throughout the medical center.

The 7-year polyp prevention study (NIH grant), now in its fourth year, headed by COL James Kikendall, MC, Gastroenterology Service, Department of Medicine, completed the enrollment phase. A total of 202 subjects are enrolled at WRAMC in this multi-center study of patients who have undergone colonoscopic removal of adenomas. Subjects were randomized to no intervention or to a low fat, high fiber, high fruit and vegetable diet. Nutrition counselling for those in the dietary intervention group was ongoing during this past year. Repeat colonoscopy and follow-up data collection visits were ongoing during this past year for both intervention and control participants.

As in years past, principal investigators conducting research under the Clinical Investigation Program at WRAMC continued to receive national recognition during FY-94 for their outstanding research.

- MAJ Louis Guzzi, MC, Anesthesia-Operative Service, Department of Surgery, was awarded First Place, Resident Research Award, from the Maryland/ District of Columbia Society of Anesthesiology, for his paper entitled "Patterns of Ischemia: Holter Monitoring Following Non-Cardiac Surgery in Patients with Previous PTCA or CABG."

- The William Beaumont Clinical Research Award was bestowed on COL James W. Kikendall, MC, Director of Clinical Services, Gastroenterology Service,
Department of Medicine. He received the award at the 20th Annual William Beaumont Symposium, Army Regional American College of Physicians Meeting, Orlando, FL, in October 1993, for his work in the areas of prevention and early detection of colonic neoplasia and adenocarcinoma.

* In October 1993, MAJ Judd W. Moul, MC, Urology Service, Department of Surgery, received the Society of Government Service Urologists Uro-Oncology Award for the best presentation on a urologic cancer topic at the Annual Kimbrough Seminar in San Diego, CA.

* For his paper entitled "The Efficacy of Different Techniques for Disinfecting Contaminated Osteoarticular Fragments and Bone-Tendon Grafts," CPT James E.B. Stuart, MC, Orthopaedic Surgery Service, Department of Surgery, received the Norman T. Kirk Award. Dr. Stuart presented his work at the 35th Annual Meeting of the Society of Military Orthopaedic Surgeons, Bethesda, MD, in December 1993.

* CPT William DeVries, MC, Orthopaedic Surgery Service, Department of Surgery, was the recipient of the Founder's Award of the Society of Military Orthopaedic Surgeons for his study "Evaluation of the Lateral Ankle Ligaments and Effectiveness of Ankle Braces During Rotational Forces Across the Ankle Joint," which he presented in Bethesda, MD, in December 1993.

* Nine WRAMC internal medicine residents received awards for their research from the American College of Physicians (ACP) and were asked to present or display their work at the ACP's scientific meeting held at the Uniformed Services University of the Health Sciences, Bethesda, MD, in January 1994. The awardees and their work were:

   - CPT Kevin I. Glass, MC, presented his work entitled "Pulse Oximetry Correction for Smoking Exposure."

   - CPT Jennifer Thompson, MC, presented her work entitled "Curative Radiation Therapy in Hodgkin's Disease: Long-Term Followup."

   - CPT Andrew R. Wiesen, MC, presented his study entitled "Equilibration of Hemoglobin Following Transfusion."

   - CPT Barry Aaronson, MC, displayed his poster entitled "Severe Hemolytic Anemia After Hepatitis B Vaccination."

   - CPT J. C. Byrd, MC, displayed a poster entitled "Fludarabine Therapy in Lymphoid Malignancies is Associated with a High Number of Opportunistic Infections."
- CPT W. Jeffrey Endenfield, MC, displayed his poster entitled "Anti-JO-I Associated Polymyositis as a Cause of Fever of Unknown Origin."

- CPT Michael Gordon, MC, displayed his poster entitled "The Effect of Anti-Rho(D) in Adult Patients with Immune Thrombocytopenic Purpura."

- CPT Duane Hospenthal, MC, displayed his poster entitled "Trends in Fungi Recovered from Urine Following the Introduction of Fluconazole."

- CPT Patrick O'Malley, MC, displayed his poster entitled "The Value of Screening for Psychiatric Disorders Prior to Upper Endoscopy."

- CPT Jennifer Thompson, MC, displayed her poster entitled "Dyspnea on Exertion and Abnormal Cardiopulmonary Testing in Addison's Disease."

- The Kershisnik Award of Excellence, Best Research Paper Presentation, was bestowed on CPT Katherine A. Ward, MC, Orthopaedic Surgery Service, Department of Surgery, in March 1994. The award was given for her research "Intraosseous Calcanea Lipoma: Review of the Literature with a Case Report."

- CPT Jeffrey J. Meier, MC, Orthopaedic Surgery Service, Department of Surgery, received the Resident Research Award, Third Place, from the Washington Orthopaedic Society Residents Competition, in April 1994 for his work entitled "A Method for Radiographic Evaluation of Pedicle Screw Violation of the Vertebral Endplate."

- The Resident/Fellow Research Award, the Eastern Orthopaedic Association, was awarded in May 1994 to MAJ Patrick St. Pierre, MC, Orthopaedic Surgery Service, Department of Surgery, for his study entitled "Tendon Healing to Cortical Bone Versus a Cancellous Trough: A Biomechanical and Histological Evaluation in the Goat."

- In June 1994, COL Cynthia A. Gurney, AN, Nursing Research Service, received the Phyllis J. Verhoinck Nursing Research Award for recognition of her research "Adaptation of Medical Personnel to Combat." The award was presented at The Army Nurse Corps Phyllis J. Verhoinck Biennial Research Symposium, Denver, CO.

2. Planned for FY-95

The Department of Clinical Investigation hopes to maintain the essence of the Clinical Investigation Program despite severe budget restrictions in FY-95. The Bailey K. Ashford Research Symposium and the
WRAMC Research Course will be continued. Areas of particular interest for the upcoming year include the following:

a. Continue close coordination and oversight of the renovation of the laboratory animal facility and the departmental space in the BRAC Building; both of which are due for completion during FY-95.

b. Develop a winter DCI course to inform staff on how to enhance their research efforts through extramural support.

c. Inaugurate a "Research Day" where investigators will be invited to present posters and oral presentations of their research.

d. Major modernization of the computer operations services, to include: (1) operation of DCINET over the new WRAMC LAN fiber infrastructure; (2) relocation of the computer lab and the hub of operations to new facilities; (3) implementation of a new WRAMC-wide client-server database/mail central workflow that will completely automate DCI business; (4) implementation of new laboratory automation features; and (5) planning of new multi-media teaching aids for research and computer automation instruction.

3. Ongoing and Future Issues

It is probable that WRAMC activities in patient care, training, and research will change substantively in the future. The major ongoing and future issue is the same as in years past, funding of the WRAMC Clinical Investigation Program in this new environment. Envisioned is a need for personnel to assist in heavily utilized research areas; such as, Pharmacy, Extramural Funding Office, Biometrics Section, and Computer Operations. In order to generate adequate funding for this growth, a 5% access fee will be instituted on all extramurally supported protocols.
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Burman, COL MC</td>
<td>Co-Chairman&lt;br&gt;Chief, Endocrine-Metabolic Service&lt;br&gt;Representing Deputy Commander</td>
</tr>
<tr>
<td>Stephen Sihelnik, LTC MC</td>
<td>Co-Chairman&lt;br&gt;Assistant Chief, Urology Service&lt;br&gt;Representing Deputy Commander</td>
</tr>
<tr>
<td>George Tsokos, MAJ, MC</td>
<td>Acting Co-Chairman&lt;br&gt;Assistant Chief, DCI</td>
</tr>
<tr>
<td>Dominic Solimando, LTC MS</td>
<td>OIC, Hematology-Oncology Pharmacy&lt;br&gt;Representing Chief, Pharmacy Service</td>
</tr>
<tr>
<td>David DeDonato, LTC CH</td>
<td>Chief, Dept of Ministry and Pastoral Care</td>
</tr>
<tr>
<td>Cheryl Hostetler, DAC</td>
<td>Clinical Instructor, Dietetic Internship Education and Research&lt;br&gt;Nutrition Care Directorate&lt;br&gt;Representing Ch, Nutrition Care Dir</td>
</tr>
<tr>
<td>Eric Marks, MD*</td>
<td>Associate Professor&lt;br&gt;Dept of Medicine, USUHS</td>
</tr>
<tr>
<td>Laurel Meaney, DAC</td>
<td>Patients' Rights Representative, WRAMC</td>
</tr>
<tr>
<td>Frederick Miller, MD PhD*</td>
<td>Medical Officer&lt;br&gt;U. S. Food and Drug Administration</td>
</tr>
<tr>
<td>Scott Murdoch, JD</td>
<td>Chief, Claims Office&lt;br&gt;Representing Center Judge Advocate</td>
</tr>
<tr>
<td>Jean Reeder, COL AN</td>
<td>Chief, Nursing Research Service&lt;br&gt;Representing Chief, Dept of Nursing</td>
</tr>
<tr>
<td>Robert Smallridge, COL MC*</td>
<td>Chief, Dept of Clinical Physiology&lt;br&gt;Division of Medicine, WRAIR&lt;br&gt;Representing Director, WRAIR</td>
</tr>
<tr>
<td>Estelle Coleman-Fraser, DAC</td>
<td>Research Review Coordinator&lt;br&gt;Department of Clinical Investigation</td>
</tr>
</tbody>
</table>

*Non-affiliated
### TABLE V: Clinical Investigation Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Tsokos, MAJ MC</td>
<td>Acting Chairman</td>
</tr>
<tr>
<td></td>
<td>Assistant Chief, DCI</td>
</tr>
<tr>
<td>Ana Rodriguez, COL MC</td>
<td>Chief, Nuclear Medicine</td>
</tr>
<tr>
<td></td>
<td>Representing Radiation Control Comm</td>
</tr>
<tr>
<td>Audrey Chang, PhD</td>
<td>Supervisory Statistician, DCI</td>
</tr>
<tr>
<td>Paul Welch, MAJ MC</td>
<td>Chief, Nephrology Service</td>
</tr>
<tr>
<td></td>
<td>Representing Chief, Dept of Medicine</td>
</tr>
<tr>
<td>Scott Murdoch, JD</td>
<td>Chief, Claims Office</td>
</tr>
<tr>
<td></td>
<td>Representing Center Judge Advocate</td>
</tr>
<tr>
<td>Jean Reeder, COL AN</td>
<td>Chief, Nursing Research Service</td>
</tr>
<tr>
<td>Douglas Hale, MAJ MC</td>
<td>Staff, General Surgery Service</td>
</tr>
<tr>
<td></td>
<td>Representing Chief, Dept of Surgery</td>
</tr>
</tbody>
</table>

### TABLE VI: Rotating Senior Investigators, Clinical Investigation Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Majorie Leek, PhD</td>
<td>Army Audiology &amp; Speech Center</td>
</tr>
<tr>
<td>Barbara Schenok, MD</td>
<td>Neurology Service</td>
</tr>
<tr>
<td>Normund Wong, COL MC</td>
<td>Department of Psychiatry</td>
</tr>
<tr>
<td>Roy Wong, COL MC</td>
<td>Gastroenterology Service</td>
</tr>
<tr>
<td>Gary Carpenter, COL MC</td>
<td>Allergy-Immunology Service</td>
</tr>
<tr>
<td>Russell Moores, MAJ MC</td>
<td>Department of Pediatrics</td>
</tr>
</tbody>
</table>
### TABLE VII: Institutional Laboratory Animal Care and Use Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Tsokos, MAJ MC</td>
<td>Acting Chairman</td>
</tr>
<tr>
<td></td>
<td>Assistant Chief, DCI</td>
</tr>
<tr>
<td>Judith Davis, MAJ VC</td>
<td>Attending Veterinarian</td>
</tr>
<tr>
<td></td>
<td>Chief, Animal Resource Department, Div of Veterinary Medicine, WRAIR</td>
</tr>
<tr>
<td>Daryl Kelly, LTC MS</td>
<td>Ch, Research Operations Service</td>
</tr>
<tr>
<td></td>
<td>Dept of Clinical Investigation, WRAMC</td>
</tr>
<tr>
<td>Hernando Mena, LTC MC*</td>
<td>Asst Chairman, Dept of Neuropathology</td>
</tr>
<tr>
<td></td>
<td>Armed Forces Institute of Pathology</td>
</tr>
<tr>
<td>Ted Hadfield, LtCol BSC*</td>
<td>Chief, Division of Microbiology</td>
</tr>
<tr>
<td></td>
<td>Armed Forces Institute of Pathology</td>
</tr>
<tr>
<td>Lynn Bailey, DAC</td>
<td>Laboratory Animal Technician</td>
</tr>
<tr>
<td></td>
<td>Dept of Clinical Investigation</td>
</tr>
</tbody>
</table>

*Non-affiliated

### TABLE VIII: HIV Research/Clinical Investigation Committee Member

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Lennox, MAJ MC</td>
<td>Staff, Infectious Disease Service</td>
</tr>
<tr>
<td></td>
<td>Representing Program Director, HIV Research, Jackson Foundation</td>
</tr>
</tbody>
</table>
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY’s ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALLERGY-IMMUNOLOGY SERVICE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1400-88</td>
<td>2,658</td>
<td>0</td>
<td>2,658</td>
<td></td>
</tr>
<tr>
<td>3343</td>
<td>737</td>
<td>0</td>
<td>737</td>
<td></td>
</tr>
<tr>
<td>3346</td>
<td>1,630</td>
<td>20</td>
<td>1,650</td>
<td></td>
</tr>
<tr>
<td>3349</td>
<td>2,763</td>
<td>0</td>
<td>2,763</td>
<td></td>
</tr>
<tr>
<td>3350</td>
<td>48</td>
<td>0</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>3351</td>
<td>331</td>
<td>0</td>
<td>331</td>
<td></td>
</tr>
<tr>
<td>3352</td>
<td>2,357</td>
<td>0</td>
<td>2,357</td>
<td></td>
</tr>
<tr>
<td>3353</td>
<td>530</td>
<td>0</td>
<td>530</td>
<td></td>
</tr>
<tr>
<td>3354</td>
<td>4,403</td>
<td>0</td>
<td>4,403</td>
<td></td>
</tr>
<tr>
<td>3355</td>
<td>655</td>
<td>0</td>
<td>655</td>
<td></td>
</tr>
<tr>
<td>3357</td>
<td>13,444</td>
<td>526</td>
<td>13,970</td>
<td></td>
</tr>
<tr>
<td>3358</td>
<td>6,362</td>
<td>320</td>
<td>6,682</td>
<td></td>
</tr>
<tr>
<td>3359</td>
<td>834</td>
<td>20</td>
<td>854</td>
<td></td>
</tr>
<tr>
<td>3360</td>
<td>632</td>
<td>0</td>
<td>632</td>
<td></td>
</tr>
<tr>
<td>3363</td>
<td>1,154</td>
<td>690</td>
<td>1,844</td>
<td></td>
</tr>
<tr>
<td>3364</td>
<td>3,509</td>
<td>1,386</td>
<td>4,895</td>
<td></td>
</tr>
<tr>
<td>3365</td>
<td>11,276</td>
<td>708</td>
<td>11,984</td>
<td></td>
</tr>
<tr>
<td>3366</td>
<td>4,505</td>
<td>47</td>
<td>4,552</td>
<td></td>
</tr>
<tr>
<td>3367</td>
<td>14,074</td>
<td>62</td>
<td>14,136</td>
<td></td>
</tr>
<tr>
<td>3368</td>
<td>3,167</td>
<td>479</td>
<td>3,646</td>
<td></td>
</tr>
<tr>
<td>3371</td>
<td>0</td>
<td>1,213</td>
<td>1,213</td>
<td></td>
</tr>
<tr>
<td>4804</td>
<td>0</td>
<td>1,143</td>
<td>1,143</td>
<td></td>
</tr>
<tr>
<td>4815</td>
<td>0</td>
<td>643</td>
<td>643</td>
<td></td>
</tr>
<tr>
<td>4817</td>
<td>0</td>
<td>4,404</td>
<td>4,404</td>
<td></td>
</tr>
<tr>
<td>6276</td>
<td>2,374</td>
<td>50</td>
<td>2,424</td>
<td></td>
</tr>
<tr>
<td>9286</td>
<td>8,272</td>
<td>1,750</td>
<td>10,022</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>85,715</strong></td>
<td><strong>13,461</strong></td>
<td><strong>99,176</strong></td>
<td></td>
</tr>
</tbody>
</table>

| DEPARTMENT OF CLINICAL INVESTIGATION | | | | |
|--------------------------------------|------------------|---------------|----------|
| 3709                                 | 56,711           | 6,419         | 63,130   |
| 3714                                 | 4,157            | 5,675         | 9,832    |
| 3715                                 | 29,592           | 21,543        | 51,135   |
| 9275                                 | 16,791           | 0             | 16,791   |
| 9284                                 | 5,792            | 1,325         | 7,117    |
| 9285                                 | 1,729            | 526           | 2,255    |
| 9288                                 | 0                | 1,750         | 1,750    |
| **TOTAL**                            | **114,772**      | **37,238**    | **152,010** |

| HIV RESEARCH                        | | | | |
|--------------------------------------|------------------|---------------|----------|
| 8802                                 | 996              | 0             | 996      |
| **TOTAL**                            | **996**          | **0**         | **996**  |

<table>
<thead>
<tr>
<th>DEPARTMENT OF MEDICINE Cardiology Service</th>
</tr>
</thead>
<tbody>
<tr>
<td>1264</td>
</tr>
<tr>
<td>1269</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY’s ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatology Service</td>
<td>1815</td>
<td>1,100</td>
<td>0</td>
<td>1,100</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>1,100</td>
<td>0</td>
<td>1,100</td>
</tr>
<tr>
<td>Endocrine-Metabolic Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1311-88</td>
<td>658</td>
<td>300</td>
<td>958</td>
<td></td>
</tr>
<tr>
<td>1312-89</td>
<td>737</td>
<td>0</td>
<td>737</td>
<td></td>
</tr>
<tr>
<td>1316-89</td>
<td>5,006</td>
<td>10,082</td>
<td>15,088</td>
<td></td>
</tr>
<tr>
<td>1328-90</td>
<td>45,637</td>
<td>39,754</td>
<td>85,391</td>
<td></td>
</tr>
<tr>
<td>1329-90</td>
<td>236</td>
<td>0</td>
<td>236</td>
<td></td>
</tr>
<tr>
<td>1330-90</td>
<td>0</td>
<td>2,888</td>
<td>2,888</td>
<td></td>
</tr>
<tr>
<td>1331-91</td>
<td>3,221</td>
<td>0</td>
<td>3,221</td>
<td></td>
</tr>
<tr>
<td>1333-91</td>
<td>31,004</td>
<td>261</td>
<td>31,265</td>
<td></td>
</tr>
<tr>
<td>1334-91</td>
<td>48,725</td>
<td>2,572</td>
<td>51,297</td>
<td></td>
</tr>
<tr>
<td>1335-91</td>
<td>35,044</td>
<td>15,959</td>
<td>51,003</td>
<td></td>
</tr>
<tr>
<td>1336-91</td>
<td>17,177</td>
<td>672</td>
<td>17,849</td>
<td></td>
</tr>
<tr>
<td>1337-91</td>
<td>0</td>
<td>6,780</td>
<td>6,780</td>
<td></td>
</tr>
<tr>
<td>1340-91</td>
<td>778</td>
<td>746</td>
<td>1,524</td>
<td></td>
</tr>
<tr>
<td>1341-92</td>
<td>0</td>
<td>827</td>
<td>827</td>
<td></td>
</tr>
<tr>
<td>1342-92</td>
<td>8,422</td>
<td>4,697</td>
<td>13,119</td>
<td></td>
</tr>
<tr>
<td>1343-92</td>
<td>70,849</td>
<td>30</td>
<td>70,879</td>
<td></td>
</tr>
<tr>
<td>1346-92</td>
<td>12,398</td>
<td>5,416</td>
<td>17,814</td>
<td></td>
</tr>
<tr>
<td>1349-92</td>
<td>7,776</td>
<td>11,747</td>
<td>19,523</td>
<td></td>
</tr>
<tr>
<td>1351-92</td>
<td>0</td>
<td>909</td>
<td>909</td>
<td></td>
</tr>
<tr>
<td>1352-92</td>
<td>0</td>
<td>15,648</td>
<td>15,648</td>
<td></td>
</tr>
<tr>
<td>1354-92</td>
<td>0</td>
<td>25,049</td>
<td>25,049</td>
<td></td>
</tr>
<tr>
<td>1356-92</td>
<td>4,352</td>
<td>16,123</td>
<td>20,475</td>
<td></td>
</tr>
<tr>
<td>1357-92</td>
<td>0</td>
<td>2,968</td>
<td>2,968</td>
<td></td>
</tr>
<tr>
<td>1358-92</td>
<td>0</td>
<td>2,075</td>
<td>2,075</td>
<td></td>
</tr>
<tr>
<td>1359-92</td>
<td>68,425</td>
<td>645</td>
<td>69,070</td>
<td></td>
</tr>
<tr>
<td>1360-93</td>
<td>0</td>
<td>16,053</td>
<td>16,053</td>
<td></td>
</tr>
<tr>
<td>1361-93</td>
<td>0</td>
<td>24,799</td>
<td>24,799</td>
<td></td>
</tr>
<tr>
<td>1362-93</td>
<td>0</td>
<td>7,887</td>
<td>7,887</td>
<td></td>
</tr>
<tr>
<td>1371-86</td>
<td>11,403</td>
<td>0</td>
<td>11,403</td>
<td></td>
</tr>
<tr>
<td>1385-87</td>
<td>65,494</td>
<td>0</td>
<td>65,494</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>437,342</td>
<td>214,887</td>
<td>652,229</td>
</tr>
</tbody>
</table>

DEPARTMENT OF MEDICINE
Gastroenterology Service

<table>
<thead>
<tr>
<th>1404</th>
<th>100</th>
<th>0</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>1406</td>
<td>10,467</td>
<td>1,116</td>
<td>11,583</td>
</tr>
<tr>
<td>1408</td>
<td>0</td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td>1410</td>
<td>0</td>
<td>1,016</td>
<td>1,016</td>
</tr>
<tr>
<td>1411</td>
<td>1,510</td>
<td>0</td>
<td>1,510</td>
</tr>
<tr>
<td>1413</td>
<td>34,319</td>
<td>5,053</td>
<td>39,372</td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastroenterology Service (continued)</td>
<td>1417</td>
<td>20,014</td>
<td>0</td>
<td>20,014</td>
</tr>
<tr>
<td>1421</td>
<td>570</td>
<td>672</td>
<td>1,242</td>
<td></td>
</tr>
<tr>
<td>1423</td>
<td>6,763</td>
<td>1,375</td>
<td>8,138</td>
<td></td>
</tr>
<tr>
<td>1425</td>
<td>0</td>
<td>792</td>
<td>792</td>
<td></td>
</tr>
<tr>
<td>1497</td>
<td>1,250</td>
<td>0</td>
<td>1,250</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>74,993</td>
<td>10,088</td>
<td>85,081</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Medicine Service</td>
<td>1032</td>
<td>0</td>
<td>605</td>
<td>605</td>
</tr>
<tr>
<td>1033</td>
<td>0</td>
<td>3,231</td>
<td>3,231</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>3,836</td>
<td>3,836</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology-Oncology Service</td>
<td>1681</td>
<td>3,621</td>
<td>1,789</td>
<td>5,410</td>
</tr>
<tr>
<td>1684</td>
<td>0</td>
<td>190</td>
<td>190</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>3,621</td>
<td>1,979</td>
<td>5,600</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nephrology Service</td>
<td>1157</td>
<td>7,796</td>
<td>0</td>
<td>7,796</td>
</tr>
<tr>
<td>1161</td>
<td>3,530</td>
<td>709</td>
<td>4,239</td>
<td></td>
</tr>
<tr>
<td>1162</td>
<td>13,641</td>
<td>1,725</td>
<td>15,366</td>
<td></td>
</tr>
<tr>
<td>1163</td>
<td>0</td>
<td>6,014</td>
<td>6,014</td>
<td></td>
</tr>
<tr>
<td>1164</td>
<td>16,810</td>
<td>18,944</td>
<td>35,754</td>
<td></td>
</tr>
<tr>
<td>1165</td>
<td>7,455</td>
<td>3,185</td>
<td>10,640</td>
<td></td>
</tr>
<tr>
<td>1166</td>
<td>4,582</td>
<td>7,527</td>
<td>12,109</td>
<td></td>
</tr>
<tr>
<td>1167</td>
<td>4,324</td>
<td>5,434</td>
<td>9,758</td>
<td></td>
</tr>
<tr>
<td>1168</td>
<td>5,593</td>
<td>5,017</td>
<td>10,610</td>
<td></td>
</tr>
<tr>
<td>1169</td>
<td>150</td>
<td>1,923</td>
<td>2,073</td>
<td></td>
</tr>
<tr>
<td>1170</td>
<td>21,208</td>
<td>10,640</td>
<td>31,848</td>
<td></td>
</tr>
<tr>
<td>1171</td>
<td>0</td>
<td>3,348</td>
<td>3,348</td>
<td></td>
</tr>
<tr>
<td>1172</td>
<td>0</td>
<td>13,866</td>
<td>13,866</td>
<td></td>
</tr>
<tr>
<td>1173</td>
<td>0</td>
<td>9,844</td>
<td>9,844</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>85,089</td>
<td>88,176</td>
<td>173,265</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary &amp; Critical Care Medicine Service</td>
<td>3011</td>
<td>0</td>
<td>697</td>
<td>697</td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>697</td>
<td>697</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary Disease Service</td>
<td>1707</td>
<td>11,787</td>
<td>0</td>
<td>11,787</td>
</tr>
<tr>
<td>1724</td>
<td>5,058</td>
<td>220</td>
<td>5,278</td>
<td></td>
</tr>
<tr>
<td>1739</td>
<td>0</td>
<td>520</td>
<td>520</td>
<td></td>
</tr>
<tr>
<td>1743</td>
<td>660</td>
<td>0</td>
<td>660</td>
<td></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS, 
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY’s ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary Disease Service (continued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1749</td>
<td>155</td>
<td>1,507</td>
<td>1,662</td>
<td></td>
</tr>
<tr>
<td>1751</td>
<td>0</td>
<td>1,154</td>
<td>1,154</td>
<td></td>
</tr>
<tr>
<td>1752</td>
<td>1,339</td>
<td>673</td>
<td>2,012</td>
<td></td>
</tr>
<tr>
<td>1753</td>
<td>1,364</td>
<td>136</td>
<td>1,500</td>
<td></td>
</tr>
<tr>
<td>1754</td>
<td>6,931</td>
<td>2,856</td>
<td>9,787</td>
<td></td>
</tr>
<tr>
<td>1762</td>
<td>0</td>
<td>779</td>
<td>779</td>
<td></td>
</tr>
<tr>
<td>9280</td>
<td>2,535</td>
<td>2,249</td>
<td>4,784</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>29,829</td>
<td>10,094</td>
<td>39,923</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatology Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3707</td>
<td>11,644</td>
<td>10,763</td>
<td>22,407</td>
<td></td>
</tr>
<tr>
<td>3710</td>
<td>12,383</td>
<td>7,712</td>
<td>20,095</td>
<td></td>
</tr>
<tr>
<td>3711</td>
<td>47,063</td>
<td>27,420</td>
<td>74,483</td>
<td></td>
</tr>
<tr>
<td>3712</td>
<td>35,816</td>
<td>11,855</td>
<td>47,671</td>
<td></td>
</tr>
<tr>
<td>3713</td>
<td>14,220</td>
<td>5,537</td>
<td>19,757</td>
<td></td>
</tr>
<tr>
<td>3717</td>
<td>0</td>
<td>9,090</td>
<td>9,090</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>121,126</td>
<td>72,377</td>
<td>193,503</td>
<td></td>
</tr>
<tr>
<td>NEUROLOGY SERVICE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7142</td>
<td>295</td>
<td>12,000</td>
<td>12,295</td>
<td></td>
</tr>
<tr>
<td>7147</td>
<td>1,744</td>
<td>1,048</td>
<td>2,792</td>
<td></td>
</tr>
<tr>
<td>7152</td>
<td>0</td>
<td>10,346</td>
<td>10,346</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>2,039</td>
<td>23,394</td>
<td>25,433</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF NURSING</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7525</td>
<td>29</td>
<td>0</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>7526</td>
<td>0</td>
<td>946</td>
<td>946</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>29</td>
<td>946</td>
<td>975</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gynecologic Oncology Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4265</td>
<td>238</td>
<td>0</td>
<td>238</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>238</td>
<td>0</td>
<td>238</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4816</td>
<td>0</td>
<td>3,316</td>
<td>3,316</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>3,316</td>
<td>3,316</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF PEDIATRICS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6064</td>
<td>32,931</td>
<td>2,873</td>
<td>35,804</td>
<td></td>
</tr>
<tr>
<td>6256</td>
<td>3,104</td>
<td>1,327</td>
<td>4,431</td>
<td></td>
</tr>
<tr>
<td>6257</td>
<td>37,021</td>
<td>4,033</td>
<td>41,054</td>
<td></td>
</tr>
<tr>
<td>6267</td>
<td>0</td>
<td>372</td>
<td>372</td>
<td></td>
</tr>
<tr>
<td>6275</td>
<td>0</td>
<td>352</td>
<td>352</td>
<td></td>
</tr>
<tr>
<td>6299</td>
<td>10,677</td>
<td>1,160</td>
<td>11,837</td>
<td></td>
</tr>
<tr>
<td>6300</td>
<td>25,523</td>
<td>269</td>
<td>25,792</td>
<td></td>
</tr>
<tr>
<td>6308</td>
<td>5,772</td>
<td>18,830</td>
<td>24,602</td>
<td></td>
</tr>
<tr>
<td>6313</td>
<td>6,024</td>
<td>1,260</td>
<td>7,284</td>
<td></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS, 
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF PEDIATRICS (continued)</td>
<td>6321</td>
<td>7,464</td>
<td>60</td>
<td>7,524</td>
</tr>
<tr>
<td></td>
<td>6324</td>
<td>0</td>
<td>2,005</td>
<td>2,005</td>
</tr>
<tr>
<td></td>
<td>6327</td>
<td>5,115</td>
<td>7,352</td>
<td>12,467</td>
</tr>
<tr>
<td></td>
<td>6331</td>
<td>0</td>
<td>4,500</td>
<td>4,500</td>
</tr>
<tr>
<td></td>
<td>6332</td>
<td>0</td>
<td>16,171</td>
<td>16,171</td>
</tr>
<tr>
<td></td>
<td>6336</td>
<td>0</td>
<td>16,601</td>
<td>16,601</td>
</tr>
<tr>
<td></td>
<td>6342</td>
<td>0</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>6350</td>
<td>0</td>
<td>576</td>
<td>576</td>
</tr>
<tr>
<td></td>
<td>6358</td>
<td>0</td>
<td>3,164</td>
<td>3,164</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td><strong>133,631</strong></td>
<td><strong>80,923</strong></td>
<td><strong>214,554</strong></td>
</tr>
</tbody>
</table>

DEPARTMENT OF PEDIATRICS
Pediatric Hematology-Oncology Service

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6213</td>
<td>14,835</td>
<td>17,502</td>
<td>32,337</td>
</tr>
<tr>
<td>6307</td>
<td>2,371</td>
<td>0</td>
<td>2,371</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>17,206</strong></td>
<td><strong>17,502</strong></td>
<td><strong>34,708</strong></td>
</tr>
</tbody>
</table>

PHYSICAL MEDICINE AND REHABILITATION SERVICE

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9614</td>
<td>0</td>
<td>1,853</td>
<td>1,853</td>
</tr>
<tr>
<td>9615</td>
<td>0</td>
<td>995</td>
<td>995</td>
</tr>
<tr>
<td>9616</td>
<td>0</td>
<td>1,154</td>
<td>1,154</td>
</tr>
<tr>
<td>9617</td>
<td>0</td>
<td>995</td>
<td>995</td>
</tr>
<tr>
<td>9620</td>
<td>0</td>
<td>1,732</td>
<td>1,732</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>0</strong></td>
<td><strong>6,729</strong></td>
<td><strong>6,729</strong></td>
</tr>
</tbody>
</table>

DEPARTMENT OF PSYCHIATRY

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7245</td>
<td>163</td>
<td>1,092</td>
<td>1,255</td>
</tr>
<tr>
<td>7246</td>
<td>7,854</td>
<td>0</td>
<td>7,854</td>
</tr>
<tr>
<td>7248</td>
<td>0</td>
<td>650</td>
<td>650</td>
</tr>
<tr>
<td>7250</td>
<td>0</td>
<td>229</td>
<td>229</td>
</tr>
<tr>
<td>7256</td>
<td>0</td>
<td>276</td>
<td>276</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>8,017</strong></td>
<td><strong>2,247</strong></td>
<td><strong>10,264</strong></td>
</tr>
</tbody>
</table>

DEPARTMENT OF RADIOLOGY

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4700</td>
<td>0</td>
<td>251</td>
<td>251</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>0</strong></td>
<td><strong>251</strong></td>
<td><strong>251</strong></td>
</tr>
</tbody>
</table>

DEPARTMENT OF SURGERY
Anesthesia-Operative Service

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2056A</td>
<td>23,113</td>
<td>520</td>
<td>23,633</td>
</tr>
<tr>
<td>2063A</td>
<td>0</td>
<td>31,313</td>
<td>31,313</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>23,113</strong></td>
<td><strong>31,833</strong></td>
<td><strong>54,946</strong></td>
</tr>
</tbody>
</table>

DEPARTMENT OF SURGERY
Army Audiology and Speech Center

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY's ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2508</td>
<td>0</td>
<td>70,975</td>
<td>70,975</td>
</tr>
<tr>
<td>2510</td>
<td>73</td>
<td>1,776</td>
<td>1,849</td>
</tr>
<tr>
<td>2515</td>
<td>1,150</td>
<td>2,040</td>
<td>3,190</td>
</tr>
<tr>
<td>2516</td>
<td>1,315</td>
<td>2,541</td>
<td>3,856</td>
</tr>
<tr>
<td>2518</td>
<td>90</td>
<td>1,120</td>
<td>1,210</td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER*</th>
<th>PRIOR FY’s ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Army Audiology and Speech Center (continued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2519</td>
<td>546</td>
<td>4,034</td>
<td>4,580</td>
<td></td>
</tr>
<tr>
<td>2520</td>
<td>0</td>
<td>1,910</td>
<td>1,910</td>
<td></td>
</tr>
<tr>
<td>2521</td>
<td>2,236</td>
<td>310</td>
<td>2,546</td>
<td></td>
</tr>
<tr>
<td>2524</td>
<td>0</td>
<td>1,801</td>
<td>1,801</td>
<td></td>
</tr>
<tr>
<td>2525</td>
<td>0</td>
<td>1,078</td>
<td>1,078</td>
<td></td>
</tr>
<tr>
<td>2528</td>
<td>0</td>
<td>3,100</td>
<td>3,100</td>
<td></td>
</tr>
<tr>
<td>2530</td>
<td>0</td>
<td>1,976</td>
<td>1,976</td>
<td></td>
</tr>
<tr>
<td>2532</td>
<td>0</td>
<td>63,912</td>
<td>63,912</td>
<td></td>
</tr>
<tr>
<td>2588</td>
<td>4,031</td>
<td>0</td>
<td>4,031</td>
<td></td>
</tr>
<tr>
<td>2590</td>
<td>15,328</td>
<td>300</td>
<td>15,628</td>
<td></td>
</tr>
<tr>
<td>2591</td>
<td>3,755</td>
<td>300</td>
<td>4,055</td>
<td></td>
</tr>
<tr>
<td>2598</td>
<td>1,995</td>
<td>750</td>
<td>2,745</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>30,519</td>
<td>157,923</td>
<td>188,442</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Surgery Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2063</td>
<td>0</td>
<td>2,233</td>
<td>2,233</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>2,233</td>
<td>2,233</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmology Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2318</td>
<td>0</td>
<td>8,882</td>
<td>8,882</td>
<td></td>
</tr>
<tr>
<td>2319</td>
<td>9,915</td>
<td>3,905</td>
<td>13,820</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>9,915</td>
<td>12,787</td>
<td>22,702</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orthopaedic Surgery Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2427</td>
<td>0</td>
<td>278</td>
<td>278</td>
<td></td>
</tr>
<tr>
<td>2432</td>
<td>0</td>
<td>2,636</td>
<td>2,636</td>
<td></td>
</tr>
<tr>
<td>2435</td>
<td>5,959</td>
<td>0</td>
<td>5,959</td>
<td></td>
</tr>
<tr>
<td>2440</td>
<td>0</td>
<td>624</td>
<td>624</td>
<td></td>
</tr>
<tr>
<td>2442</td>
<td>0</td>
<td>726</td>
<td>726</td>
<td></td>
</tr>
<tr>
<td>2452</td>
<td>0</td>
<td>910</td>
<td>910</td>
<td></td>
</tr>
<tr>
<td>2455</td>
<td>0</td>
<td>4,360</td>
<td>4,360</td>
<td></td>
</tr>
<tr>
<td>2456</td>
<td>0</td>
<td>9,161</td>
<td>9,161</td>
<td></td>
</tr>
<tr>
<td>2458</td>
<td>0</td>
<td>2,330</td>
<td>2,330</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>5,959</td>
<td>21,025</td>
<td>26,984</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Otolaryngology-Head &amp; Neck Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2522</td>
<td>0</td>
<td>50,050</td>
<td>50,050</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>50,050</td>
<td>50,050</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urology Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2864</td>
<td>500</td>
<td>0</td>
<td>500</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>500</td>
<td>0</td>
<td>500</td>
<td></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
### ADDENDUM

EXPENSES FOR PROTOCOLS APPROVED DURING FY-94
(FIRST ANNUAL PROGRESS REPORT TO BE SUBMITTED IN FY-94)
AND EXPENSES FOR PROTOCOLS PREVIOUSLY CLOSED
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER</th>
<th>PRIOR FY'S ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALLERGY-IMMUNOLOGY SERVICE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3372</td>
<td>0</td>
<td>2,534</td>
<td>2,534</td>
<td>2,534</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td>0</td>
<td>2,534</td>
<td>2,534</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF CLINICAL INVESTIGATION</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9289</td>
<td>0</td>
<td>2,451</td>
<td>2,451</td>
<td>2,451</td>
</tr>
<tr>
<td>9291</td>
<td>0</td>
<td>19,075</td>
<td>19,075</td>
<td>19,075</td>
</tr>
<tr>
<td>9292</td>
<td>0</td>
<td>8,524</td>
<td>8,524</td>
<td>8,524</td>
</tr>
<tr>
<td>9293</td>
<td>0</td>
<td>950</td>
<td>950</td>
<td>950</td>
</tr>
<tr>
<td>9295</td>
<td>0</td>
<td>5,231</td>
<td>5,231</td>
<td>5,231</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td>0</td>
<td>38,765</td>
<td>38,765</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiology Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1283</td>
<td>0</td>
<td>828</td>
<td>828</td>
<td>828</td>
</tr>
<tr>
<td>1284</td>
<td>0</td>
<td>2,423</td>
<td>2,423</td>
<td>2,423</td>
</tr>
<tr>
<td>1293</td>
<td>0</td>
<td>1,645</td>
<td>1,645</td>
<td>1,645</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td>0</td>
<td>4,905</td>
<td>4,905</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatology Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1822</td>
<td>0</td>
<td>23,679</td>
<td>23,679</td>
<td>23,679</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td>0</td>
<td>23,679</td>
<td>23,679</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocrine-Metabolic Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1300</td>
<td>0</td>
<td>800</td>
<td>800</td>
<td>800</td>
</tr>
<tr>
<td>1345</td>
<td>0</td>
<td>216</td>
<td>216</td>
<td>216</td>
</tr>
<tr>
<td>1364</td>
<td>0</td>
<td>10,039</td>
<td>10,039</td>
<td>10,039</td>
</tr>
<tr>
<td>1365</td>
<td>0</td>
<td>8,884</td>
<td>8,884</td>
<td>8,884</td>
</tr>
<tr>
<td>1366</td>
<td>0</td>
<td>1,751</td>
<td>1,751</td>
<td>1,751</td>
</tr>
<tr>
<td>1368</td>
<td>0</td>
<td>3,874</td>
<td>3,874</td>
<td>3,874</td>
</tr>
<tr>
<td>1369</td>
<td>0</td>
<td>2,629</td>
<td>2,629</td>
<td>2,629</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td>0</td>
<td>28,193</td>
<td>28,193</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastroenterology Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1450</td>
<td>16,101</td>
<td>2,482</td>
<td>18,583</td>
<td></td>
</tr>
<tr>
<td>1496</td>
<td>525</td>
<td>296</td>
<td>821</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>16,626</td>
<td>2,778</td>
<td>19,404</td>
<td></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Medicine Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1034</td>
<td>0</td>
<td>928</td>
<td>928</td>
<td></td>
</tr>
<tr>
<td>1035</td>
<td>0</td>
<td>8,000</td>
<td>8,000</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>8,928</td>
<td>8,928</td>
<td></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious Disease Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1916</td>
<td>0</td>
<td>9,346</td>
<td>9,346</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>0</td>
<td>9,346</td>
<td>9,346</td>
<td></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nephrology Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1174</td>
<td>0</td>
<td>6,734</td>
<td>6,734</td>
<td></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
ADDENDUM
EXPENSES FOR PROTOCOLS APPROVED DURING FY-94
(FIRST ANNUAL PROGRESS REPORT TO BE SUBMITTED IN FY-94)
AND EXPENSES FOR PROTOCOLS PREVIOUSLY CLOSED
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/ SERVICE</th>
<th>PROTOCOL NUMBER</th>
<th>PRIOR FY'S ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nephrology Service (continued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1175</td>
<td>0</td>
<td>12,020</td>
<td>12,020</td>
<td></td>
</tr>
<tr>
<td>1176</td>
<td>0</td>
<td>150</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>1178</td>
<td>0</td>
<td>852</td>
<td>852</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>19,756</td>
<td>19,756</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary Service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1740</td>
<td>0</td>
<td>1,158</td>
<td>1,158</td>
<td></td>
</tr>
<tr>
<td>1755</td>
<td>0</td>
<td>679</td>
<td>679</td>
<td></td>
</tr>
<tr>
<td>1756</td>
<td>1,502</td>
<td>155</td>
<td>1,657</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>1,502</td>
<td>1,992</td>
<td>3,494</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td>Rheumatology Service</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3719</td>
<td>0</td>
<td>2,028</td>
<td>2,028</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>2,028</td>
<td>2,028</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4818</td>
<td>0</td>
<td>5,761</td>
<td>5,761</td>
<td></td>
</tr>
<tr>
<td>4819</td>
<td>0</td>
<td>6,886</td>
<td>6,886</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>12,647</td>
<td>12,647</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF PEDIATRICS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6320</td>
<td>0</td>
<td>141</td>
<td>141</td>
<td></td>
</tr>
<tr>
<td>6366</td>
<td>0</td>
<td>2,575</td>
<td>2,575</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>2,716</td>
<td>2,716</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF RADIOLOGY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4702</td>
<td>934</td>
<td>261</td>
<td>1,195</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>934</td>
<td>261</td>
<td>1,195</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Army Audiology and Speech Center</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2514</td>
<td>3,540</td>
<td>955</td>
<td>4,495</td>
<td></td>
</tr>
<tr>
<td>2533</td>
<td>0</td>
<td>1,706</td>
<td>1,706</td>
<td></td>
</tr>
<tr>
<td>2534</td>
<td>0</td>
<td>740</td>
<td>740</td>
<td></td>
</tr>
<tr>
<td>2540</td>
<td>0</td>
<td>2,249</td>
<td>2,249</td>
<td></td>
</tr>
<tr>
<td>2575</td>
<td>0</td>
<td>955</td>
<td>955</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>3,540</td>
<td>6,605</td>
<td>10,145</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td>Ophthalmology Service</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2321</td>
<td>0</td>
<td>1,130</td>
<td>1,130</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>0</td>
<td>1,130</td>
<td>1,130</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td>Orthopaedic Service</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2410</td>
<td>8,439</td>
<td>710</td>
<td>9,149</td>
<td></td>
</tr>
<tr>
<td>2463</td>
<td>0</td>
<td>5,100</td>
<td>5,100</td>
<td></td>
</tr>
<tr>
<td>2466</td>
<td>0</td>
<td>126</td>
<td>126</td>
<td></td>
</tr>
<tr>
<td>2468</td>
<td>0</td>
<td>1,671</td>
<td>1,671</td>
<td></td>
</tr>
<tr>
<td>2470</td>
<td>0</td>
<td>580</td>
<td>580</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>8,439</td>
<td>8,187</td>
<td>16,626</td>
<td></td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
**ADDENDUM**

EXPENSES FOR PROTOCOLS APPROVED DURING FY-94
(FIRST ANNUAL PROGRESS REPORT TO BE SUBMITTED IN FY-94)
AND EXPENSES FOR PROTOCOLS PREVIOUSLY CLOSED
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<table>
<thead>
<tr>
<th>DEPARTMENT/SERVICE</th>
<th>PROTOCOL NUMBER</th>
<th>PRIOR FY'S ($)</th>
<th>CURRENT FY ($)</th>
<th>TOTAL ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHYSICAL MEDICINE AND REHABILITATION SERVICE</td>
<td>9025</td>
<td>0</td>
<td>507</td>
<td>507</td>
</tr>
<tr>
<td></td>
<td>9634</td>
<td>0</td>
<td>1,664</td>
<td>1,664</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>0</td>
<td>2,171</td>
<td>2,171</td>
</tr>
</tbody>
</table>

* Protocol is not listed if total expense is zero.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1400-88</td>
<td>Engler, Renata COL MC. A Pilot Study Evaluating Intestinal and Serum Immunoglobulin Levels in Patients with Acquired Hypogammaglobulinemia and Recurrent/Chronic Diarrhea of Undefined Etiology (2/88)</td>
<td>1</td>
</tr>
<tr>
<td>3336</td>
<td>Engler, Renata COL MC. The Effect of Human Breast Milk Cell Supernatants on In Vitro Immunoglobulin Secretion (11/87)</td>
<td>2</td>
</tr>
<tr>
<td>3343</td>
<td>Salata, Kalman PhD. Standardized Vs. Nonstandardized Allergen Products Containing Dust Mite Antigens (10/88)</td>
<td>3</td>
</tr>
<tr>
<td>3346</td>
<td>Salata, Kalman PhD. Comparison of Three Methods of Assessing Induction of Mitogen and Allergen Specific Lymphocyte Proliferation (6/89)</td>
<td>4</td>
</tr>
<tr>
<td>3348</td>
<td>Engler, Renata COL MC. Immunotherapy Reactions (11/89)</td>
<td>5</td>
</tr>
<tr>
<td>3349</td>
<td>Salata, Kalman PhD. Mitogen-Inducible T Suppressor Cell Assay by Flow Cytometry (12/89)</td>
<td>6</td>
</tr>
<tr>
<td>3350</td>
<td>Salata, Kalman PhD. Flow Cytometric Analysis of Natural Killer Cell Activity and Antibody-Dependent Cell-Mediated Cytotoxicity (1/90)</td>
<td>7</td>
</tr>
<tr>
<td>3351</td>
<td>Salata, Kalman PhD. In Vitro House Dust Mite Allergy Assays: Comparison of a Monoclonal Antibody/Allergen Capture Method with a Fluorescent Allergosorbant Test (1/90)</td>
<td>8</td>
</tr>
<tr>
<td>3352</td>
<td>Squire, Edward LTC MC. Use of Steroid Sparing Agents Among Asthmatics Doing Poorly on Corticosteroids: A Pilot Study (1/90)</td>
<td>9</td>
</tr>
<tr>
<td>3353</td>
<td>Salata, Kalman PhD. Contrasuppressor Cells in Allergy Immunotherapy (3/90)</td>
<td>10</td>
</tr>
<tr>
<td>3354</td>
<td>Salata, Kalman PhD. Two Way Mixed Lymphocyte Culture: Analysis by Two Color Flow Cytometry (4/90)</td>
<td>11</td>
</tr>
<tr>
<td>3355</td>
<td>Salata, Kalman PhD. Effect of Methotrexate on Expression of Interacellular Adhesion Molecule I in Interleukin-1 Stimulated Cultured Human Cells (5/90)</td>
<td>12</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
3357 Engler, Renata COL MC. Serum and Secretory Immune Status of Patients with Chronic Sinusitis and Normals (9/90) 13

3358 Salata, Kalman PhD. Plasma Level of Mast Cell Tryptase in Patients Undergoing Immunodiagnostic or Immunotherapy Procedures who Experience Adverse Reactions (9/90) 14

3359 Salata, Kalman PhD. Leukotriene B4 Receptor Downregulation: Flow Cytometry Analysis (11/90) 15

3360 Salata, Kalman PhD. 3,3'-Dioctadecylxocarbocyanine (DiO) Induced Immunosuppression: Inhibition of Mitogen, Antigen and Alloantigen Stimulated CD69 Expression (11/90) 16

3362 Salata, Kalman PhD. Immunologic Evaluation of Acute and Persistent Ectopic Gestation: A Collaborative Project with Portsmouth Naval Hospital (1/91) 17

3363 Salata, Kalman PhD. Stability of Cat and House Dust Mite Allergens in Allergy Immunotherapy Preparations (4/91) 18

3364 Salata, Kalman PhD. Effect of N-(Fluorenyl-9-methoxycarbonyl)-L-Leucine (FMOC-LEU) on Neutrophil Activation (5/91) 19

3365 Salata, Kalman PhD. Leucocyte Subset Analysis in Patients Treated with Intravenous Immunoglobulin (IVIG) (7/91) 20

3366 Salata, Kalman PhD. Bird Antigen Detection in the Home and IgG and IgG Subclass Titers in Healthy Bird Owners Versus Those With Hypersensitivity Pneumonitis (8/91) 21

3367 Carregal, Valerie CPT MC. Naive Versus Memory T Lymphocytes in Patients Undergoing Aeroallergen Immunotherapy (6/92) 22

3368 Engler, Renata COL MC. ELISA Measurement of the Humoral Immune Response to a Primary Rabies Vaccine Series (9/92) 23

3369 Kosisky, Susan. Survey of Prevalent Pollen and Fungal Aeroallergens in the Washington DC Area (5/93) 24

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLERGY-IMMUNOLOGY SERVICE (continued)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3371</td>
<td>Radford, Bennett MAJ MC. The Effect of Acetylsalicylic Acid (ASA) and Hydrocortisone (HC) on Urushiol Stimulated Lymphocytes and Epithelial Cells In Vitro (7/93)</td>
<td>25</td>
</tr>
<tr>
<td>4804</td>
<td>Salata, Kalman PhD. Antigen Typing Reticulocytes in Mixed Red Blood Cell Populations by Flow Cytometry (10/89)</td>
<td>26</td>
</tr>
<tr>
<td>4815</td>
<td>Salata, Kalman Ph.D.. Preparation and Characterization of Antibodies Directed Toward Enzymatically Treated Type AI Erythrocytes (7/93)</td>
<td>27</td>
</tr>
<tr>
<td>4817</td>
<td>Salata, Kalman PhD. Flow Cytometry Analysis of Plasma Factors Affecting Reticulocyte Maturation in Refrigerated Blood (9/93)</td>
<td>28</td>
</tr>
<tr>
<td>6276</td>
<td>Salata, Kalman PhD. In Vivo Persistence of Reticulocyte and Antigen Phenotype in Post-Transfusion Patients Analyzed by Flow Cytometry (11/90)</td>
<td>29</td>
</tr>
<tr>
<td>9286</td>
<td>Salata, Kalman, PhD. Major Histocompatibility Complex DNA Typing of Hemophilia A Patients (6/92)</td>
<td>30</td>
</tr>
<tr>
<td>DEPARTMENT OF CLINICAL INVESTIGATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3709</td>
<td>Tsokos, George MAJ MC. Pathogenesis of Systemic Sclerosis: Role of Transforming Growth Factor-Beta (10/91)</td>
<td>31</td>
</tr>
<tr>
<td>3714</td>
<td>Tsokos, George MAJ MC. Role of Adhesion Molecules in the Activation of T Cells From Patients with Systemic Lupus Erythematosus (SLE) (6/92)</td>
<td>32</td>
</tr>
<tr>
<td>3715</td>
<td>Tsokos, George MAJ MC. Metabolic Parameters in Systemic Lupus Erythematosus with Neuropsychiatric Manifestations (7/92)</td>
<td>33</td>
</tr>
<tr>
<td>9275</td>
<td>Schaudies, Paul MAJ MS. Quantitation and Characterization of EGF Levels in Rat Milk (10/88)</td>
<td>34</td>
</tr>
<tr>
<td>9284</td>
<td>Dobek, Arthur PhD. Comparison of the Hela Cell Monolayer Vs. the Toxi-titer System for Their Respective Ability to Detect Clostridium Difficile Toxin B in Stool Filtrate (4/91)</td>
<td>35</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9285</td>
<td>Dobek, Arthur PhD. Honey: Antibacterial Activity Against Multiple Antibiotic Resistant Clinical Isolates In Vitro (1/92)</td>
<td>36</td>
</tr>
<tr>
<td>9287</td>
<td>Bailey, Lynn. The Effect of Lipid Emulsion on the Duration of Ketamine/Xylazine Sedation in Rats (1/93)</td>
<td>37</td>
</tr>
<tr>
<td>9288</td>
<td>Hamm, Carolyn Ph.D.. Effects of Trendelenburg Position on Cardiopulmonary Parameters During Sleep (6/93)</td>
<td>38</td>
</tr>
<tr>
<td>9411</td>
<td>Patterson, Adrian COL DC. Evaluation of Collagen Plugs to Prevent Localized Osteitis in the Sockets of Mandibular Third Molars Susceptible to Acute Pericoronitis (1/91)</td>
<td>39</td>
</tr>
<tr>
<td>9412</td>
<td>Brousseau, Steven LTC DC. Comparison of Presurgical and Postsurgical Condylar Measurements as a Function of Orthognathic Surgical Fixation Technique (3/91)</td>
<td>40</td>
</tr>
<tr>
<td>9088</td>
<td>O'Connor, Francis CPT MC. Prevention of Low Back Pain in Military Basic Trainees (3/91)</td>
<td>41</td>
</tr>
<tr>
<td>8200</td>
<td>Grabenstein, John EdM, MS. Prescribed Medication Use Among Troops Deploying and Deployed to Somalia: Pharmacoepidemiologic Analysis (1/93)</td>
<td>42</td>
</tr>
<tr>
<td>1952</td>
<td>Oster, Charles COL MC. The Clinical Presentation of HIV Infected Patients at Walter Reed Army Medical Center (1/87)</td>
<td>43</td>
</tr>
<tr>
<td>2529</td>
<td>Turnicky, Ronald LTC MC. Pharyngeal Tonsillar Biopsy Protocol: Feasibility Study (6/93)</td>
<td>44</td>
</tr>
<tr>
<td>3370</td>
<td>Birx, Deborah LTC MC. A Phase I Study of the Safety and Immunogenicity of MNrpg 120/HIV-1 Vaccine Comparing HIV-1 Seropositive Subjects Previously Immunized with IIIB rpg120/HIV-1 Vaccine on Protocol VO200g and HIV-1 Seropositive Subjects Who Have Not Previously Received HIV (6/93)</td>
<td>45</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volumes II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6264</td>
<td>Robb, Merlin LTC MC. Perinatal HIV Infection: Epidemiology and Natural History (4/90)</td>
<td>46</td>
</tr>
<tr>
<td>6346</td>
<td>Robb, Merlin MAJ MC. Pediatric Vaccine Therapy: A Phase I, Feasibility Trial of Vaxsyn (rgp160 vaccine) in HIV Infected Symptomatic and Asymptomatic Children and Adolescents (1/93)</td>
<td>47</td>
</tr>
<tr>
<td>7243</td>
<td>Tomoshok, Lydia PhD. Psychiatric Natural History Study: Factors Related to Human Immunodeficiency Virus Transmission and Morbidity (4/90)</td>
<td>48</td>
</tr>
<tr>
<td>8802</td>
<td>Hawkes, Clifton LTC MC. VA Cooperative Study No. 298, Treatment of AIDS and AIDS Related Complex; Part I: Treatment of Patients with ARC (AZT Vs. Placebo) (4/88)</td>
<td>49</td>
</tr>
<tr>
<td>8803</td>
<td>Chung, Raymond COL MC. Core Protocol for HIV Developmental Diagnostics (Adults) (5/88)</td>
<td>50</td>
</tr>
<tr>
<td>8804</td>
<td>Chung, Raymond COL MC. The Natural History of HIV Infection and Disease in United States Military Beneficiaries (5/88)</td>
<td>51</td>
</tr>
<tr>
<td>8805</td>
<td>Konzelman, Joseph DDS. Natural History of Oral Manifestations of HIV Infection in a United States Military Population (10/88)</td>
<td>52</td>
</tr>
<tr>
<td>8806</td>
<td>Redfield, Robert LTC MC. Active Immunization of HIV Infected Patients with Recombinant GP160 HIV Protein: Phase I Study of Immunotherapy, Immunogenicity and Toxicity (11/88)</td>
<td>53</td>
</tr>
<tr>
<td>8812</td>
<td>Smith, Kathleen COL MC. The Investigation of the Cutaneous Manifestations of HIV Infection in Relation to the Onset, Severity and Progression of Disease, Dermatologic Natural History (5/89)</td>
<td>54</td>
</tr>
<tr>
<td>8814</td>
<td>Cortese, Linda RPh, MS. Pharmacoepidemiologic Study to Develop a Database to Document Variations in the Outcome of Illness Which May be Due to Drug Effects and To Document Patterns of Drug use in HIV Infected Patients (8/89)</td>
<td>55</td>
</tr>
<tr>
<td>8817</td>
<td>Johnson, Steven MAJ MC. The Effect of HIV Infection on the Initial Manifestations and Response to Treatment of Syphilis (11/89)</td>
<td>56</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>8818</td>
<td>Mayers, Douglas CDR MC. Prospective Study of the Emergence of Zidovudine Resistance in Patients Infected with the Human Immunodeficiency Virus who are Treated with Zidovudine (6/90)</td>
</tr>
<tr>
<td>8819</td>
<td>Redfield, Robert LTC MC. Active Immunization of Early HIV Infected Patients with Recombinant GP160 HIV Protein: Phase II Study of Toxicity, Immunotherapy, In Vivo Immunoregulation and Clinical Efficacy (9/90)</td>
</tr>
<tr>
<td>8820</td>
<td>Redfield, Robert LTC MC. A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1-111B Vaccine in HIV-1 Seropositive Adult Volunteers (9/90)</td>
</tr>
<tr>
<td>8825</td>
<td>Burrell, Linda MAJ MC. Role of Accessory Cells in Hematopoietic Suppression After HIV-Infection (10/91)</td>
</tr>
<tr>
<td>8826</td>
<td>Chung, Raymond COL MC. A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of the Use of Weekly Azithromycin as Prophylaxis Against the Development of Mycobacterium avium Complex Disease in HIV Infected People (7/92)</td>
</tr>
<tr>
<td>8827</td>
<td>Redfield, Robert LTC MC. Active Immunization of AZT-Treated HIV-Infected Patients with Recombinant GP160 HIV Protein: Phase I/II Study of Immunogenicity Toxicity, and Effect In Vivo Immunoregulation (8/92)</td>
</tr>
<tr>
<td>8828</td>
<td>Hawkes, Clifton LTC MC. Evaluation of SQ 32,756 (BV-araU) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV-Infected Patients (-38/-022) (ACTG 169) (12/92)</td>
</tr>
<tr>
<td>8829</td>
<td>Hawkes, Clifton LTC MC. A Phase III Comparative Study of Dapsone/Trimethoprim and Clindamycin/Primaquine Versus Trimethoprim/Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients with AIDS (ACTG 108) (12/92)</td>
</tr>
<tr>
<td>8830</td>
<td>Hawkes, Clifton LTC MC. A Pilot Study Evaluating Penicillin G and Cetriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals (ACTG 145) (2/93)</td>
</tr>
<tr>
<td>8831</td>
<td>Redfield, Robert, LTC MC. Active Immunization of Early HIV-Infected Pregnant Women with Recombinant GP160 HIV Protein: A Pilot Study of Toxicity, Dosing, Immunogenicity and Feasibility (4/93)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>8102</td>
<td>Isaac, Joseph MAJ DC. Carpal Tunnel Syndrome: An Occupational Hazard of the Dental Practice (9/93)</td>
<td>67</td>
</tr>
<tr>
<td>1504</td>
<td>Weiss, Raymond MD. CALGB 8662 Monitoring Circulating Breast Cancer Associated Antigens with the 15-3 Radioimmunoassay in Metastatic Breast Cancer (1/90)</td>
<td>68</td>
</tr>
<tr>
<td>1505</td>
<td>Weiss, Raymond MD. CALGB 8963 Psychological Adaptation of Survivors of Acute Leukemia (2/90)</td>
<td>69</td>
</tr>
<tr>
<td>1509</td>
<td>Weiss, Raymond MD. CALGB 9011 A Study of Fludarabine Vs. Chlorambucil Vs. Both Drugs for Chronic Lymphatic Leukemia (11/90)</td>
<td>70</td>
</tr>
<tr>
<td>1510</td>
<td>Weiss, Raymond MD. CALGB 9051 A Study of Combination Chemotherapy Plus Irradiation for Early Stage Hodgkin's Disease (11/90)</td>
<td>71</td>
</tr>
<tr>
<td>1511</td>
<td>Weiss, Raymond MD. CALGB 9081: An Intergroup Study of Rectal Cancer Adjuvant Therapy (11/90)</td>
<td>72</td>
</tr>
<tr>
<td>1513</td>
<td>Weiss, Raymond MD. CALGB 8923 Randomized Studies of Induction Therapy Adjuncts and Intensification Therapy Regimens for Older Patients with Acute Myelocytic Leukemia (12/90)</td>
<td>73</td>
</tr>
<tr>
<td>1514</td>
<td>Weiss, Raymond MD. CALGB 9021 Induction Therapy for Relapsed or Refractory Acute Myelocytic Leukemia or Blast Crisis of Chronic Myelocytic Leukemia (12/90)</td>
<td>74</td>
</tr>
<tr>
<td>1516-84</td>
<td>Weiss, Raymond MD. CALGB 8364: Immunological Diagnostic Studies in Adult ALL (10/83)</td>
<td>75</td>
</tr>
<tr>
<td>1517</td>
<td>Weiss, Raymond MD. CALGB 9013: Alpha Interferon and Cytarabine for Untreated Chronic Myelogenous Leukemia (2/91)</td>
<td>76</td>
</tr>
<tr>
<td>1518</td>
<td>Weiss, Raymond MD. CALGB 8761: Prognostic Implications of Chromosomal Abnormalities in Chronic Myelogenous Leukemia (2/91)</td>
<td>77</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
### DEPARTMENT OF MEDICINE
Cancer & Leukemia Group B (continued)

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1519</td>
<td>Weiss, Raymond MD. CALGB 9142 Comparison of Chemotherapy Vs. Chemohormonotherapy in Premenopausal Women with Stage II Receptor Positive Breast Cancer (3/91)</td>
<td>78</td>
</tr>
<tr>
<td>1520</td>
<td>Weiss, Raymond MD. CALGB 9143 Comparison of Combination Chemotherapy with the CAF Regimen Vs. A 16-week 6-Drug Regimen for Stage II Receptor Negative Breast Cancer (3/91)</td>
<td>79</td>
</tr>
<tr>
<td>1521-91</td>
<td>Weiss, Raymond MD. CALGB 9194: Comparison of Adjuvant Chemotherapy with Concurrent or Delayed Tamoxifen vs. Tamoxifen Alone in Postmenopausal Patients with Receptor Positive Stage II Breast Cancer (4/91)</td>
<td>80</td>
</tr>
<tr>
<td>1522-84</td>
<td>Weiss, Raymond MD. CALGB 8461: Cytogenic Studies in Acute Leukemia: A Companion to CALGB 8011, 8323, 8321, and 8411 (9/84)</td>
<td>81</td>
</tr>
<tr>
<td>1525-92</td>
<td>Weiss, Raymond M.D. CALGB 9130: A Trial of Chemotherapy and Radiation with or Without Carboplatin for Inoperable Lung Cancer (1/92)</td>
<td>82</td>
</tr>
<tr>
<td>1526-92</td>
<td>Weiss, Raymond M.D. CALGB 9140: A Phase III Study of CAF-Leucovorin vs. *CAF for Visceral Crisis Breast Cancer (1/92)</td>
<td>83</td>
</tr>
<tr>
<td>1527-92</td>
<td>Weiss, Raymond M.D. CALGB 9190: A Trial of Postoperative Interferon in Resected High Risk Melanoma (1/92)</td>
<td>84</td>
</tr>
<tr>
<td>1528-92</td>
<td>Weiss, Raymond M.D. CALGB 9195: A Trial of Adjuvant Chemoradiation vs. Observation After Gastric Resection of Adenocarcinoma (1/92)</td>
<td>85</td>
</tr>
<tr>
<td>1531-92</td>
<td>Weiss, Raymond MD, DAC. CALGB 9160: A Phase III Trial of High Dose Cyclophosphamide With G-CSF With or Without Amifostine (4/92)</td>
<td>86</td>
</tr>
<tr>
<td>1532-92</td>
<td>Weiss, Raymond M.D. CALGB 9261 A Phase I Study of Topotecan and Cisplatin (6/92)</td>
<td>87</td>
</tr>
<tr>
<td>1533-92</td>
<td>Weiss, Raymond MD. CALGB 9134: Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (11/92)</td>
<td>88</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1534-92</td>
<td>Weiss, Raymond MD. CALGB 9191: A Randomized Study of All-Trans Retinoic Acid vs Standard Induction Therapy for Acute Promyelocytic Leukemia (11/92)</td>
<td>89</td>
</tr>
<tr>
<td>1535-92</td>
<td>Weiss, Raymond MD. CALGB 9222: A Randomized Study of Intensification Therapy for Patients Under Age 60 with Acute Myelogenous Leukemia (11/92)</td>
<td>90</td>
</tr>
<tr>
<td>1536-92</td>
<td>Weiss, Raymond MD. CALGB 9263: Detection of Trisomy Genetic Change in Chronic Lymphatic Leukemia (11/92)</td>
<td>91</td>
</tr>
<tr>
<td>1537-92</td>
<td>Weiss, Raymond MD. CALGB 9162 Study of Pharmacokinetic Parameters in the Efficacy and Toxicity of 5-FU (12/92)</td>
<td>92</td>
</tr>
<tr>
<td>1538-92</td>
<td>Weiss, Raymond MD. CALGB 9163 A Randomized Study of Vinblastine with Modulators in Metastatic Renal Cancer (12/92)</td>
<td>93</td>
</tr>
<tr>
<td>1539-92</td>
<td>Weiss, Raymond MD. CALGB 9242 Topotecan for Advanced Breast Cancer (12/92)</td>
<td>94</td>
</tr>
<tr>
<td>1540-92</td>
<td>Weiss, Raymond MD. CALGB 9092 A Study of 5-Fluorouracil (5-FU) With or Without Modulators in Advanced Colorectal Cancer (12/92)</td>
<td>95</td>
</tr>
<tr>
<td>1541-93</td>
<td>Weiss, Raymond MD. CALGB 9153: A Trial of Cladribine in Advance Stage, Low Grade non-Hodgkin’s Lymphoma (3/93)</td>
<td>96</td>
</tr>
<tr>
<td>1542-93</td>
<td>Weiss, Raymond MD. CALGB 9154: A Comparison of Two Dose Levels of Chepe Combination Chemotherapy and G-CSF for Non-Hodgkin’s Lymphoma (3/93)</td>
<td>97</td>
</tr>
<tr>
<td>1544-86</td>
<td>Weiss, Raymond MD. CALGB 8525: A Phase III Comparative Study of Post-Remission Intensive Ara-C in Patients with Acute Nonlymphocytic Leukemia in First Remission (addendum CALGB 8661 Epidemiology of Acute Leukemias in Adults .... Cytogenically Determined Subgroups) (10/92)</td>
<td>99</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
DEPARTMENT OF MEDICINE
Cancer & Leukemia Group B (continued)

1544-93 Weiss, Raymond M.D. CALGB 9294. An Intergroup Study of Colon Cancer Adjuvant Therapy (5/93) 100

1545-93 Weiss, Raymond MD. WRAMC 9302. A WRAMC/NCI Collaborative Phase I Study of Taxol Given as a Continuous Infusion (6/93) 101

1546-93 Weiss, Raymond MD. CALGB 9362: A Phase I Study of Topotecan and Taxol (6/93) 102


1573-87 Weiss, Raymond MD. CALGB 8762: Molecular Subtypes in Acute Lymphatic Leukemia with Philadelphia Chromosome (10/87) 104

1574-87 Weiss, Raymond MD. CALGB 8763: Immunoglobulin and T Cell Receptor Gene Rearrangement in Adult Acute Lymphatic Leukemia (10/87) 105

1577-80 Weiss, Raymond MD. CALGB 8361: Immunologic Diagnostic Studies in AML (blood drawing phase); previously CALGB 7921: A Comparative Study of 3 Remission Induction Regimens and 2 Maintenance Regimens for AML (treatment phase); previously CALGB 8321 (12/81) 106

1579-88 Weiss, Raymond MD. CALGB 8861: Monitoring Circulating Breast Cancer-Associated 15-3 Antigen in Stage II Breast Cancer (1/88) 107

1590-89 Weiss, Raymond MD. CALGB 8852: A Study of CHOPE in Diffuse Lymphomas (1/89) 108

1595-89 Weiss, Raymond MD. CALGB 8961 RAS Mutations in Myelodysplasia (4/89) 109

1598-89 Weiss, Raymond MD. CALGB 8952 Combination Chemotherapy for Advanced Hodgkin's Disease, Phase III (8/89) 110

1685 Weiss, Raymond M.D. WRAMC 9301. A WRAMC/NCI Collaborative Phase I Study of Topotecan and Adriamycin (5/93) 111

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1260</td>
<td>Hull, Robert MAJ MC. Antiarrhythmic Therapy in Congestive Heart Failure, VA Cooperative Study #320 (10/89)</td>
<td>112</td>
</tr>
<tr>
<td>1264</td>
<td>Carter, Andrew MAJ MC. The Role of Tumor Necrosis Factor After Balloon Angioplasty in a Pig Model (10/90)</td>
<td>113</td>
</tr>
<tr>
<td>1265</td>
<td>Prewitt, Kerry CPT MC. Cardiac Safety of Sexual Intercourse Following Myocardial Infarction as Assessed by High Resolution Holter Monitor (10/90)</td>
<td>114</td>
</tr>
<tr>
<td>1267</td>
<td>Gorman, Patrick MAJ MC. Cholesterol and Recurrent Events (5/91)</td>
<td>115</td>
</tr>
<tr>
<td>1269</td>
<td>Carter, Andrew MAJ MC. The Porcine Restenosis Model: Characterization of the Vascular Proliferative Response to Injury (7/91)</td>
<td>116</td>
</tr>
<tr>
<td>1270</td>
<td>Wiley, Thomas MAJ MC. Electrophysiologic Identification of Concealed Accessory Pathway Conduction as a Potential Predisposing Factor in &quot;Lone&quot; Atrial Fibrillation (7/91)</td>
<td>117</td>
</tr>
<tr>
<td>1272</td>
<td>Cantilena, Louis MD PhD. Pharmacokinetic Drug Interactions with Terfenadine (10/91)</td>
<td>118</td>
</tr>
<tr>
<td>1273</td>
<td>Pearson, Clarence LTC MC. A Study Investigating the Safety and Duration of Effect of Isosorbide-5-Mononitrate in a Controlled-Release Formulation in Patients with Stable Effort Angina Pectoris (1/92)</td>
<td>119</td>
</tr>
<tr>
<td>1274</td>
<td>Hull, Robert MAJ MC. Transcoronary Mapping of Accessory Pathways in Patients Undergoing Percutaneous Accessory Pathway Radiofrequency Ablation (1/92)</td>
<td>120</td>
</tr>
<tr>
<td>1275</td>
<td>Laird, John MAJ MC. Percutaneous Balloon Pericardotomy for the Treatment of Pericardial Effusion/Tamponade (7/92)</td>
<td>121</td>
</tr>
<tr>
<td>1276</td>
<td>Pearson, Clarence LTC MC. CAVEAT II. A Study Investigating the Primary and Long-Term Outcome in Patients with De Novo Vein Graft Lesion Randomly Assigned to Either Balloon Angioplasty or Directional Atherectomy (8/92)</td>
<td>122</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
## DEPARTMENT OF MEDICINE

### Cardiology Service (continued)

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Investigator(s)</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1277</td>
<td>Campos, Miguel MAJ MC.</td>
<td>Side Branch Occlusion with Directional Coronary Atherectomy: Incidence and Risk Factors</td>
<td>123</td>
</tr>
<tr>
<td>1278</td>
<td>Cantilena, Louis, M.D., Ph.D.</td>
<td>Investigation of Non-Linear Pharmacokinetics and Electrocardiographic Pharmacodynamics of Terfenadine</td>
<td>124</td>
</tr>
<tr>
<td>1279</td>
<td>Cantilena, Louis Jr MD PhD.</td>
<td>Pharmacokinetic and Pharmacodynamic Interactions Between Terfenadine and Erythromycin</td>
<td>125</td>
</tr>
<tr>
<td>1280</td>
<td>Collier, Edward MAJ MC.</td>
<td>Treatment and Outcome of Acute Myocardial Infarction in a Military Medical Center: Participation in the National Registry</td>
<td>126</td>
</tr>
<tr>
<td>1281</td>
<td>Gorman, Patrick MAJ MC.</td>
<td>Coumadin-Aspirin Reinfarction Study</td>
<td>127</td>
</tr>
</tbody>
</table>

### DEPARTMENT OF MEDICINE

#### Dermatology Service

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Investigator(s)</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1815</td>
<td>James, William COL MC.</td>
<td>Investigation of a Viral Etiology in Pityriasis Rosea</td>
<td>128</td>
</tr>
<tr>
<td>1817</td>
<td>Turiansky, George MAJ MC.</td>
<td>5-Fluorouracil Iontophoretic Therapy for Bowenoid Conditions</td>
<td>129</td>
</tr>
<tr>
<td>1818</td>
<td>Beard, Jeffrey CPT MC.</td>
<td>Topical Corticosteroid Inhibition of Dermal Delayed Type Hypersensitivity</td>
<td>130</td>
</tr>
</tbody>
</table>

### DEPARTMENT OF MEDICINE

#### Endocrine-Metabolic Service

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Investigator(s)</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1311-88</td>
<td>Solomon, Barbara DNSc.</td>
<td>Incidence of Fractures in Post-Menopausal Women</td>
<td>131</td>
</tr>
<tr>
<td>1312-89</td>
<td>Glass, Allan COL MC.</td>
<td>Treatment of Oligospermia with Antiestrogens</td>
<td>132</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1316-89</td>
<td>Burman, Kenneth COL MC. Identification of Unique Nucleotides in the Thyroid Gland of Patients with Various Thyroid Disorders (7/89)</td>
<td>133</td>
</tr>
<tr>
<td>1324-90</td>
<td>Schaaf, Marcus MD. Use of Corticotropin Release Hormone in the Evaluation of Hypercortisolemia and Hypocortisolemia (5/90)</td>
<td>134</td>
</tr>
<tr>
<td>1328-90</td>
<td>Carr, Frances PhD. Mechanisms of Thyrotropin Releasing Hormone Regulation of Thyrotropin Gene Expression (10/90)</td>
<td>135</td>
</tr>
<tr>
<td>1329-90</td>
<td>Burch, Henry MAJ MC. Search for p53 Genetic Abnormalities in Tissue obtained from Normal and Pathological Thyroid Glands (12/90)</td>
<td>136</td>
</tr>
<tr>
<td>1330-90</td>
<td>Clement, Stephen MAJ MC. A 16 Week Double-Blind Placebo Controlled Dose Response Study Using Glipizide GITS Tablets for the Treatment of Noninsulin Dependent Diabetes Mellitus (12/90)</td>
<td>137</td>
</tr>
<tr>
<td>1331-91</td>
<td>Burman, Kenneth COL MC. Response of Multinodular Goiters with Substernal Extension to Therapeutic Doses of Iodine-131 (2/91)</td>
<td>138</td>
</tr>
<tr>
<td>1333-91</td>
<td>Lahiri, Sabita MS. Endothelin and Cultured Human Thyroid Cells (4/91)</td>
<td>139</td>
</tr>
<tr>
<td>1334-91</td>
<td>Clement, Stephen MAJ MC. A Search for Glycosylated Insulin in Patients with Non-Insulin Dependent Diabetes Mellitus (5/91)</td>
<td>140</td>
</tr>
<tr>
<td>1335-91</td>
<td>Francis, Thomas CPT MC. The Preparation of a Selective Pericentromeric Chromosome 10 YAC (Yeast Artificial Chromosome) DNA Library to Further Define MEN2 Gene Location (6/91)</td>
<td>141</td>
</tr>
<tr>
<td>1336-91</td>
<td>Burch, Henry MAJ MC. Investigation of Cross-Reactivity in the Immune Response Against the Human Thyrotropin Receptor and the HIV-1 New Protein in Rabbits (10/91)</td>
<td>142</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1337-91</td>
<td>Solomon, Barbara DNSc. Treatment of Graves' Disease with Cholestyramine (10/91)</td>
<td>143</td>
</tr>
<tr>
<td>1340-91</td>
<td>Duncan, William LTC MC. The Bone Mineral Density of Women Treated with Thyroid Hormone (12/91)</td>
<td>145</td>
</tr>
<tr>
<td>1341-92</td>
<td>Kushner, Jonathan MAJ MC. Recognition of Hospital Malnutrition by Primary Physicians (1/92)</td>
<td>146</td>
</tr>
<tr>
<td>1342-92</td>
<td>Burman, Kenneth COL MC. The Interaction of Steroids and Atrial Natriuretic Peptide in Cultured Thyroid Cells (2/92)</td>
<td>147</td>
</tr>
<tr>
<td>1344-92</td>
<td>Taylor, Thomas COL MC. The Vascular Endothelium: A Critical Site of Toxin Action (3/92)</td>
<td>149</td>
</tr>
<tr>
<td>1346-92</td>
<td>Nicholson, Diarmuid Ph.D., DAC. Development of a Quantitative Polymerase Chain Reaction for Vitamin D Receptor mRNA (4/92)</td>
<td>150</td>
</tr>
<tr>
<td>1348-92</td>
<td>Burch, Henry MAJ, MC. Combined Free Thyroxine and Sensitive TSH Testing in a Large Clinical Practice: Comparison with Conventional Thyroid Laboratory Testing in Patients with Various States of Thyroid Function and Acquired Binding Protein Abnormality (5/92)</td>
<td>151</td>
</tr>
<tr>
<td>1349-92</td>
<td>Burch, Henry MAJ MC. Acute Changes in Total and Free Thyroid Hormone Levels Following Radioiodine Ablation Therapy in the Treatment of Graves' Disease (5/92)</td>
<td>152</td>
</tr>
<tr>
<td>1350-92</td>
<td>Torrens, Javier CPT MC. The Effect of Etidronate on Bone Mineral Density (BMD) in Patients on Levothyroxine Suppression (8/92)</td>
<td>153</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service (continued)

1351-92 Solomon, Barbara DNSc. The Management of Papillary Thyroid Carcinoma in the United States (10/92) 154

1352-92 Lasswell, William MAJ MC. Effects of 1,25-Dihydroxyvitamin D on the Growth of Human Breast Carcinoma Cells in Culture (11/92) 155

1353-92 Lasswell Jr, William MAJ MC. Effects of Administration of the Contrast Agent Hexabrix on Thyroid Function Tests and Thyroid Uptake of Iodine (11/92) 156

1354-92 Burman, Kenneth COL MC. Analysis of MHC Bound Peptides on the Surface of Epithelial Cells (11/92) 157

1355-92 Bernet, Victor CPT MC. Longitudinal Study on Bone Metabolism in Patients Receiving Sequentially Increasing Doses of Levothyroxine (12/92) 158

1356-92 Burman, Kenneth COL MC. L-Tryptophan Eosinophilia Myalgia Syndrome (91-M-12) and Other Autoimmune Disorders (12/92) 159

1357-92 Burman, Kenneth COL MC. The Effects of Arginine Vasopressin Administration on Neuroendocrine Response and Cognition in Patients with Major Psychiatric Illness (12/92) 160

1358-92 Burman, Kenneth COL MC. Dose Dependent Effects of Graded Exercise on Hypothalamic-Pituitary Adrenal Function in Patients with Putative Central Adrenal Insufficiency (12/92) 161

1359-92 Lahiri, Sabita MS. Interactions of Cytokines, Thyrotropin, and Iodide in the Thyroid Gland (12/92) 162

1360-93 Burman, Kenneth COL MC. Identification of Mutations by Single Stranded Conformational Polymorphisms (SSCP) (3/93) 163

1361-93 Burman, Kenneth COL MC. Development of Graves' Disease and Graves' Ophthalmopathy in Patients with Hodgkin's Disease: Relationship to Prior History of Radiation Therapy (3/93) 164

1362-93 Bernet, Victor CPT MC. Nycotohemeral Plasma Concentrations of TSH and FT4 in Patients Receiving Suppressive Doses of LT4 (3/93) 165

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1371-86</td>
<td>Glass, Allan COL MC. Transplantation Antigens on Spermatozoa</td>
<td>166</td>
</tr>
<tr>
<td></td>
<td>(11/85)</td>
<td></td>
</tr>
<tr>
<td>1385-87</td>
<td>Burman, Kenneth COL MC. Molecular Biology of Thyroid Disease</td>
<td>167</td>
</tr>
<tr>
<td></td>
<td>(10/86)</td>
<td></td>
</tr>
<tr>
<td>1812</td>
<td>Burman, Kenneth COL MC. Oncogenes in Basal Cell Nevus Syndrome, Cowden's Disease and Tore's Disease (9/89)</td>
<td>168</td>
</tr>
<tr>
<td>DEPARTMENT OF MEDICINE</td>
<td>Gastroenterology Service</td>
<td></td>
</tr>
<tr>
<td>1404</td>
<td>Moses, Frank LTC MC. Treatment of the Microscopic Colitis/Collagenous Colitis Syndrome with Sulfasalazine: A Double-Blind Crossover Controlled Trial (12/88)</td>
<td>169</td>
</tr>
<tr>
<td>1406</td>
<td>Cheney, Christopher LTC MC. Campylobacter Pylori: Serologic Studies as a Measure of Efficacy of Treatment (3/89)</td>
<td>170</td>
</tr>
<tr>
<td>1407</td>
<td>Wong, Roy COL MC. Effectiveness of Pneumatic Dilations in the Treatment of Achalasia (4/89)</td>
<td>171</td>
</tr>
<tr>
<td>1408</td>
<td>Wong, Roy COL MC. Nocturnal Gastroesophageal Reflux--Factors Associated with Reflux Events: A Retrospective Review of 24 Hour Esophageal pH Monitoring Data (5/89)</td>
<td>172</td>
</tr>
<tr>
<td>1410</td>
<td>Moses, Frank LTC MC. Open Label Trial of Low Dose Oral Pulse Methotrexate Therapy for Primary Sclerosing Cholangitis (10/89)</td>
<td>173</td>
</tr>
<tr>
<td>1411</td>
<td>DeMarkles, Michael CPT MC. The Effect of Lithium Carbonate on Gastric Emptying and Gastrointestinal Hormones in Humans: A Double Blind Randomized Study (1/90)</td>
<td>174</td>
</tr>
<tr>
<td>1412</td>
<td>Sjogren, Maria COL MC. Clinical and Serologic Evaluation of Blood Donors at Walter Reed Army Medical Center (2/90)</td>
<td>175</td>
</tr>
<tr>
<td>1413</td>
<td>Kikendall, J. Walter COL MC. Large Bowel Adenomatous Polyp Dietary Intervention Study-Clinical Centers (2/90)</td>
<td>176</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1415</td>
<td>Sjogren, Robert COL MC. The Compassionate Use of Cisapride in the Treatment of Patients with Refractory Nonulcer Dyspepsia, Diabetic Gastroparesis with Intolerance to Metoclopramide and Chronic Intestinal Pseudo-obstruction (4/90)</td>
<td>177</td>
</tr>
<tr>
<td>1417</td>
<td>Wong, Roy COL MC. Incidence of Gastric Mucosal Injury in Patients Ingesting Liquid Versus Solid Ibuprofen (6/90)</td>
<td>178</td>
</tr>
<tr>
<td>1418</td>
<td>Moses, Frank LTC MC. Prospective Evaluation of 99mTcTechnetium Sulfur Colloid Liver Spleen Scan and 99mTcTechnetium Mebrofenin Hepatobiliary Radionuclide Scan for Diagnosis of Diffuse Hepatocellular Disease (6/91)</td>
<td>179</td>
</tr>
<tr>
<td>1420</td>
<td>Sjogren, Maria COL MC. Household Transmission of Hepatitis C Virus in Military Populations (11/91)</td>
<td>180</td>
</tr>
<tr>
<td>1421</td>
<td>Sjogren, Maria COL MC. A Randomized, Controlled Trial of Interferon Alpha and Thymosin Alpha l in Patients with Hepatitis C Antibody Positive Chronic Active Hepatitis (11/91)</td>
<td>181</td>
</tr>
<tr>
<td>1422</td>
<td>Sjogren, Maria COL MC. Significance and Natural History of Detectable Hepatitis C Antibody in Military Populations (11/91)</td>
<td>182</td>
</tr>
<tr>
<td>1423</td>
<td>Kikendall, James COL MC. Intermediate Markers of Colonic Neoplasia (3/92)</td>
<td>183</td>
</tr>
<tr>
<td>1425</td>
<td>Yavorski, Robert CPT MC. Evaluation of Gastroesophageal Reflux as a Cause of Hoarseness: Evaluation of Pepsin as a Marker of Reflux-Induced Esophageal Injury (7/93)</td>
<td>184</td>
</tr>
<tr>
<td>1497</td>
<td>Wong, Roy COL MC. The Effect of Indomethacin on Rectosigmoid Mucosal Blood Flow and Rectosigmoid Mucosal Prostaglandin Levels in Humans (10/87)</td>
<td>185</td>
</tr>
<tr>
<td>1498</td>
<td>Cremins, James CPT MC. Pathophysiology and Treatment for Non-Ulcer Dyspepsia (Using Cisapride) (12/87)</td>
<td>186</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1029</td>
<td>Kroenke, Kurt LTC MC. Common Symptoms in Ambulatory Medicine: The Effects of Attributions and Expectations on Symptom Outcome and Patient Satisfaction (1/92)</td>
<td>187</td>
</tr>
<tr>
<td>1030</td>
<td>Kroenke, Kurt LTC MC. Development of a Primary Care Evaluation of Mental Disorders System (PRIME-MD) (1/92)</td>
<td>188</td>
</tr>
<tr>
<td>1031</td>
<td>Kroenke, Kurt LTC MC. Advance Directives: Implementation into Clinical Practice (2/92)</td>
<td>189</td>
</tr>
<tr>
<td>1032</td>
<td>O'Malley, Patrick CPT MC. Value of the PRIME-MD Questionnaire Prior to Upper Endoscopy (1/93)</td>
<td>190</td>
</tr>
<tr>
<td>1033</td>
<td>Byrd, John CPT MC. Funguria in a Tertiary Care Medical Center (5/93)</td>
<td>191</td>
</tr>
<tr>
<td>1523-91</td>
<td>Weiss, Raymond M.D. CALGB 9111. A Trial of G-CSF vs Placebo During Remission Induction and Consolidation Chemotherapy for Adult Acute Lymphatic Leukemia (10/91)</td>
<td>192</td>
</tr>
<tr>
<td>1524-91</td>
<td>Dawson, Nancy LTC MC. A NCI/WRAMC Collaborative Phase I Trial of Suramin in Patients with Advanced Solid Tumors (11/91)</td>
<td>193</td>
</tr>
<tr>
<td>1530-92</td>
<td>Weiss, Raymond MD. CALGB 9181. A Comparative Study of Two Doses of Megace in Advanced Prostate Cancer (3/92)</td>
<td>194</td>
</tr>
<tr>
<td>1668-89</td>
<td>Burrell, Linda MAJ MC. WRAMC 8904: High Dose Chemotherapy and Autologous Bone Marrow Transplantation for Poor Prognosis Lymphomas, Phase II (8/89)</td>
<td>195</td>
</tr>
<tr>
<td>1669-89</td>
<td>Burrell, Linda MAJ MC. WRAMC 8905: Chemotherapy with Autologous Bone Marrow Support for Selected Advanced Solid Tumors, Phase II (9/89)</td>
<td>196</td>
</tr>
<tr>
<td>1676</td>
<td>Alving, Barbara COL MC. Detection of Lupus Anticoagulants in Patients with Anticardiolipin Antibodies (9/90)</td>
<td>197</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1677</td>
<td>Burrell, Linda MAJ MC. Fludarabine Phosphate (FAMP: NSC-312887) in Compassionate Circumstances (4/91)</td>
<td>198</td>
</tr>
<tr>
<td>1680</td>
<td>Ward, Frank LTC MC. An Open Protocol for the Use of Agrelin (Anagrelide) for Patients with Thrombocytopenia (11/91)</td>
<td>199</td>
</tr>
<tr>
<td>1681</td>
<td>Hartman, Kip LTC MC. Characterization of Human Autoantibodies to Neutrophils and to Bone Marrow Myeloid Precursor Cells (4/92)</td>
<td>200</td>
</tr>
<tr>
<td>1682</td>
<td>Reid, Thomas, MAJ MC. Solvent/Detergent Treated Pooled Human Plasma for Patients with Coagulopathies Requiring Fresh Frozen Plasma (10/92)</td>
<td>201</td>
</tr>
<tr>
<td>1683</td>
<td>Reid, Thomas MAJ MC. Intravenous Anti-Rho(D) [WinRhoSD Preparation] for the Treatment of Immune Thrombocytopenic Purpura (11/92)</td>
<td>202</td>
</tr>
<tr>
<td>1684</td>
<td>Wiesen, Andrew CPT MC. Equilibration of Hemoglobin After Transfusion (12/92)</td>
<td>203</td>
</tr>
<tr>
<td>1686</td>
<td>Reid, Thomas MAJ MC. Studies of the Proliferation and Differentiation of Pluripotent Stem Cells and Committed Hematopoietic Precursors from Human Bone Marrow Maintained in Continuous Long-Term Cultures (9/93)</td>
<td>204</td>
</tr>
<tr>
<td>9022-83</td>
<td>Reid, Thomas MAJ MC. Studies of the Proliferation and Differentiation of Pluripotent Stem Cells and Committed Hematopoietic Precursors from Normal Bone Marrow Maintained in Continuous Long-term Cultures (10/82)</td>
<td>205</td>
</tr>
</tbody>
</table>

DEPARTMENT OF MEDICINE
Infectious Disease Service

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1965</td>
<td>Johnson, Steven MAJ MC. Treatment of Cutaneous Leishmaniasis with Pentostam (2/89)</td>
<td>206</td>
</tr>
<tr>
<td>1967</td>
<td>Cross, Alan COL MC. Pharmacokinetics of Polyvalent Hyperimmune Globulin Directed Against Pseudomonas and Klebsiella (6/89)</td>
<td>207</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
DEPARTMENT OF MEDICINE
Infectious Disease Service (continued)

1975  Kester, Kent MAJ MC. A Retrospective Analysis of Corynebacterial Bacteremias at Walter Reed Army Medical Center (9/93) 208

DEPARTMENT OF MEDICINE
Nephrology Service

1157  Moore, Jack LTC MC. Effects of Thyroid Hormone and Thyrotropin (TSH) on Cultured Kidney Cells: Modulation of ANP Receptors and Epithelial Function (11/88) 209

1161  Yuan, Christina CPT MC. Mechanisms of Action of Thiorphan and Atrial Natriuretic Peptide on Renal Function During Hemorrhagic Shock (11/90) 210

1162  Carome, Michael CPT MC. The Regulation of Insulin-like Growth Factor I and Insulin-like Growth Factor Binding Protein Gene Expression in the Mouse Glomerulus (1/91) 211

1163  Yuan, Christina CPT MC. Effects of Cyclosporin A on the Production of Vasoactive Hormones by Endothelial Cells in Culture (3/91) 212

1164  Moore, Jack LTC MC. Synthesis and Degradation of Collagen and Modulation of its Biology in Sclerosing Forms of Human Glomerulonephritis: Analysis of Gene Expression (4/91) 213

1165  Bohen, Erin CPT MC. The Effects of Cisplatin on the Production of Endothelin and Other Vasoactive Hormones by Endothelial Cells in Culture (8/91) 214

1166  Yuan, Christina CPT MC. The Effects of Gentamicin on the Production of Vasoactive Hormones by Endothelial Cells in Culture (11/91) 215

1167  Bohen, Erin CPT MC. The Effect of Enalapril on Hypertension, Proteinuria, and Renal Function in a New Model of Diabetes Mellitus in Wistar Rats (11/91) 216

1168  Bohen, Erin CPT MC. The Acute Effect of Enalapril on Hypertension in a New Model of Hypertension Associated with Diabetes Mellitus in Wistar Rats (1/92) 217

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1169</td>
<td>Welch, Paul MAJ MC. Safety and Immunogenicity of Staphylococcus Aureus Capsular Polysaccharide - Pseudomonas Aeruginosa, r-exoprotein A type 5 Conjugate Vaccine Given to Patients with End-Stage Renal Disease (ESRD) (2/92)</td>
<td>218</td>
</tr>
<tr>
<td>1170</td>
<td>Yuan, Christina MAJ MC. Stress Proteins and Cytoprotection in MDCK Cells in Culture (9/92)</td>
<td>219</td>
</tr>
<tr>
<td>1171</td>
<td>Carome, Michael CPT MC. Analysis of the Distribution of Cellular Uptake of radiolabeled Oligodeoxynucleotides Within the Rat kidney (6/93)</td>
<td>220</td>
</tr>
<tr>
<td>1172</td>
<td>Carome, Michael MAJ MC. Analysis of Glomerular Gene Expression in Diabetic Nephropathy (6/93)</td>
<td>221</td>
</tr>
<tr>
<td>1173</td>
<td>Popham, Sandy CPT MC. Relationship of Heat Shock Protein expression to Proliferation in Mesangial Cells (9/93)</td>
<td>222</td>
</tr>
<tr>
<td>3011</td>
<td>Poropatich, Ronald MAJ MC. Comparison of Work of Breathing During Mechanical Ventilation Using Assist Control and Intermittent Mandatory Ventilation (2/91)</td>
<td>223</td>
</tr>
<tr>
<td>1707</td>
<td>Rajagopal, Krishnan LTC MC. Relationship Between Respiratory Control Mechanisms and Nocturnal Desaturation in Diffuse Pulmonary Fibrosis (2/81)</td>
<td>224</td>
</tr>
<tr>
<td>1724</td>
<td>Dillard, Thomas LTC MC. Mechanisms of Hypoxia During Simulated Air Travel in Patients with Chronic Obstructive Pulmonary Disease (1/88)</td>
<td>225</td>
</tr>
<tr>
<td>1725</td>
<td>Rajagopal, Krishnan LTC MC. Evaluation of Inspiratory Parameters in the Response to Inhaled Bronchodilators (2/88)</td>
<td>226</td>
</tr>
<tr>
<td>1726</td>
<td>Rajagopal, Krishnan LTC MC. Physiologic Assessment of Exercise Limitation in Upper Airway Obstruction (2/88)</td>
<td>227</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1736</td>
<td>Poropatich, Ronald MAJ MC. Treatment of Pulmonary Sarcoïdosis with High Dose Inhaled Triamcinolone Acetonide (1/90)</td>
<td>228</td>
</tr>
<tr>
<td>1737</td>
<td>Dillard, Thomas MAJ MC. Predicting Exercise Responses in COPD Patients (2/90)</td>
<td>229</td>
</tr>
<tr>
<td>1739</td>
<td>Eliasson, Arn MAJ MC. VA Cooperative Study No. 316: Efficacy of Passive Immunization in the Prevention of Infection due to Klebsiella Pneumoniae and Pseudomonas Aeruginosa (7/90)</td>
<td>230</td>
</tr>
<tr>
<td>1743</td>
<td>Hnatiuk, Oleh CPT MC. Maximum Inspiratory Flow Rate as a Determinant of Maximum Voluntary Ventilation in Normal Patients and Patients with Obstructive Lung Disease (10/90)</td>
<td>231</td>
</tr>
<tr>
<td>1746</td>
<td>Hnatiuk, Oleh MAJ MC. Clinical Utility of Post-Thoracentesis Radiography (4/91)</td>
<td>232</td>
</tr>
<tr>
<td>1749</td>
<td>Torrington, Kenneth COL MC. Air Transport of Patients with Pulmonary Defects (9/91)</td>
<td>233</td>
</tr>
<tr>
<td>1751</td>
<td>Torrington, Kenneth LTC MC. Postoperative Pulmonary Changes Following Laparoscopic vs. Right Subcostal Cholecystectomy (11/91)</td>
<td>234</td>
</tr>
<tr>
<td>1752</td>
<td>Hurwitz, Kenneth CPT MC. Eucapnic Voluntary Hyperventilation as a Bronchoprovocation Technique: Comparison with Methacholine Inhalation in Asthmatics (2/92)</td>
<td>235</td>
</tr>
<tr>
<td>1753</td>
<td>Parker, Joseph MAJ MC. Accuracy of Predicted Normal Values in Clinical Spirometry (6/92)</td>
<td>236</td>
</tr>
<tr>
<td>1754</td>
<td>Kumke, Kevin, CPT MC. The Effects of Buspirone on Respirat on in Asthma Patients (6/92)</td>
<td>237</td>
</tr>
<tr>
<td>1758</td>
<td>Parker, Joseph CPT MC. Withholding and Withdrawing Life-Sustaining Treatment from Patients in the Intensive Care Unit (12/92)</td>
<td>238</td>
</tr>
<tr>
<td>1759</td>
<td>Torrington, Kenneth LTC MC. Postoperative Pulmonary Changes Following Video Assisted Thoracic Surgery versus Lateral Thoracotomy (1/93)</td>
<td>239</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
1760  Lepler, Lawrence CPT MC. The Utility of Capnography and Transcutaneous Capnometry in the Evaluation of Airflow Obstruction and Gas Exchange in Obstructive Lung Disease (3/93)  240

1761  Hnatiuk, Oleh MAJ MC. Adherence to Established Guidelines for Preoperative Pulmonary Function Testing (7/93)  241

1762  Torrington, Kenneth LTC MC. Determination of Bronchoalveolar Lavage Volume Required for Diagnosis of Pneumocystis Carinii Pneumonia in Immunocompromised Patients (9/93)  242

1763  Doyle, James CPT MC. Airway Hyperreactivity in Rheumatoid Arthritis (9/93)  243

1764  Argyros, Gregory MAJ MC. Eucapnic Voluntary Hyperventilation (EVH) as a Bronchoprovocation Technique: An Analysis of the Late Phase Response After EVH in Asthmatics (9/93)  244

9280  Derderian, Sarkis LTC MC. Sleep and Respiratory Control in Kyphoscoliosis (2/90)  245

DEPARTMENT OF MEDICINE
Rheumatology Service

3704  Klipple, Gary COL MC. Iontophoresis Therapy for Rheumatoid Arthritis (4/89)  246

3705  Klipple, Gary COL MC. Iontophoresis Therapy for Osteoarthritis (4/89)  247

3706  Klipple, Gary COL MC. Iontophoresis Therapy for Bursitis and Tendinitis (4/89)  248

3707  Hartman, Kip MAJ MC. A Study of Autoantibodies to Neutrophil Integrin Proteins in Patients with Rheumatoid Arthritis (8/90)  249

3710  Dennis, Greg LTC MC. Effects of Anti-IgD-dextran Conjugates on Human B Lymphocyte Antibody Production (11/91)  250

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3711</td>
<td>Tsokos, George MAJ MC. Lymphocyte Abnormalities in Patients with Systemic Lupus Erythematosus (10/91)</td>
<td>251</td>
</tr>
<tr>
<td>3712</td>
<td>Tsokos, George MAJ MC. Autoreactive T Lymphocytes in the Pathogenesis of Systemic Sclerosis (5/92)</td>
<td>252</td>
</tr>
<tr>
<td>3713</td>
<td>Tesar, Joseph MD DAC. Antiphospholipid Antibody Syndrome (APAS): Role of Antiphospholipid Antibodies (APLA) and B2-glycoprotein (gp)-I in the Clinical Manifestations of APAS (5/92)</td>
<td>253</td>
</tr>
<tr>
<td>3716</td>
<td>Dennis, Gregory LTC MC. A Prospective Evaluation of Indeterminate Western Blot Patterns in Patients with Autoimmune Disorders (6/93)</td>
<td>254</td>
</tr>
<tr>
<td>3717</td>
<td>Tesar, Joseph MD. Plasma Endothelin-1 Levels After Cold Provocation in Hypothyroidism (8/93)</td>
<td>255</td>
</tr>
</tbody>
</table>

**NEUROLOGY SERVICE**

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7136</td>
<td>Salazar, Andres COL MC. An Investigation of Frontal Lobe Mediated Knowledge Representation (2/88)</td>
<td>256</td>
</tr>
<tr>
<td>7141</td>
<td>Salazar, Andres COL MC. Recombinant Beta Interferon as Treatment for Multiple Sclerosis: A Multicenter Protocol (2/89)</td>
<td>257</td>
</tr>
<tr>
<td>7142</td>
<td>Salazar, Andres COL MC. Intramuscular Poly-ICLC and CCNU in the Management of Malignant Gliomas: An Open Trial (3/89)</td>
<td>258</td>
</tr>
<tr>
<td>7144</td>
<td>Salazar, Andres COL MC. A Controlled Efficacy Study of a Brief Multidisciplinary Brain Injury Rehabilitation Program in Moderately Head Injured Service Members (7/90)</td>
<td>259</td>
</tr>
<tr>
<td>7146</td>
<td>Jabbari, Bahman COL MC. Investigation of Cardiac and Cerebrovascular Effects of the Diving Reflex (12/90)</td>
<td>260</td>
</tr>
<tr>
<td>7147</td>
<td>Jabbari, Bahman COL MC. Investigation of the Localizing Value of Clinical Signs Observed During Epileptic Seizures (4/91)</td>
<td>261</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE
BY DEPARTMENT AND SERVICE

PROTOCOL
NUMBER
PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE

NEUROLOGY SERVICE (continued)

7148 Rosenberg, Michael Col MC. Computer Modelling of Pupillary Light Reflexes (11/91) 262

7149 Jabbari, Bahman COL MC. Investigation of the Yield of Magnetic Motor Evoked Potentials in Neurosurgical Disorders: Spinal Cord and Posterior Fossa Lesions and Hydrocephalus (7/92) 263

7150 Jabbari, Bahman COL MC. Investigation of the Effectiveness of Botulinum Toxin-A Against Increased Muscle Tone (9/92) 264

7151 Kobylarz, Erik MAJ MC. Retinal Modulation of Pupil Size (3/93) 265

7152 Kobylarz, Erik CPT MC. The Role of GABA in the Control of Ventilation in the Cirrhotic Rat Model (3/93) 266

7153 Sinoff, Stuart MAJ MC. Extraocular Muscle Balance in Carino-Cervical Dystonia and Normal Subjects (3/93) 267

7154 Salazar, Andres COL MC. Defense and Veterans Head Injury Program (DVHIP): WRAMC Core Evaluation Protocol (8/93) 268

7155 Maldonado, Janice CPT MC. Investigation of the Effect of Solitary Brain Stem Lesion on Sleep Architecture (8/93) 269

DEPARTMENT OF NURSING

7521 Rich, Irene LTC AN. Pregnancy Attitudes, Ambivalence and Symptom Distress (12/90) 270

7525 Gurney, Cynthia LTC AN. Determinants of Effective Coping and Adaptation Among Army Medical Department Soliders During Operation Desert Storm (4/91) 271

7526 Petrov, Jean RN MS. The Effect of a Self Learning Module for Cancer Pain Management on Nurses’ Knowledge, Interventions, and Pain Relief for Cancer Patients (7/91) 272

7527 Shotkin, Jane RN. Use of an Indwelling Peripheral Catheter for 3-5 Days Sequential Chemotherapy Doses in the Outpatient Setting (1/92) 273

* Reference is to page number(s) in Volume II.
### DEPARTMENT OF NURSING (continued)

<table>
<thead>
<tr>
<th>Number</th>
<th>Investigator</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7529</td>
<td>Jones, Kathleen RN MS</td>
<td>The Oncology Patient's Experience in Making a Treatment Decision (12/92)</td>
<td>274</td>
</tr>
<tr>
<td>7532</td>
<td>Rich, Irene LTC AN</td>
<td>Psychology of Pregnancy: Peace and War-Time (8/93)</td>
<td>275</td>
</tr>
<tr>
<td>7533</td>
<td>Sarnecky, Mary COL AN</td>
<td>A History of the Army Nurse Corps (8/93)</td>
<td>276</td>
</tr>
<tr>
<td>7534</td>
<td>Gurney, Cynthia LTC AN</td>
<td>Quality of Life in Soldiers with HIV Infection (9/93)</td>
<td>277</td>
</tr>
<tr>
<td>8302</td>
<td>DeCesare, Elaine LTC AN</td>
<td>Army Women's Breast Cancer Risk (8/93)</td>
<td>278</td>
</tr>
</tbody>
</table>

### NUTRITION CARE DIRECTORATE

<table>
<thead>
<tr>
<th>Number</th>
<th>Investigator</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9305</td>
<td>Smith, Sandra RD CNSD</td>
<td>Evaluation of Nutritional Needs Based on Non-Protein Calories Versus Total Calories in Total Parenteral Nutrition (TPN) (6/93)</td>
<td>279</td>
</tr>
</tbody>
</table>

### DEPARTMENT OF OBSTETRICS AND GYNECOLOGY

<table>
<thead>
<tr>
<th>Number</th>
<th>Investigator</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4304</td>
<td>Farley, John CPT, MC</td>
<td>Evaluation of Inflammatory Pap Smears (1/92)</td>
<td>280</td>
</tr>
<tr>
<td>4307</td>
<td>Teneriello, Michael LCDR MC</td>
<td>The Role of the P53 and Rasw Oncogenes in the Development of Malignant and Premalignant Lesions of the Female Genital Tract (5/92)</td>
<td>281</td>
</tr>
</tbody>
</table>

### DEPARTMENT OF OBSTETRICS AND GYNECOLOGY

Gynecologic Oncology Group

<table>
<thead>
<tr>
<th>Number</th>
<th>Investigator</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4113</td>
<td>Mayer, Allan COL MC</td>
<td>Cooperative Gynecologic Oncology Group (1/74)</td>
<td>282</td>
</tr>
<tr>
<td>4163</td>
<td>Mayer, Allan COL MC</td>
<td>GOG 26C: A Phase II Trial of Cis-platinum in the Treatment of Advanced Gyn Cancer (3/79)</td>
<td>283</td>
</tr>
<tr>
<td>4187</td>
<td>Mayer, Allan COL MC</td>
<td>GOG 26N: A Phase II Trial of Dihydroxyanthracenedione (DHAD) in Patients with Advanced Pelvic Malignancies (4/81)</td>
<td>284</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4203</td>
<td>Mayer, Allan LTC(P) MC. GOG 26Q: A Phase II Trial of Aminothiadiazole in Patients with Advanced Pelvic Malignancies (1/83)</td>
</tr>
<tr>
<td>4212</td>
<td>Mayer, Allan COL MC. GOG 72: Ovarian Tumors of Low Malignant Potential: A Study of the Natural History and a Phase II Trial of Melphalan and Secondary Treatment with Cisplatin in Patients with Progressive Disease (5/84)</td>
</tr>
<tr>
<td>4225</td>
<td>Mayer, Allan COL MC. GOG 71: Treatment of Patients with Suboptimal (Bulky) Stage IB Carcinoma of the Cervix: A Randomized Comparison of Radiation Therapy Vs. Radiation Therapy plus Adjuvant Extrafascial Hysterectomy, Phase III (7/85)</td>
</tr>
<tr>
<td>4229</td>
<td>Mayer, Allan COL MC. GOG 86A: Master Protocol for Phase II Drug Studies in Treatment of Advanced or Recurrent Carcinoma of the Endometrium (4/86)</td>
</tr>
<tr>
<td>4231</td>
<td>Mayer, Allan COL MC. GOG 87A: Master Protocol for Phase II Drug Studies in the Treatment of Recurrent or Advanced Uterine Sarcomas (5/86)</td>
</tr>
<tr>
<td>4232</td>
<td>Mayer, Allan COL MC. GOG 87B: A Phase II Trial of Ifosfamide and the Uroprotector, Mesna, in the Treatment of Recurrent or Advanced Uterine Sarcomas (5/86)</td>
</tr>
<tr>
<td>4234</td>
<td>Mayer, Allan COL MC. GOG 26U: A Phase II Trial of Ifosfamide and the Uroprotector, Mesna, in Patients with Advanced Pelvic Malignancies (8/86)</td>
</tr>
<tr>
<td>4244</td>
<td>Mayer, Allan COL MC. GOG 90: Evaluation of Cisplatin, Etoposide and Bleomycin (BEP) Induction Followed by Vincristine, Dactinomycin and Cyclophosphamide (VAC) Consolidation in Advanced Ovarian Germ Cell Tumors, Phase II (3/87)</td>
</tr>
<tr>
<td>4247</td>
<td>Mayer, Allan COL MC. GOG 95: Randomized Clinical Trial for the Treatment of Women with Selected Stage IC and II (A,B,C) and Selected Stage IAI and IBi and IAii and IBii Ovarian Cancer, Phase III (5/87)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>4254</td>
<td>Mayer, Allan COL MC. GOG 93: Evaluation of Intraperitoneal Chromic Phosphate Suspension Therapy Following Negative Second-Look Laparotomy for Epithelial Ovarian Carcinoma, Stage III, Phase III (7/87)</td>
</tr>
<tr>
<td>4255</td>
<td>Mayer, Allan COL MC. GOG 78: Evaluation of Adjuvant Vinblastine, Bleomycin and Cisplatin Therapy in Totally Reducing Choriocarcinoma, Endodermal Sinus Tumor or Embryonal Carcinoma of the Ovary, Pure and Mixed with Other Elements, Phase II (9/87)</td>
</tr>
<tr>
<td>4257</td>
<td>Mayer, Allan COL MC. GOG 99: A Phase III Randomized Study of Adjunctive Radiation Therapy in Intermediate Risk Endometrial Adenocarcinoma (10/87)</td>
</tr>
<tr>
<td>4262</td>
<td>Mayer, Allan COL MC. A Multicenter Randomized Trial of Adjuvant Cisplatin/Bleomycin Plus Whole Pelvis Irradiation Vs. Cisplatin/Bleomycin Alone in High Risk Stage IB and IIA Carcinoma of the Cervix (5/88)</td>
</tr>
<tr>
<td>4263</td>
<td>Mayer, Allan COL MC. GOG 26X: A Phase II Trial of Gallium Nitrate in Patients with Advanced Pelvic Malignancies (6/88)</td>
</tr>
<tr>
<td>4265</td>
<td>Mayer, Allan COL MC. GOG 102 A (Master Protocol): Intraperitoneal Administration of Cisplatin and 5-FU in Residual Ovarian Carcinoma, Phase II (6/88)</td>
</tr>
<tr>
<td>4266</td>
<td>Mayer, Allan COL MC. GOG 76A: Master Protocol for Phase II Drug Studies in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Cervix. (7/88)</td>
</tr>
<tr>
<td>4268</td>
<td>Mayer, Allan COL MC. GOG 26DD: A Phase II Trial of Amonafide in Patients with Advanced Pelvic Malignancies (11/88)</td>
</tr>
<tr>
<td>4274</td>
<td>Mayer, Allan COL MC. GOG 104: Intraperitoneal Cisplatinum/Intravenous Cyclophosphamide Vs. Intravenous Cisplatinum/Intravenous Cyclophosphamide in Patients with Nonmeasurable Disease Stage III Ovarian Cancer, Phase III (1/89)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4277</td>
<td>Mayer, Allan COL MC. GOG 108: Ifosfamide and the Uroprotector, Mesna, with or without Cisplatin in Patients with Advanced or Recurrent Mixed Mesodermal Tumors of the Uterus, Phase III (5/89)</td>
</tr>
<tr>
<td>4281</td>
<td>Mayer, Allan COL MC. GOG 8801 A Phase I Evaluation of Multiple Daily Fraction Radiation and Hydroxyurea in Patients with Stage IIB, III and IVA Carcinoma of the Cervix with Negative Para-aortic Nodes (1/90)</td>
</tr>
<tr>
<td>4282</td>
<td>Mayer, Allan COL MC. GOG 8901 A Phase I Evaluation of Multiple Daily Fraction Radiation and 5FU Plus Cisplatin in Stage IIB, III and IVA Carcinoma of the Cervix with Negative Para-aortic Nodes (1/90)</td>
</tr>
<tr>
<td>4291</td>
<td>Mayer, Allan COL MC. GOG 26GG A Phase II Trial of Fazarabine in Patients with Advanced or Recurrent Pelvic Malignancies (5/90)</td>
</tr>
<tr>
<td>4294</td>
<td>Mayer, Allan COL MC. GOG 8803 Flow Cytometrically Determined Tumor DNA Content in Advanced Epithelial Ovarian Cancer (6/90)</td>
</tr>
<tr>
<td>4295</td>
<td>Mayer, Allan COL MC. GOG 8809 Flow Cytometrically Determined Tumor DNA Content in Ovarian Tumors of Low Malignant Potential (6/90)</td>
</tr>
<tr>
<td>4296</td>
<td>Mayer, Allan COL MC. GOG 8810 Flow Cytometrically Determined DNA Content in Endometrial Carcinoma (6/90)</td>
</tr>
<tr>
<td>4298</td>
<td>Mayer, Allan COL MC. GOG 111 A Phase III Randomized Study of Cyclophosphamide and Cisplatin Vs. Taxol and Cisplatin in Patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma (6/90)</td>
</tr>
<tr>
<td>4302</td>
<td>Mayer, Allan COL MC. GOG 8906 Extended Radiation Therapy With Concomitant 5-FU Infusion and Cisplatin Chemotherapy in Patients with Cervical Carcinoma Metastatic to Para-Aortic Lymph Nodes (10/91)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
### DEPARTMENT OF OBSTETRICS AND GYNECOLOGY

**Gynecologic Oncology Group (continued)**

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>4303</td>
<td>Mayer, Allan COL MC. GOG 26-11 Phase II Trial of 5-Fluorouracil and High Dose Leucovorin in Advanced or Recurrent Pelvic Malignancies (11/91)</td>
<td>312</td>
</tr>
<tr>
<td>4305</td>
<td>Mayer, Allan COL MC. GOG 101 A Phase II Evaluation of Preoperative Chemoradiation for Advanced Vulvar Cancer (3/92)</td>
<td>313</td>
</tr>
<tr>
<td>4306</td>
<td>Mayer, Allan COL MC. GOG 132 A Phase III Randomized Study of Cisplatin Versus Taxol Versus Taxol and Cisplatin in Patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma (4/92)</td>
<td>314</td>
</tr>
<tr>
<td>4308</td>
<td>Mayer, Allan COL MC. GOG 125: Extended Field Radiation Therapy with Concomitants 5-FU Infusion and Cisplatin Chemotherapy in Patients with Cervical Carcinoma Metastatic to Para-Aortic Lymph Nodes (5/92)</td>
<td>315</td>
</tr>
<tr>
<td>4309</td>
<td>Mayer, Allan COL MC. GOG 102: A Randomized Comparison of Hydroxyurea vs. Hydroxyurea, 5-FU Infusion and Cisplatin vs. Weekly Cisplatin as Adjunct to Radiation Therapy in Patients with Stages II-B, III, or IV-A Carcinoma of the Cervix and Negative Para-Aortic Nodes (6/92)</td>
<td>316</td>
</tr>
<tr>
<td>4310</td>
<td>Mayer, Allan COL MC. GOG: 136 Acquisition of Human Ovarian and Other Tissue Specimens and Serum to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer (8/92)</td>
<td>317</td>
</tr>
<tr>
<td>4311</td>
<td>Mayer, Allan COL MC. GOG 134: A Phase III Trial of Taxol at Three Dose Levels and G-CSFF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma (9/92)</td>
<td>318</td>
</tr>
<tr>
<td>4312</td>
<td>Mayer, Allan COL MC. GOG 122: Whole Abdominal Radiotherapy versus Combination Doxorubicin-Cisplatin Chemotherapy in Advanced Endometrial Carcinoma (10/92)</td>
<td>319</td>
</tr>
<tr>
<td>4313</td>
<td>Mayer, Allan COL MC. GOG 114: A Phase III Randomized Study of Intravenous Cisplatin and Cyclophosphamide Versus Intravenous Cisplatin and Taxol Versus High Dose Intravenous Carboplatin Followed by Intravenous Taxol and Intraperitoneal Cisplatin in Patients with Optimal (11/92)</td>
<td>320</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
SUMMARY:

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>4314</td>
<td>Mayer, Allan COL MC. GOG 127B: Evaluation of Isotretinoin and Alpha Interferon in Advanced or Recurrent Squamous Cell Carcinoma of the Cervix (3/93)</td>
</tr>
<tr>
<td>4816</td>
<td>Salata, Kalman PhD. The Effect of Irradiation on Red Blood Cell Antigen Densities: A Flow Cytometric Analysis (9/93)</td>
</tr>
<tr>
<td>6064</td>
<td>Francis, Gary LTC MC. The Effect of Somatomedin C on Androgen Receptor and 5-a-reductase Activities in a Hormonally Responsive Tissue, the Penile Foreskin (8/89)</td>
</tr>
<tr>
<td>6256</td>
<td>Francis, Gary LTC MC. The In Vitro Effect of Tumor Necrosis Factor on the Function of the Pituitary Gonadotrophs of the Rat (1/90)</td>
</tr>
<tr>
<td>6257</td>
<td>Francis, Gary LTC MC. The In Vitro Effect of Tumor Necrosis Factor on the Function of the Gonadal Axis of the Rat (1/90)</td>
</tr>
<tr>
<td>6266</td>
<td>Edwards, E. Glenn MAJ MC. High Dose Chemotherapy with Autologous Bone Marrow Rescue in Children with Recurrent or Progressive Solid Tumors or Primary CNS Malignancies, Phase II (4/90)</td>
</tr>
<tr>
<td>6267</td>
<td>Maybee, David COL MC. The Value of Sequential C-Reactive Protein Levels in Sickle Cell Anemia Patients Presenting with Symptoms of Crisis or Infection (4/90)</td>
</tr>
<tr>
<td>6275</td>
<td>Weisman, Leonard COL MC. Modified Immune Serum Globulin in Neonates (1990) (10/90)</td>
</tr>
<tr>
<td>6290</td>
<td>Moores, Russell MAJ MC. Utilization of Foot Length as an Estimation of Gestational Age in the Neonate (6/91)</td>
</tr>
<tr>
<td>6299</td>
<td>Pierce, John COL MC. The Neonatal Rat Pup as a Model for Staphylococcus Epidermidis Sepsis in the Newborn: The Effects of a Lipid Emulsion on Survival and Neutrophil Function (9/91)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6300</td>
<td>Moores, Russell MAJ MC. The Use of Surfactant Therapy During the Early Management of the Meconium Aspiration Syndrome in a Piglet Model Ventilated with Either High Frequency or Conventional Mechanical Ventilation (10/91)</td>
<td>331</td>
</tr>
<tr>
<td>6301</td>
<td>Edwards, E. Glenn MAJ MC. High Dose Chemotherapy with Autologous Bone Marrow Support Using Ex-Vivo Marrow Treatment with 4-Hydroxyperoxyxyclophosphamide (4-HC) for Relapsed Acute Myelogenous Leukemia (10/91)</td>
<td>332</td>
</tr>
<tr>
<td>6308</td>
<td>Francis, Gary L. LTC MC. The In Vitro Effect of Cytokines on Placental Steroidogenesis (1/92)</td>
<td>333</td>
</tr>
<tr>
<td>6313</td>
<td>Francis, Gary LTC MC. Soluble Interleukin-2 Receptor (sIL2R) Levels in New Onset Insulin Dependent Diabetes Mellitus During Biostator Therapy (3/92)</td>
<td>334</td>
</tr>
<tr>
<td>6321</td>
<td>Poth, Merrily MD. The Effects of Sex Steroids and Vitamin E on Lipid Peroxidation in the Diabetic Rat Model (5/92)</td>
<td>335</td>
</tr>
<tr>
<td>6324</td>
<td>Pineiro, Victor MAJ, MC. Electrogastrogram and Gastric Emptying in Infants with Hypertrophic Pyloric Stenosis and Gastroesophageal Reflux (5/92)</td>
<td>336</td>
</tr>
<tr>
<td>6326</td>
<td>Robinson, C. Anita MD. The Status of Adolescent Medicine in the Military Health Service System (6/92)</td>
<td>337</td>
</tr>
<tr>
<td>6327</td>
<td>Poth, Merrily MD. Effect of Somatostatin on Glomerular PGE2 Production in the Diabetic Rat (6/92)</td>
<td>338</td>
</tr>
<tr>
<td>6330</td>
<td>Miller, James LCDR MC. Infrared Thermometry in the Evaluation of Localized Infection (6/92)</td>
<td>339</td>
</tr>
<tr>
<td>6331</td>
<td>Moores, Russell MAJ MC. In Vivo Dating of the Time Interval from the Initial Presence of Meconium to Birth (7/92)</td>
<td>340</td>
</tr>
<tr>
<td>6332</td>
<td>Darling, Bryan LT MC USNR. The Effect of Profound Hypoglycemia on the Release of Excitatory Amino Acids in the Central Nervous System of the Developing Pig (7/92)</td>
<td>341</td>
</tr>
<tr>
<td>6336</td>
<td>Moores, Russell MAJ MC. The Use of Saline Lavage and Surfactant Therapy for the Management of the Meconium Aspiration Syndrome in Newborn Piglets - A Model for Intrapartum Management (8/92)</td>
<td>342</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6337</td>
<td>Poth, Merrily MD. Oxandrolone to Increase Growth in Turners Syndrome Patients: Treatment Protocol (8/92)</td>
<td>343</td>
</tr>
<tr>
<td>6340</td>
<td>Degnan, Bernie CPT MC. The Incidence of Celiac Disease in North American Children with Short Stature (10/92)</td>
<td>344</td>
</tr>
<tr>
<td>6341</td>
<td>Latimer, John COL MC USAF. Interferon-alfa2a Therapy of Children with Chronic Hepatitis B Infection (10/92)</td>
<td>345</td>
</tr>
<tr>
<td>6342</td>
<td>Moores, Russell Jr MAJ MC. The Developmental Regulation of Serine Oxidation in the Fetal Hindlimb (11/92)</td>
<td>346</td>
</tr>
<tr>
<td>6344</td>
<td>Raszka, William MAJ MC. Solid Media Determination of MICs of Clinical Isolates of Mycobacterium Avium Complex to Trimethoprim, Sulfamethoxazole, and Sulfisoxazole (12/92)</td>
<td>347</td>
</tr>
<tr>
<td>6350</td>
<td>Raszka, William MAJ MC. Comparison of the In Vitro Susceptibility of Clinical Isolates of Non-Tuberculous Mycobacteria in HIV Infected and non-HIV Infected Patients (3/93)</td>
<td>349</td>
</tr>
<tr>
<td>6358</td>
<td>Hinson, Roger CPT MC. Evaluation of the Mechanism of Inhibition of Interleukin-6 Synthesis by Indomethacin (9/93)</td>
<td>350</td>
</tr>
<tr>
<td>6359</td>
<td>Robinson, C. Anita MD. Risk and Prevalence of Hepatitis B in Adolescents (9/93)</td>
<td>351</td>
</tr>
</tbody>
</table>

DEPARTMENT OF PEDIATRICS
Pediatric Hematology-Oncology Service

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6121</td>
<td>Maybee, David COL MC. POG 7799 Rare Tumor Registry (1/80)</td>
<td>352</td>
</tr>
<tr>
<td>6144</td>
<td>Maybee, David COL MC. POG 8158 NWTS Long Term Follow-up Study (1/82)</td>
<td>353</td>
</tr>
<tr>
<td>6177</td>
<td>Maybee, David COL MC. POG 8602 Evaluation of Treatment Regimens in Acute Lymphoid Leukemia of Childhood (ALinC14), A POG Phase III Study (5/86)</td>
<td>354</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6181</td>
<td>Maybee, David COL MC. POG 8625/8626 Combined Therapy and Restaging in the Treatment of Stages I, IIA, IIA1 Hodgkin's Disease in Pediatric Patients, A Phase II Study (6/86)</td>
</tr>
<tr>
<td>6188</td>
<td>Maybee, David COL MC. POG 8650 National Wilm's Tumor Study - 4; A POG Phase III Study (10/86)</td>
</tr>
<tr>
<td>6192</td>
<td>Maybee, David COL MC. POG 8651 Osteosarcoma Study 2: A Randomized Trial of Pre-Surgical Chemotherapy Vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma, A POG Phase III Study (1/87)</td>
</tr>
<tr>
<td>6193</td>
<td>Maybee, David COL MC. POG 8615 A Phase III Study of Large Cell Lymphomas in Children and Adolescents, A Comparison of Two Treatment Regimens, ACOP+ Vs. APO (2/87)</td>
</tr>
<tr>
<td>6195</td>
<td>Maybee, David COL MC. POG 8633/8634 The Treatment of Children Less Than Three Years of Age with Malignant Brain Tumors Using Postoperative Chemotherapy and Delayed Irradiation, A POG Phase II Study (4/87)</td>
</tr>
<tr>
<td>6199</td>
<td>Maybee, David COL MC. POG 8704: T-Cell #3 Protocol, A POG Phase III Study (6/87)</td>
</tr>
<tr>
<td>6204</td>
<td>Maybee, David COL MC. POG 8751: Low Dose Methotrexate in the Treatment of Rhabdomyosarcoma, A POG Phase II Study (7/87)</td>
</tr>
<tr>
<td>6210</td>
<td>Maybee, David COL MC. POG 8761: A Phase II Study of Homoharringtonine for the Treatment of Children with Refractory Nonlymphoblastic Leukemia (9/87)</td>
</tr>
<tr>
<td>6213</td>
<td>Maybee, David COL MC. POG 8823/24: Recombinant Alpha Interferon in Childhood Chronic Myelogenous Leukemia, Phase II (12/87)</td>
</tr>
<tr>
<td>6217</td>
<td>Maybee, David COL MC. POG 8725: Randomized Study of Intensive Chemotherapy (MOPP/ABVD Plus/Minus Low Dose Total Nodal Radiation Therapy in the Treatment of Stages IIB, IIIA2, IIIB, IV Hodgkin's Disease in Pediatric Patients, Phase III (5/88)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
DEPARTMENT OF PEDIATRICS
Pediatric Hematology-Oncology Service (continued)

6221  Maybee, David COL MC.  POG 8821: Intensive Multiagent Therapy Vs. Autologous Bone Marrow Transplant Early in First CR for Children with Acute Myelocytic Leukemia - A Phase III Study (9/88) 365

6227  Maybee, David COL MC.  POG 8862: Treatment of First Marrow and/or Extramedullary Relapse of Childhood Acute T-Lymphoblastic Leukemia and T-Non-Hodgkin's Lymphoma with Combination Chemotherapy Including 2'-Deoxycoformycin (1/89) 366

6229  Maybee, David COL MC.  POG 8850: Evaluation of Vincristine, Adriamycin, Cyclophosphamide and Dactinomycin with or without the Addition of Ifosfamide and Etoposide in the Rx of Patients with Newly Diagnosed Ewing's Sarcoma of Primitive Neuroectodermal Tumor or Bone, Phase III (1/89) 367

6233  Maybee, David COL MC.  POG 8820 VP-16, AMS, and 5-Azacytidine in Refractory ANLL, Phase II-III Study (2/89) 368

6236  Maybee, David COL MC.  POG 8829 A Protocol for a Case Control Study of Hodgkin's Disease in Childhood (4/89) 369

6242  Maybee, David COL MC.  POG 8828 Late Effects of Treatment of Hodgkin's Disease: A POG Nontherapeutic Study (5/89) 370

6250  Maybee, David COL MC.  POG 8935 A Study of Biological Behavior of Optic Pathway Tumors (7/89) 371

6251  Maybee, David COL MC.  POG 8936 Carboplatin in Progressive Optic Pathway Tumors: Phase II (7/89) 372

6252  Maybee, David COL MC.  POG 8945: An Intergroup Protocol for the Treatment of Hepatoblastoma and Hepatocellular Carcinoma, Phase III (10/89) 373

6253  Maybee, David COL MC.  POG 8930 Comprehensive Genetic Analysis of Brain Tumors (12/89) 374

6260  Maybee, David COL MC.  POG 9046 A Molecular Genetic Analysis of Wilms' Tumors and Nephrogenic Rests (2/90) 375

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6261</td>
<td>Maybee, David COL MC. POG 9047 Neuroblastoma Biology Protocol (2/90)</td>
<td>376</td>
</tr>
<tr>
<td>6263</td>
<td>Maybee, David COL MC. POG 9049 A Study of High Risk Malignant Germ Cell Tumors in Children: A Phase III Treatment Study (3/90)</td>
<td>377</td>
</tr>
<tr>
<td>6265</td>
<td>Maybee, David COL MC. POG 9082 Development of Intervention Strategies to Reduce the Time between Symptom Onset and Diagnosis of Childhood Cancer (4/90)</td>
<td>378</td>
</tr>
<tr>
<td>6270</td>
<td>Maybee, David COL MC. POG 9048 The Treatment of Children with Localized Germ Cell Tumors, Phase II (6/90)</td>
<td>379</td>
</tr>
<tr>
<td>6271</td>
<td>Maybee, David COL MC. POG 9061 The Treatment of Isolated Central Nervous System Leukemia (6/90)</td>
<td>380</td>
</tr>
<tr>
<td>6272</td>
<td>Maybee, David COL MC. POG 9031 The Treatment of Children with High Stage Medulloblastoma: Cisplatin/VP-16 Pre Vs. Post Irradiation, Phase III (7/90)</td>
<td>381</td>
</tr>
<tr>
<td>6278</td>
<td>Maybee, David COL MC. POG 9000 Acute Lymphocytic Leukemia in Childhood #15 Classification Protocol: A Non-therapeutic Study (12/90)</td>
<td>382</td>
</tr>
<tr>
<td>6279</td>
<td>Maybee, David COL MC. POG 9005 Dose Intensification of Methotrexate and 6-Mercaptopurine for ALL in Childhood, Phase III (12/90)</td>
<td>383</td>
</tr>
<tr>
<td>6280</td>
<td>Maybee, David COL MC. POG 9006: Acute Lymphocytic Leukemia in Children Study #15: Up Front Alternating 6-MP and Methotrexate Vs. Up Front Alternating Chemotherapy (12/90)</td>
<td>384</td>
</tr>
<tr>
<td>6281</td>
<td>Maybee, David COL MC. POG 9140 Treatment for Recurrent or Refractory Neuroblastoma (1/91)</td>
<td>385</td>
</tr>
<tr>
<td>6285</td>
<td>Maybee, David COL MC. POG 9107 The Treatment of Acute Lymphocytic Leukemia in Infants: Phase III (3/91)</td>
<td>386</td>
</tr>
<tr>
<td>6287</td>
<td>Maybee, David COL MC. NPC-1: A Phase II Study of Pre-Irradiation Chemotherapy for Pediatric and Adolescent Patients with Nasopharyngeal Carcinoma (4/91)</td>
<td>387</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
DEPARTMENT OF PEDIATRICS
Pediatric Hematology-Oncology Service (continued)

6292  Maybee, David COL MC. POG 9135: Pre-Radiation Chemotherapy for Children with Supratentorial Malignant Gliomas and Poorly Differentiated Embryonal Tumors of Childhood (7/91) 388

6293  Maybee, David COL MC. POG 9136: Phase I/II Dose Escalating Trial of Hyperfractionated Irradiation in the Treatment of Supratentorial Malignant Tumors of Childhood (7/91) 389

6294  Maybee, David COL MC. POG: 9170: Etoposide and Ifosfamide Plus G-CSF in Children with Recurrent Sarcomas: Including Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma, and Osteosarcoma: A Pediatric Oncology Group Pilot Study (7/91) 390

6296  Maybee, David COL MC. POG 9150 Intergroup Rhabdomyosarcoma Study IV: STAGE I Disease: A POG Phase III Study (8/91) 391

6297  Maybee, David COL MC. POG 9152: Intergroup Rhabdomyosarcoma Study IV: Stage IV, Clinical Group IV, and All Patients with Metastatic Disease: A POG Phase III Study (8/91) 392

6302  Maybee, David COL MC. POG: 9151 Intergroup Rhabdomyosarcoma Study IV: Treatment for Stage 2 and 3 Diseases: A Phase III Trial (11/91) 393

6303  Maybee, David COL MC. POG 9160: Idarubicin Cytosine Arabinoside, for Multiply Recurrent or Refractory ALL: A POG Phase II Study (11/91) 394

6307  Maybee, David COL MC. POG 9130: Treatment of Newly Diagnosed Astrocytomas A Pediatric Oncology Group Phase III Study (1/92) 395

6309  Maybee, David COL MC. POG 9132: Hyperfractionated Irradiation for Posterior Fossa Ependymoma: A Phase II/III Study (1/92) 396

6310  Maybee, David COL MC. POG 9259: Carboplatin in the Treatment of Newly Diagnosed Metastatic Osteosarcoma or Unresectable Osteosarcoma: A Phase III Study (1/92) 397

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>6311</td>
<td>Maybee, David COL MC. POG 9182: HIV/Malignancy Biology Study: A Pediatric Oncology Group Aids/Malignancy Network Study (1/92)</td>
</tr>
<tr>
<td>6314</td>
<td>Maybee, David COL MC. POG 9284/85: Barriers to Enrollment on POG Frontline Therapeutic Clinical Trials and Development of Intervention Strategies: A POG Non-therapeutic Study (3/92)</td>
</tr>
<tr>
<td>6315</td>
<td>Maybee, David COL MC. POG 9280: Neuroblastoma Epidemiology Protocol: A Non-Therapeutic Study (3/92)</td>
</tr>
<tr>
<td>6316</td>
<td>Maybee, David COL MC. POG 9225: Study for Advanced Stage Hodgkin's Disease: A Phase II Study (3/92)</td>
</tr>
<tr>
<td>6317</td>
<td>Mosijczuk, Askold COL MC. Salvage Therapy for Recurrent Medulloblastoma, Ependymoma, Cerebral Pnet, and Cerebral Low Grade Astrocytoma (3/92)</td>
</tr>
<tr>
<td>6318</td>
<td>Maybee, David COL MC. POG 9264: Chemotherapy Regimen for Initial Induction Failures in Childhood ALL: A Phase II Study (4/92)</td>
</tr>
<tr>
<td>6319</td>
<td>Maybee, David COL MC. POG 9243: Treatment for Children with Intermediate-Risk Neuroblastoma: A Phase III Study (4/92)</td>
</tr>
<tr>
<td>6322</td>
<td>Maybee, David A COL MC. POG 9222: Mitoxantrone, Etoposide and Cyclosporine Therapy in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia: A Phase II Study (5/92)</td>
</tr>
<tr>
<td>6323</td>
<td>Maybee, David A COL MC. POG 9233/34: A Phase III Randomized Trial of Standard vs. Dose-Intensified Chemotherapy &lt;3 Years of Age with a CNS Malignancy Treated With or Without Radiation Therapy (5/92)</td>
</tr>
<tr>
<td>6328</td>
<td>Maybee, David COL MC. POG 9239: Treatment of Children with Newly Diagnosed Brainstem Glioma Using Cisplatin as a Radiosensitizer with Either Conventional or Hyperfractionated Radiotherapy: A Pediatric Oncology Group Phase III Study (6/92)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6329</td>
<td>Maybee, David COL MC.  POG 9296: T-Cell Leukemia Pilot Study #4 (with IV MTX/IV6-MP) A Pediatric Oncology Group Limited Institution Pilot Study (Phase III) (6/92)</td>
<td>408</td>
</tr>
<tr>
<td>6333</td>
<td>Maybee, David COL MC.  POG 9237: Idarubicin in Recurrent and Progressive Childhood Brain Tumor Patients: A Pediatric Oncology Group Phase II Study (6/92)</td>
<td>409</td>
</tr>
<tr>
<td>6334</td>
<td>Maybee, David COL MC.  POG 9265: Evaluation of 13 Cis-Retinoic Acid in Children with Juvenile Chronic Myelogenous Leukemia: A Phase II Study (7/92)</td>
<td>410</td>
</tr>
<tr>
<td>6338</td>
<td>Maybee, David COL MC.  POG 9219: The Treatment of localized Non-Hodgkin's Lymphoma in Children: A POG Phase IV Study (9/92)</td>
<td>411</td>
</tr>
<tr>
<td>6339</td>
<td>Maybee, David COL MC.  POG 9227: Treatment of Recurrent or Refractory Hodgkin's Disease with Cyclosporine-A, Actinomycin-D, and Vincristine: A POG Phase II Study (9/92)</td>
<td>412</td>
</tr>
<tr>
<td>6343</td>
<td>Maybee, David COL MC.  POG 9220: Treatment for Previously Untreated Acute Promyelocytic Leukemia: A Phase III Intergroup Study (11/92)</td>
<td>413</td>
</tr>
<tr>
<td>6347</td>
<td>Maybee, David COL MC.  POG 9262: The Treatment of Children with Recurrent/Refractory Solid Malignancies with Taxol: A Phase II Study (1/93)</td>
<td>414</td>
</tr>
<tr>
<td>6348</td>
<td>Maybee, David COL MC.  POG 9244: Treatment for Children with Newly Diagnosed Stages 2B and 3 Neuroblastoma Older than One Year of Age: A Phase II Pilot Study (2/93)</td>
<td>415</td>
</tr>
<tr>
<td>6349</td>
<td>Maybee, David COL MC.  POG 9226: Treatment of Stage I, IIA and IIIA1 Hodgkin's Disease with ABVE and Low Dose Irradiation (2/93)</td>
<td>416</td>
</tr>
<tr>
<td>6351</td>
<td>Maybee, David COL MC.  POG 9317: Chemotherapy for Children with Advanced-Stage (III/IV) Diffuse Undifferentiated Burkitt's Lymphoma and B-Cell ALL: A Phase III Study (3/93)</td>
<td>417</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>6352</td>
<td>Maybee, David COL MC. POG 9340/41/42: Treatment of Patients One Year and Older at Diagnosis with Stages 2/B3 or 4 High-Risk Neuroblastoma: A Phase II Study (4/93)</td>
<td>418</td>
</tr>
<tr>
<td>6353</td>
<td>Maybee, David COL MC. POG 9310: SIMAL 7: Escalating Rotational Drug Therapy After 1st Marrow Relapse of Non-T, Non-B ALL: A Phase II Pilot Study (6/93)</td>
<td>419</td>
</tr>
<tr>
<td>6354</td>
<td>Maybee, David COL MC. POG 9357: The Use of Cyclosporfin A To Overcome Multiple Drug Resistance in Osteogenic Sarcoma: A POG Phase II Study (6/93)</td>
<td>420</td>
</tr>
<tr>
<td>6355</td>
<td>Maybee, David COL MC. POG 9330: Taxol in Progressive or Recurrent Childhood Brain Tumors: A Phase II Study (7/93)</td>
<td>421</td>
</tr>
<tr>
<td>6356</td>
<td>Maybee, David COL MC. POG 9345: Treatment of Unresetable/Metastatic Hepatoblastoma with Chemotherapy and Surgery: A Phase II Study (7/93)</td>
<td>422</td>
</tr>
<tr>
<td>6357</td>
<td>Maybee, David COL MC. POG 9360: GM-CSF Randomization + High-Dose ICE in the Treatment of Recurrent/Resistant Malignant Solid Tumors of Childhood: Phase II Study (7/93)</td>
<td>423</td>
</tr>
</tbody>
</table>

**PHARMACY SERVICE**

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3600</td>
<td>Nelson, Bruce COL MS. Determination of Noncompliance in Prescription Pickup (10/89)</td>
<td>424</td>
</tr>
<tr>
<td>3604</td>
<td>Solimando, Dominic Jr MAJ MC. Pharmacodynamic Analysis of Morphine and Its Metabolites in the Treatment of Chronic Cancer Pain (10/92)</td>
<td>425</td>
</tr>
</tbody>
</table>

**PHYSICAL MEDICINE AND REHABILITATION SERVICE**

<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9614</td>
<td>Dillingham, Timothy MAJ MC. A Descriptive Analysis of Patient Referrals to Army Physical Medicine Services During Armed Conflict (2/91)</td>
<td>426</td>
</tr>
<tr>
<td>9615</td>
<td>Dillingham, Timothy MAJ MC. An Analysis of the Extensor Digitorium Brevis Deep Tendon Reflex in Normals and in Patients with L5 Radicular Compression Syndromes (3/91)</td>
<td>427</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9616</td>
<td>Braverman, Steven CPT MC. Intern Perceptions of Physical Medicine and Rehabilitation (6/91)</td>
<td>428</td>
</tr>
<tr>
<td>9617</td>
<td>Dillingham, Timothy MAJ MC. Use of Topical Capsaicin in Myofascial Pain Syndromes and Primary Fibromyalgia Syndrome (3/92)</td>
<td>429</td>
</tr>
<tr>
<td>9620</td>
<td>Lauder, Tamara CPT MC. Radiculopathy Screen: Choosing the Most Sensitive Muscles (8/92)</td>
<td>430</td>
</tr>
<tr>
<td>9622</td>
<td>Dillingham, Timothy MAJ MC. A Description of Soldiers with Amputation: Implications for Return to Active Duty (12/92)</td>
<td>431</td>
</tr>
<tr>
<td>9623</td>
<td>Beattie, Bonita LTC SP. Descriptive Analysis of a Collaborative Practice Model Developed by the Physical Therapy and Occupational Therapy Sections at Walter Reed Army Medical Center in Response to Desert Shield/Storm Contingencies (5/93)</td>
<td>432</td>
</tr>
<tr>
<td>9624</td>
<td>Dillingham, Timothy MAJ MC. Motor Nerve Conduction in the Deep Temporal and Mylohyoid Nerves (8/93)</td>
<td>433</td>
</tr>
</tbody>
</table>

**Department of Psychiatry**

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7245</td>
<td>Hall, Donald CPT MC. Investigation of Ultradian Rhythms of Mood in Depression (5/91)</td>
<td>434</td>
</tr>
<tr>
<td>7246</td>
<td>Oleshansky, Marvin LTC MC. A Randomized Concentration-Controlled Trial of Fluoxetine in the Treatment of Major Despressive Disorder (8/91)</td>
<td>435</td>
</tr>
<tr>
<td>7248</td>
<td>Esposito, Maria COL MC. Psychiatric Diagnoses Included in Medical Discharge Summaries (4/92)</td>
<td>436</td>
</tr>
<tr>
<td>7249</td>
<td>Lande, Raymond LTC MC. The Art Therapy Assessment of a Criminally Insane Population (4/92)</td>
<td>437</td>
</tr>
<tr>
<td>7250</td>
<td>Brown, James CPT MC. Proto-oncogene Expression in Peripheral Blood Mononuclear Cells in Schizophrenia: A Pilot Study (4/92)</td>
<td>438</td>
</tr>
</tbody>
</table>

*Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>7251</td>
<td>Joslin, Scott CPT MC. An Outcome Study of Schizophreniform Disorder Diagnosed at Walter Reed Army Medical Center (9/92)</td>
<td>439</td>
</tr>
<tr>
<td>7252</td>
<td>Belliveau, Paul CPT MC. A Referral Coordinator: Implication with Compliance (11/92)</td>
<td>440</td>
</tr>
<tr>
<td>7253</td>
<td>Erbe, Edward CPT MC. Greater Referral Specificity and Its Effect on the Rate of Compliance (7/93)</td>
<td>441</td>
</tr>
<tr>
<td>7254</td>
<td>Stewart, Frances, CDR, MC. Effectiveness of Rapid Biofeedback-Assisted Relaxation Training (7/93)</td>
<td>442</td>
</tr>
<tr>
<td>7255</td>
<td>Wain, Harold Ph.D. Differences in Hypnotic Capacity Between Patients Referred to a Psychiatric Consultation Liaison Service and Patients Referred to a Psychiatric Outpatient Clinic (8/93)</td>
<td>443</td>
</tr>
<tr>
<td>7256</td>
<td>Lande, R. Gregory LTC MC. The Association of Caffeine Blood Level With Diagnosis in an Outpatient Psychiatric Population (9/93)</td>
<td>444</td>
</tr>
<tr>
<td>9106</td>
<td>Jones, Franklin MD. Differences in Proportions of Diagnosis Between Ethnic Groups: The Case of Puerto Rican Psychiatric Patients in the Military (12/84)</td>
<td>445</td>
</tr>
<tr>
<td>4525</td>
<td>Anderson, Jay COL MC. Intravenous Administration of I-131-6-B Iodomethylnorcholesterol for Adrenal Evaluation and Imaging (11/80)</td>
<td>446</td>
</tr>
<tr>
<td>4539</td>
<td>Williams, Scott CPT MC. Evaluation of Breast Masses Using Technetium-99m-Sestamibi Scintigraphy (4/93)</td>
<td>447</td>
</tr>
<tr>
<td>4700</td>
<td>Earls, James CPT MC. CT Evaluation of Postoperative Pneumoperitoneum (4/92)</td>
<td>448</td>
</tr>
<tr>
<td>4701</td>
<td>Earls, James CPT MC. CT Directed Needle Localization of Peripheral Pulmonary Nodules Prior to Thoracoscopic Resection (6/92)</td>
<td>449</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2045A</td>
<td>Stamatos, John CPT MC. Multicenter Study of the Davol Intraspinal Port (10/89)</td>
<td>450</td>
</tr>
<tr>
<td>2051A</td>
<td>Guzzi, Louis MAJ MC. Perioperative Myocardial Ischemia or Infarction During and Following Noncardiac Surgery in Patients who have Undergone Previous Coronary Artery Bypass Graft or Percutaneous Transluminal Coronary Artery Surgery (4/90)</td>
<td>451</td>
</tr>
<tr>
<td>2054A</td>
<td>Carvill, Kathleen LTC NC. The Effect of the Sprotte Atraumatic 24 Gauge Spinal Needle on the Incidence of Postdural Puncture Headache (1/91)</td>
<td>452</td>
</tr>
<tr>
<td>2056A</td>
<td>Kline, Mark MAJ MC. Development of Ultra Long Duration Local Anesthetic Agents in a Rat Model (10/91)</td>
<td>453</td>
</tr>
<tr>
<td>2058A</td>
<td>Stamatos, John CPT MC. The Effect of Anesthesia and Surgery on Patients with Mildly Elevated Liver Enzymes (10/91)</td>
<td>454</td>
</tr>
<tr>
<td>2061A</td>
<td>Kline, Mark CPT MC. Medtronic Model 3885 PISCES-Delta Lead for Spinal Cord Stimulation (1/92)</td>
<td>455</td>
</tr>
<tr>
<td>2063A</td>
<td>Karan, Steven MAJ MC. Normothermic vs. Hypothermic Cardiopulmonary Bypass: The Stress Response with Varying Sufentanil Doses (1/92)</td>
<td>456</td>
</tr>
<tr>
<td>2064A</td>
<td>Fontana, John CPT MC. A Study of the Effect of Acadesine on Adverse Cardiac Outcomes in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery (2/92)</td>
<td>457</td>
</tr>
<tr>
<td>2065A</td>
<td>Bettecourt, Joseph MAJ MC. Intraoperative Utilization and Effect on Brain Relaxation (3/92)</td>
<td>458</td>
</tr>
<tr>
<td>2066A</td>
<td>Fontana, John CPT MC. Multicenter Study of Perioperative Ischemia Research Group - Cardiac Surgery Epidemiologic Database (McSPI-CSDEDB) (5/92)</td>
<td>459</td>
</tr>
<tr>
<td>2067A</td>
<td>Matson, Michael LTC MC. Fiberoptically Assisted Intravenous Catheter Placement (6/92)</td>
<td>460</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2069A</td>
<td>Karan, Steven MAJ MC. In Vitro Determination of the Response of Skeletal Muscle to Halothane, Caffeine, and Halothane plus Caffeine (10/92)</td>
</tr>
<tr>
<td>2070A</td>
<td>Guzzi, Louis MAJ MC. Efficacy of Ketoralac in Reducing the Symptoms of Post Dural Puncture (1/93)</td>
</tr>
<tr>
<td>2071A</td>
<td>Karan, Steven MAJ MC. A Comparison of Caudal vs Lumbar Epidural Steroid Injection with Local Anesthetic in the Treatment of Sciatica (2/93)</td>
</tr>
<tr>
<td>2072A</td>
<td>Greilich, Philip CPT MC. Assessment of the Mechanical and Structural Properties of Clots in Healthy Adults and Patients with Known Coronary Artery Disease Using Two Methods (4/93)</td>
</tr>
<tr>
<td>2508</td>
<td>Grant, Kenneth PhD. Auditory Supplements to Speechreading (11/90)</td>
</tr>
<tr>
<td>2510</td>
<td>McClean, Michael PhD. Prediction of Stuttering Severity from Physiologic Measures of Speech Motor Systems (1/91)</td>
</tr>
<tr>
<td>2515</td>
<td>Leek, Marjorie Ph.D.. Frequency Resolution and the Detection of Spectral Contrast (10/91)</td>
</tr>
<tr>
<td>2516</td>
<td>Thompson, Patryce MA. Orofacial Force Control and Acoustics of Speech Production in Adult Dysarthria Patients (10/91)</td>
</tr>
<tr>
<td>2518</td>
<td>McClean, Michael PhD. Prespeech Modulation of Lip Muscle Reflexes in Stutterers and Nonstutterers (11/91)</td>
</tr>
<tr>
<td>2519</td>
<td>McClean, Michael Ph.D.. Computer Modeling and Analysis of Lip Muscle Activation for Speech (1/92)</td>
</tr>
<tr>
<td>2520</td>
<td>Surr, Rauna MS. Comparison of Linear and K-Amp Hearing Aid Fittings by Experienced Hearing Aid Users (5/92)</td>
</tr>
<tr>
<td>2521</td>
<td>Leek, Marjorie PhD. Spectral Contrast Perception and the Internal Signal-To-Noise Ration in Hearing-Impaired Listeners (5/92)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2524</td>
<td>Summers, Van Ph.D. Discrimination of Frequency Transitions by Hearing-Impaired Listeners (11/92)</td>
<td>473</td>
</tr>
<tr>
<td>2525</td>
<td>Beamer, Sharon MA. A Comparison of the Benefit Derived from Two Classes of Hearing Aids in Patients with Hearing Loss Above 2000 Hz (12/92)</td>
<td>474</td>
</tr>
<tr>
<td>2527</td>
<td>Clay, John PhD. An Investigation of the Role of Hearing Loss in the Perception of a Stop Consonant (2/93)</td>
<td>475</td>
</tr>
<tr>
<td>2528</td>
<td>Grant, Kenneth PhD. Relations Among Auditory-Visual Sentence Benefit, Auditory Consonant Recognition, and Auditory-Visual Integration in Hearing-Impaired Listeners (6/93)</td>
<td>476</td>
</tr>
<tr>
<td>2530</td>
<td>McClean, Michael PhD. Serum and Urinary Ion Levels and Lip Muscle Reflex excitability in Adult Stutterers (6/93)</td>
<td>477</td>
</tr>
<tr>
<td>2531</td>
<td>Podraza, Bonnie PhD. The Effect of Closed-Head Injury on Auditory Information Processing (6/93)</td>
<td>478</td>
</tr>
<tr>
<td>2532</td>
<td>Leek, Marjorie PhD. Hearing Loss and the Perception of Complex Sounds (7/93)</td>
<td>479</td>
</tr>
<tr>
<td>2588</td>
<td>Leek, Marjorie PhD. Hearing Loss and the Perception of Complex Sounds (8/88)</td>
<td>480</td>
</tr>
<tr>
<td>2590</td>
<td>Leek, Marjorie PhD. Modeling Impaired Frequency Resolution in Normal Ears (1/89)</td>
<td>481</td>
</tr>
<tr>
<td>2591</td>
<td>Leek, Marjorie PhD. Nonlinear Cochlear Processing in Normal Hearing and Hearing Impaired Listeners (2/89)</td>
<td>482</td>
</tr>
<tr>
<td>2598</td>
<td>Leek, Marjorie PhD. Frequency Resolution on Hearing Impaired and Noise Masked Normal Hearing Listeners (2/90)</td>
<td>483</td>
</tr>
<tr>
<td>2060A</td>
<td>Stoltzfus, Daniel LTC MC. The Relationship Between Right Ventilator Volume by Thermodilation Catheter and Left Ventilator Volume by Transesophageal Echo-Cardiography (1/92)</td>
<td>484</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3009</td>
<td>Whatmore, Douglas LTC MC. Effect of Empiric Low Dose Amphotericin B on the Development of Disseminated Candidiasis in a Surgical Intensive Care Unit (3/90)</td>
</tr>
<tr>
<td>3012</td>
<td>Whatmore, Douglas LTC MC. Work of Breathing as a Predictor of Failure to Wean from Mechanical Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease (COPD) (1/92)</td>
</tr>
<tr>
<td>3014</td>
<td>Ries, Marianne CPT MC. The Effect of Leukocyte Filters on the Development of Extravascular Lung Water in Patients Undergoing Coronary Artery Bypass Grafting (CABG) (2/93)</td>
</tr>
<tr>
<td>2061</td>
<td>Hale, Douglas MAJ MC. Prevention of Unresectable Lung Cancer Found at Thoracotomy (5/93)</td>
</tr>
<tr>
<td>2062</td>
<td>Hale, Douglas MAJ, MC. Role of Intracellular Calcium in Bile Acid Induced Injury of Gastric Cells (6/93)</td>
</tr>
<tr>
<td>2063</td>
<td>Hale, Douglas MAJ MC. Development of Autoradiographic Assay for Detection of Insulin-Like Growth Factor 1 Receptors in Guinea Pig Mucosa (8/93)</td>
</tr>
<tr>
<td>2318</td>
<td>Wertz, Fleming COL MC. The Effects Upon Ocular Structures of Optical Polycarbonate and of Various Eye Protective Substances Applied to and Incorporated Within It (1/90)</td>
</tr>
<tr>
<td>2319</td>
<td>Wertz, Fleming COL MC. The Efficacy of Cyanoacrylates in the Primary Closure of Conjunctival Scleral Lacerations (1/90)</td>
</tr>
<tr>
<td>2320</td>
<td>Blaydon, Sean CPT MC. Mood and Behavior Changes with Topical Ophthalmic Beta-Adrenergic Blockade (2/90)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Investigator(s)</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2633</td>
<td>Shaver, Timothy MAJ MC.</td>
<td>Use of Anti-lymphocyte Preparations in Solid Organ Transplantation (12/89)</td>
<td>494</td>
</tr>
<tr>
<td>3361</td>
<td>Polly, Shirley MAJ MC.</td>
<td>Pneumococcal Polysaccharide Vaccine: Adverse Reactions to Immunization (12/90)</td>
<td>495</td>
</tr>
<tr>
<td>2417</td>
<td>McHale, Kathleen MAJ MC.</td>
<td>A Prospective Study of Back Pain in Pregnancy (8/89)</td>
<td>496</td>
</tr>
<tr>
<td>2418</td>
<td>Polly, David Jr MAJ MC.</td>
<td>Clinical Investigation of the PWB Spine System (10/89)</td>
<td>497</td>
</tr>
<tr>
<td>2420</td>
<td>Temple, Thomas MAJ MC.</td>
<td>MRI Characteristics following Surgical Excision of Soft Tissue Sarcomas and Radiation Therapy in Determining Normal Postsurgical and Radiation Changes from Recurrent Disease (3/90)</td>
<td>498</td>
</tr>
<tr>
<td>2427</td>
<td>Hopkinson, William COL MC.</td>
<td>The Effects of Intraoperative Blood Loss on Serum Antibiotic Level in Patients Undergoing Total Joint Arthroplasty (3/91)</td>
<td>499</td>
</tr>
<tr>
<td>2432</td>
<td>Xenos, John CPT MC.</td>
<td>Evaluation of the Syndesmosis in Ankle Diastasis Injuries (10/91)</td>
<td>500</td>
</tr>
<tr>
<td>2433</td>
<td>Hayda, Roman CPT MC.</td>
<td>Foot and Ankle Injuries During Operation Desert Storm/Shield: An Analysis (10/91)</td>
<td>501</td>
</tr>
<tr>
<td>2434</td>
<td>Xenos, John CPT MC.</td>
<td>Aggressive Osteolysis Behind Well-fixed Acetabular Components with Perforations (3/92)</td>
<td>502</td>
</tr>
<tr>
<td>2435</td>
<td>Brown, Maurice CPT MC.</td>
<td>The Effect of Extracorporeal Shockwaves on Bone and Soft Tissue in Rabbits (4/92)</td>
<td>503</td>
</tr>
<tr>
<td>2436</td>
<td>Xenos, John CPT MC.</td>
<td>Evaluation of Bone Healing in Osteotomies Produced with Excimer Laser and Er:YAG Laser in the Rabbit Model (7/92)</td>
<td>504</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2437</td>
<td>Stuart, James CPT MC. The Role of Topical Antibiotic in the Prevention of Bone Infection of the Rabbit Model. Treatment of Contaminated Open Tibial Fractures Stabilized with Internal Fixation (11/92)</td>
</tr>
<tr>
<td>2438</td>
<td>Stuart, James CPT MC. Techniques for Soft Tissue Reattachment to Bone (11/92)</td>
</tr>
<tr>
<td>2439</td>
<td>Grosso, Nicholas CPT MC. Results of Coccygectomy for Coccygodynia (12/92)</td>
</tr>
<tr>
<td>2440</td>
<td>Stuart, James CPT MC. Methods of Decontaminating Soft Tissue Grafts and Osteoarticular Fragments After Experimental Contamination (1/93)</td>
</tr>
<tr>
<td>2441</td>
<td>DeVries, William CPT MC. Effectiveness of Ankle Bracing for Lateral Ankle Ligament Sprains (1/93)</td>
</tr>
<tr>
<td>2442</td>
<td>DeVries, William CPT MC. Articular and Meniscal Cartilaginous Response to Nd:YAG and Excimer Laser Exposure in the Rabbit Model (1/93)</td>
</tr>
<tr>
<td>2444</td>
<td>Popovic, Neven DVM, MD, PhD. Evaluation of Biodegradable Delivery System to Regenerate Long Bones in Rabbits: Guided Tissue Regeneration in an Ostectomyomized Radius (1/93)</td>
</tr>
<tr>
<td>2445</td>
<td>Popovic, Neven DVM, MD, PhD. The Effect of Extracorporeal Shock Waves on Compartment Pressures in the Rabbit Leg (1/93)</td>
</tr>
<tr>
<td>2446</td>
<td>Polly, David MAJ MC. The Effects of Different Braces on Pain Relief in Patients with Multiple Myeloma Involving the Spine (1/93)</td>
</tr>
<tr>
<td>2447</td>
<td>McHale, Kathleen LTC MC. Subtalar Stabilization in Progressive Planovalgus Deformity in Children (2/93)</td>
</tr>
<tr>
<td>2448</td>
<td>Polly, David MAJ MC. Thoracoplasty in Scoliosis (2/93)</td>
</tr>
<tr>
<td>2449</td>
<td>Polly, David MAJ MC. Measurement of Lumbar Lordosis: Evaluation of Intraobserver, Interobserver and Technique Variability (3/93)</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Principal Investigator, Title, and Approval Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2450</td>
<td>Popovic, Neven DVM, MD, PhD. Regeneration of Segmental Defects in the Radii of Rabbits Using Recombinant Human Bone Morphogenetic-2 Protein (3/93)</td>
<td>517</td>
</tr>
<tr>
<td>2451</td>
<td>Cook, Jonathan MAJ MC. Carpal Ligament Injuries in Intra-articular Fractures of the Distal Radius (4/93)</td>
<td>518</td>
</tr>
<tr>
<td>2452</td>
<td>Popovic, Neven MD DVM PhD. The Osteoconductive Potential of a Polycaprolactone Foam in the Rat Tibia (4/93)</td>
<td>519</td>
</tr>
<tr>
<td>2453</td>
<td>DeVries, William CPT MC. Evaluation of the Incidence of Progression and Pathologic Fracture of Long Bones Involved with Breast Cancer (4/93)</td>
<td>520</td>
</tr>
<tr>
<td>2454</td>
<td>Choma, Theodore CPT MC. Pilot Study on the Use of CO2, Argon, and 808nm Diode Lasers for Laser Welding the Achilles Tendon in the Rat Model: A Comparison (5/93)</td>
<td>521</td>
</tr>
<tr>
<td>2455</td>
<td>Popovic, Neven, DVM, MD, PhD. Effects of Extracorporeal Shockwaves on the Rabbit Physis (6/93)</td>
<td>522</td>
</tr>
<tr>
<td>2456</td>
<td>Kil Kelly, Francis CPT MC. The Effect of Chlorhexidine and Povidine Iodine on Bone Healing in the Rabbit Model: A Histologic and Biomechanical Investigation (6/93)</td>
<td>523</td>
</tr>
<tr>
<td>2457</td>
<td>McHale, Kathleen MAJ MC. Orthopaedic Injuries in Operation Desert Shield/Storm: A 2-Year Follow-up (7/93)</td>
<td>524</td>
</tr>
<tr>
<td>2458</td>
<td>Popovic, Neven DVM, MD, PhD. Evaluation of Rabbit Ulna as a Model for Testing of Bone Substitute Materials (7/93)</td>
<td>525</td>
</tr>
<tr>
<td>2459</td>
<td>Polly, David MAJ MC. Measurement of Spondylolisthesis Parameters Evaluation of Intraobserver, Interobserver and Technique Reliability and Variability (8/93)</td>
<td>526</td>
</tr>
<tr>
<td>2460</td>
<td>Polly, David MAJ MC. Progression of Idiopathic Scoliosis After Menarche (8/93)</td>
<td>527</td>
</tr>
<tr>
<td>2461</td>
<td>Popovic, Neven MD, DVM, PhD. Effects of Extracorporeal Shockwaves on the Rabbit Ulna Cadaver (8/93)</td>
<td>528</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>DEPARTMENT OF SURGERY</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orthopaedic Surgery Service (continued)</td>
<td></td>
</tr>
<tr>
<td>2462</td>
<td>Popovic, Neven MD DVM PhD. A Pilot Study: The Effect of Extracorporeal Shockwaves on the Rate of Bone Healing in a Rabbit Radius Diaphysis: Effects on Healing of Autografts, Comminuted Fractures, and Diaphysial Critical Size Bone Defects (9/93)</td>
</tr>
<tr>
<td>529</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td>Otolaryngology-Head &amp; Neck Service</td>
</tr>
<tr>
<td>530</td>
<td></td>
</tr>
<tr>
<td>2526</td>
<td>Cukier, Andrew CPT MC. Radiation Effects on Salivary Epithelial Growth Factor (EGF): A Pilot Study (1/93)</td>
</tr>
<tr>
<td>531</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td>Plastic Surgery Service</td>
</tr>
<tr>
<td>2910</td>
<td>Mayer, Michael LTC MC. The Use of Bone Repair Materials for Maxillary Alveolar Clefts (10/90)</td>
</tr>
<tr>
<td>532</td>
<td></td>
</tr>
<tr>
<td>2911</td>
<td>Mayer, Michael LTC MC. Orbital Floor Reconstruction with Bone Repair Materials (10/90)</td>
</tr>
<tr>
<td>533</td>
<td></td>
</tr>
<tr>
<td>2912</td>
<td>Mayer, Michael LTC MC. Rigid Skeletal Fixation of the Immature Craniofacial Skeleton (10/90)</td>
</tr>
<tr>
<td>534</td>
<td></td>
</tr>
<tr>
<td>DEPARTMENT OF SURGERY</td>
<td>Thoracic Surgery Service</td>
</tr>
<tr>
<td>2713</td>
<td>Zurcher, Robert MAJ MC. Secondary Prospective Study for the Evaluation of the Safety and Effectiveness of Cryopreserved Human Allograft Heart Valves (LifeNet) (10/91)</td>
</tr>
<tr>
<td>535</td>
<td></td>
</tr>
<tr>
<td>2714</td>
<td>Zurcher, Robert MAJ MC. Cryovalve Heart Valve Allografts, Replacement Heart Valve Allograft (CryoLife) (10/91)</td>
</tr>
<tr>
<td>536</td>
<td></td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
<table>
<thead>
<tr>
<th>PROTOCOL NUMBER</th>
<th>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</th>
<th>PAGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2837</td>
<td>McLeod, David COL MC. NPCP 2200 A Comparison of Leuprolide with Leuprolide and Flutamide in Previously Untreated Patients with Clinical Stage D2 Cancer of the Prostate (2/85)</td>
<td>537</td>
</tr>
<tr>
<td>2843</td>
<td>McLeod, David COL MC. ECOG EST 1887 A Phase III Trial of Cystectomy Alone Vs. Neoadjuvant M-VAC + Cystectomy in Patients with Locally Advanced Bladder Cancer (10/88)</td>
<td>538</td>
</tr>
<tr>
<td>2859</td>
<td>McLeod, David COL MC. SWOG 8894 A Comparison of Bilateral Orchietomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D2 Prostate Cancer (9/89)</td>
<td>539</td>
</tr>
<tr>
<td>2864</td>
<td>Moul, Judd MAJ MC. ECOG EST 9887 A Phase III Trial of Treatment of Pathologic Stage C Carcinoma of the Prostate with Adjuvant Radiotherapy (7/90)</td>
<td>540</td>
</tr>
<tr>
<td>2865</td>
<td>Sihelnik, Stephen LTC MC. A Randomized Trial of Transurethral Resection of the Prostate Vs. Open Prostatectomy or Nonoperative Treatment (7/90)</td>
<td>541</td>
</tr>
<tr>
<td>2868</td>
<td>McLeod, David COL MC. Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockade in Clinical B2 (T2bNxMo) Prostate Cancer (9/91)</td>
<td>542</td>
</tr>
<tr>
<td>2869</td>
<td>Sihelnik, Stephen LTC MC. Response Patterns to DDAVP (Desmopressin Acetate) in the Treatment of Nocturnal Enuresis as a Function of Change in Urine Osmolality (10/91)</td>
<td>543</td>
</tr>
<tr>
<td>2871</td>
<td>McLeod, David COL MC. A Randomized, Comparative Trial of Casodex Versus Flutamide Used in Combination with Medical Castration in Patients with Untreated Metastatic Prostate Cancer (1/92)</td>
<td>544</td>
</tr>
<tr>
<td>2872</td>
<td>Moul, Judd MAJ MC. EOG EST C-0490: Phase II Study of Difluromethylornithine (DFMO) in Patients with Superficial and Superficially-Invasive Bladder Cancer (2/92)</td>
<td>545</td>
</tr>
<tr>
<td>2873</td>
<td>Lewis, Donald MAJ MC. Evaluation of the P53 Tumor Suppressor Gene in Human Testicular Cancer (10/92)</td>
<td>546</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume II.
PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE
BY DEPARTMENT AND SERVICE

DEPARTMENT OF SURGERY
Urology Service (continued)

2874  McLeod, David COL MC. Multicenter Study of Intravenously Administered 111 In-CYT-356 in the Evaluation of Patients with Primary Prostate Cancer Prior to Staging Pelvic Lymph Node Dissection (Protocol 356In15) (12/92) 547

2875  McLeod, David COL MC. Administration of Intravenous Doses of 111 In-CYT-356 in the Detection of Occult Prostate Carcinoma (Protocol 356In14) (12/92) 548

2876  Moul, Judd MAJ MC. Detection of the c-erbB-2 Oncogene Protein in Serum and Tissue of Patients with Prostate Cancer, Benign Prostate Conditions, and No Prostate Disease (12/92) 549

2877  Moul, Judd MAJ MC. Detection of Cathepsin D in the Seminal Plasma and Tissues of Patients with Prostate Cancer, Benign Prostate Conditions, and No Prostate Disease (2/93) 550

2878  Sihelnik, Stephen. Treatment of Benign Prostatic Hyperplasia: Pilot Study (7/93) 551

2879  Sihelnik, Stephen LTC MC. Early Medical Treatment of BPH (7/93) 552

2880  Zorn, Burkhardt MAJ MC. Nerve Growth Factor and Basic Fibroblast Growth Factor in the Urine of Patients with Prostatism and Interstitial Cystitis (7/93) 553

2881  Costabile, Raymond MAJ MC. Program for Treatment of Erectile Failure with MUSE (Medicated Urethral System for Erection) (8/93) 554

2882  Irby, Pierce LTC MC. Incidence of Stool Guaiac Conversion Following Extracorporeal Shock Wave Lithotripsy (ESWL) (8/93) 555

IRELAND AH, FORT KNOX, KY

8101  Zuehlke, Robert MAJ DC. The Effect of Antituberculosis Drugs on Human Gingival Indices - A Clinical Study (6/93) 556

* Reference is to page number(s) in Volume II.
CITATION*  TYPE**

ALLERGY-IMMUNOLOGY SERVICE


Carregal V, Davis W, Hershey J, Berger T, Salata K: Expression of CD45RA and CD45RO on lymphocytes during aeroallergy immunotherapy. 49th Annual Meeting of the American Academy of Allergy and Immunology, Chicago, IL, 1993. [3367]  Pr

Carregal V, Davis W, Hershey J, Berger T, Salata K: Expression of CD45RA and CD45RO on lymphocytes during aeroallergen immunotherapy. 8th Annual Harold S. Nelson Allergy, Immunology Symposium, Fitzsimons Army Medical Center, Denver, CO, February, 1994. [3367]  Pr


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

ALLERGY-IMMUNOLOGY SERVICE (continued)


DEPARTMENT OF CLINICAL INVESTIGATION


Dobek A, Chung R, Rothman S: Comparison of detection of Clostridium difficile toxin by a commercial ELISA test kit versus HeLa cell assay from patient stools. The General Meeting of the American Society for Microbiology, Las Vegas, NV, May, 1994. [9284]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
### PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

**CITATION**

**TYPE**

<table>
<thead>
<tr>
<th>DEPARTMENT OF CLINICAL INVESTIGATION (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
</tr>
<tr>
<td>P</td>
</tr>
<tr>
<td>P</td>
</tr>
<tr>
<td>Sfikakis PP, Oglesby R, Charalampopoulos S, Sfikakis P, Tsokos G: Correlation of elevated levels of soluble intercellular adhesion molecule-1 (sICAM-1) and IL-2 receptor (sIL2R) in the blood of patients with systemic lupus erythematosus. Riv Espanola de Rheumatologia 1993;20 (XVII ILAR):344. [3714]</td>
</tr>
<tr>
<td>Ab</td>
</tr>
<tr>
<td>P</td>
</tr>
<tr>
<td>Ab</td>
</tr>
<tr>
<td>Ab</td>
</tr>
<tr>
<td>Ab</td>
</tr>
<tr>
<td>Ab</td>
</tr>
</tbody>
</table>

* Number in [ ] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation**


FORT DIX, NEW JERSEY


FORT DRUM, NY


HIV RESEARCH


Atkinson J, Patterson T, Chandler J, Sciolla A: Predicting depression in HIV disorder. 10th International Conference on AIDS, Yokohama, Japan, August, 1994. [7243]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
Burrell L: Negative regulators may mediate hematopoietic suppression in HIV-infected marrow long term cultures. Medicine Branch Research Seminar, National Cancer Institute, Bethesda, MD, 1993. [8825]

Burrell L: Negative regulators may mediate hematopoietic suppression in HIV-infected marrow long term cultures. Immunology Section Seminar, National Cancer Institute, Bethesda, MD, 1993. [8825]


Konzelman J: Oral manifestations of HIV infection. Oral Pathology Continuing Education Course, National Naval Dental Center, Bethesda, MD, 1993. [8805]

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
HIV RESEARCH (continued)


Law W: Neurobehavioral aspects of HIV/AIDS. The Medical Psychology Seminar, Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD, May, 1994. [7243]


Mapou R, Law W: Neurobehavioral aspects of HIV disease: focus on studies from the military's HIV research program. Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD, January, 1994. [7243]


Martinez M, Konzelman J, Engler R: Oral hairy leukoplakia associated with low CD4 counts in a patient without HIV infection. Proceedings of the 50th Anniversary Meeting of the American Academy of Allergy and Immunology, Chicago, IL, 1993. [8805]

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation

89
CITATION*

HIV RESEARCH (continued)

Martinez M, Konzelman J, Engler R: Oral hairy leukoplakia associated with low CD4 counts in a patient without HIV infection. 50th Anniversary Meeting of the American Academy of Allergy and Immunology, Chicago, IL, 1993. [8805]


Mayers D: Clinical significance of in vitro zidovudine resistance. 3rd Workshop on Viral Resistance, Gaithersburg, MD, 1993. [8818]


* Number in [] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
**CITATION**

**HIV RESEARCH (continued)**


Patterson T, Semple S, Grant I: Findings from an HIV-positive risk relevant behavior survey: implications for the development of an intervention to reduce HIV transmission potential. The Society of Behavioral Medicine's 15 Anniversary Meeting, Boston, MA, April, 1994. [7243]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr94 presentation
HIV RESEARCH (continued)

Raszka W, Meyer C, Waecker N, Ascher D, Moriarty R, Robb M:
Variability of serial absolute and percent CD4+ lymphocyte counts
in uninfected children born to human immunodeficiency

Raszka W, Moriarty R, Ascher D, Waecker N, Ottolini M, Goldberg D,
Krober M, Robb M: Analysis of serial absolute and percent CD4+
lymphocyte counts in HIV-1-infected infants and children. 1st
National Conference on Human Retroviruses and Related Infections,
Washington, DC, December, 1993. [6264]

Ratto S, Sitz K, Loomis L, Manca F, Redfield R, Birx D: Epitope
mapping of CD4+ T-lymphocyte lines from seropositive patients
enrolled in a rgpl60 vaccine trial. J Cellular Biochem 1994;(Suppl 18D):V120. [8806]

Redfield R, Birx D, Brundage J, Aronson N, Johnson S, Kim J, Lennox J,
Michael N, Robb M, Sitz K, Oster C, Burke D: Long-term clinical
follow-up of volunteers enrolled in a rgpl60 phase I safety and
immunogenicity vaccine therapy trial. Proceedings of the 6th
National Cooperative Vaccine Development Group Conference,
Alexandria, VA, October, 1993. [8806]

Redfield R, Birx D, Brundage J, Aronson N, Johnson S, Kim J, Lennox J,
Michael N, Robb M, Sitz K, Oster C, Burke D: Long term clinical
follow-up of volunteers enrolled in a rgpl60 Phase I safety and
immunogenicity vaccine therapy trial. 6th National Cooperative
Vaccine Development Group Conference, Alexandria, VA, October,
1993. [8806]

Robb M, Vahey M, Waecker N: Development of a marker for HIV viral
burden in pediatric patients using quantitative RNA and DNA PCR of
[6264]

Rubin H, Patterson T, Atkinson J, Kaplan R, Koch W, McCutchan J,
Chandler J, Grant J: Quality of life in people with depressive
symptoms and HIV. 10th International Conference on AIDS,
Yokohama, Japan, August, 1994. [7243]

Schwartz G, Kessler S, Francis M, Burrell L, Hoover D, Meltzer M:
Negative regulators may mediate hematopoietic suppression in
HIV-infected marrow long-term cultures. 3rd International
Conference on the Negative Regulation of Hemopoietic Cell Growth
and Differentiation, Paris, France, 1993. [8825]

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
HIV RESEARCH (continued)


Smith K, Wagner K, Skelton H, Yeager J: Staphylococcus aureus carriage and HIV-1 disease: association with increased mucocutaneous infections as well as deep soft tissue and sepsis, and a possible role in disease progression. Arch Derm 1994;130:521-2. [8812]

* Number in [ ] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
HIV RESEARCH (continued)


Smith K: Histologic and immunohistochemical features seen in biopsy sites in which bovine collagen matrix was used for hemostasis. Meeting of the American Society of Dermatopathology, Washington, DC, December, 1993. [8812]  


* Number in [ ] is the protocol number.  
** P = publication, Ab = abstract, Pr = presentation
CITATION*  

HIV RESEARCH (continued)  

Straits-Troster K, Patterson T, Semple S, Temoshok L, Atkinson J, 
Chaired J, Grant I: Type of social support predicting depression 
varies according to stage of HIV disease: a prospective study. 
Ann Behav Medicine 1994;16:185. [7243]  

Straits-Troster K, Patterson T, Semple S, Temoshok L, Roth P, McCutchan 
J, Chandler J, Grant I: The relationship between loneliness, 
interpersonal competence, and immunologic status in HIV-infected 

Swango P, Kleinman D, Konzelman J: Epidemiology of oral effects of HIV 
infection in a U.S. military population. Proceedings of the 2nd 
International Workshop on the Oral Manifestations of HIV 
Infection, San Francisco, CA, 1993. [8805]  

Swango P, Kleinman D, Konzelman J: Epidemiology of oral effects of HIV 
infection in a U.S. military population. 2nd International 
Workshop of the Oral Manifestations of HIV Infection, San 
Francisco, CA, 1993. [8805]  

Swango P, Kleinman D, Ries L: Incidence trends in HIV-related cancers 
[8805]  

Temoshok L, Nannis E, Brandt U, Newby J, Johnson C, Sharp-Breslau E, 
Blake S: Seropositive behavior survey. Tri-Service 
biopsychosocial HIV study. 5th Biennial AMEDD HIV/AIDS Symposium, 
Tysons Corner, VA, June, 1994. [7243]  

Turnicky R, Anderson D, Nau M, Zhao F, Coates J: Variant HIV RNA 
distribution within lymph nodes and tonsils of stage-matched 
patients. Proceedings of the 10th International Conference on 
AIDS, Yokohama, Japan, August, 1994. [2529]  

Turnicky R, Anderson D, Nau M, Zhao F, Coates J, Mayers D: Variant HIV 
RNA distribution within lymph nodes and tonsils of stage matched 
patients. 10th International Conference on AIDS, Yokohama, Japan, 
August, 1994. [2529]  

Turnicky R, Anderson D, Nau M, Zhao F, Coates J, Mayers D: Phenotypic 
profile of HIV lymph nodes and tonsils using quantitative image 
analysis. Proceedings of the 10th International Conference on 
AIDS, Yokohama, Japan, August, 1994. [2529]  

* Number in [] is the protocol number.  
** P = publication, Ab = abstract, Pr = presentation
HIV RESEARCH (continued)


DEPARTMENT OF MEDICINE
Cancer & Leukemia Group B


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

DEPARTMENT OF MEDICINE
Cardiology Service


* Number in [] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
CITATION*  

DEPARTMENT OF MEDICINE  
Cardiology Service (continued)  


* Number in [] is the protocol number.  
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*  

DEPARTMENT OF MEDICINE  
Cardiology Service (continued)


Zamani K, Honig P, Lu X, Yang S, Almirez R, Cantilena L: Differences in enantioselective metabolism of terfenadine by humans and rats. 5th World Congress of Chirality, Toronto, Canada, 1993. [1272]

DEPARTMENT OF MEDICINE  
Endocrine-Metabolic Service

Bernet V, Solomon B, Cranston T, Burman K: TSH suppression: daytime values may rise to unacceptable values at night. 75th Annual Meeting of the American Thyroid Association, Chicago, IL, September, 1994. [1362-93]

* Number in [ ] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service (continued)

Bhatia S, Lukes Y, Kuppers R, Rose N: Sequence analysis of antigenic
determinants of thyroglobulin. Proceedings of the Annual Meeting
[1316-89]

Bhatia S, Lukes Y, Kuppers R, Rose N: Sequence analysis of antigenic
determinants of thyroglobulin. Annual Meeting of the American
Thyroid Association, Tampa, FL, November, 1993. [1316-89]

Burch H, Sellitti D, Barnes S, Nagy E, Bahn S, Burman K: Thyrotropin
receptor antisera for the detection of immunoreactive protein
species in retroocular fibroblasts obtained from patients with
Graves' ophthalmopathy. J Clin Endocrinol Metab
1994;78(6):1384-91. [1336-91]

therapy for Graves' disease with and without antithyroid drug
pretreatment. Meeting of the Endocrine Society, Anaheim, CA,
June, 1994. [1349-92]

therapy for Graves' disease with and without antithyroid drug
pretreatment. Proceedings of the Meeting of the Endocrine

Burch H, Solomon B, Wartofsky L, Burman K: Discontinuation of
antithyroid therapy before ablation with radiiodine in Graves'

Burch H, Solomon B: Acute changes in thyroid hormone levels in Graves'
disease following discontinuation of antithyroid therapy and
ablation with radiiodine. 69th Annual Meeting of the American
Thyroid Association, Tampa, FL, November, 1993. [1349-92]

Carr F, Fisher C, Smallridge R: Inhibition of Cjun and Cfos by
antisense vectors blocks TRH-stimulation of TSH gene expression.
69th Annual Meeting of the American Thyroid Association, Tampa,
FL, November, 1993. [1328-90]

Carr F, Fisher C, Smallridge R: Inhibition of cjun and cfos by
antisense vector blocks TRH-stimulation of TSH gene expression.
21st European Thyroid Association, Cardiff, Wales, 1993. [1328-90]

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation

100


Kushner J: Awareness of nutrition by hospital health care providers. Clinical Investigator Recognition Seminar, Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, January, 1994. [1341-92]

Kushner J: Awareness of nutrition by hospital health care providers. 34th Annual Meeting of the American College of Nutrition, Chicago, IL, October, 1993. [1341-92]

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
Endocrine-Metabolic Service (continued)


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service (continued)


DEPARTMENT OF MEDICINE
Gastroenterology Service

Cremins J, Salata K, Kikendall J, Hershey J, Nair P, Wong R:
PNA-binding to isolated colonocytes may diagnose colon carcinoma.
Digestive Disease Week, Meeting of the American Gastroenterological Association, New Orleans, LA, May, 1994. [1423]

Cremins J, Salata K, Kikendall J, Hershey J, Nair P, Wong R:
PNA-binding to isolated colonocytes may diagnose colon carcinoma.

Cremins J, Salata K, Kikendall J, Hershey J, Nair P, Wong R:
Colonocyte expression of CD and HLA markers in patients with normal and neoplastic colons. Gastroenterology 1994;106:A379. [1423]

DeMarkles M, Murphy J, Maydonovitch C, Greenwall S, Wong R, Sjogren M:
Hepatitis C viral transmission in a military population. Annual Meeting of the American College of Gastroenterology, New York, NY, October, 1993. [1422]


* Number in [] is the protocol number.
** P - publication, Ab - abstract, Pr - presentation

103
DEPARTMENT OF MEDICINE
Gastroenterology Service (continued)


DEPARTMENT OF MEDICINE
General Medicine Service


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF MEDICINE
General Medicine Service (continued)


DEPARTMENT OF MEDICINE
Hematology-Oncology Service


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF MEDICINE
Hematology-Oncology Service (continued)


La Russo V, Mosca J, Kaushal S, Cutting M, Kessler S, Reid T: CD34+ stromal cell precursors are possible targets for HIV. Meeting of the American Society of Hematology, St. Louis, MO, December, 1993. [1686]

La Russo V, Mosca J, Kaushal S, Cutting M, Kessler S, Reid T: CD34+ stromal cell precursors are possible targets for HIV. Blood 1993; 82:414a. [1686]


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


Wiesen A: Equilibration of hemoglobin following transfusion. 10th Annual Scientific Meeting of the American College of Physicians, Buena Vista, FL, November, 1993. [1684]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
DEPARTMENT OF MEDICINE
Infectious Disease Service


DEPARTMENT OF MEDICINE
Nephrology Service


PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

DEPARTMENT OF MEDICINE
  Nephrology Service (continued)


Welch P: Safety and immunogenicity of a conjugate vaccine against Staphylococcus Aureus type 5 capsular polysaccharide in hemodialysis patients. 26th Annual Meeting of the American Society of Nephrology, Boston, MA, November, 1993. [1169]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation

111
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

DEPARTMENT OF MEDICINE
Nephrology Service (continued)


DEPARTMENT OF MEDICINE
Pulmonary & Critical Care Medicine Service

Stoltzfus D: Patterns of ischemia-Holter monitoring in patients with previous PTCA or CABC. Clinical Investigator Recognition Seminar, Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, 1993. [3011]

DEPARTMENT OF MEDICINE
Pulmonary Disease Service


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation

113
CITATION*

DEPARTMENT OF MEDICINE
Pulmonary Disease Service (continued)

DeRectorian S, Kumke K, Hamm C, Phillips Y, Rajagopal K: Ambient
ventilatory response to flow resistive loading in asthmatics with
chronic airflow obstruction. Proceedings of the American College
[1754]

Dillard T, Moores L, Bilello K, Phillips Y: The pre-flight evaluation:
a comparison of the hypoxic inhalation test with hypobaric
exposure. International Conference of the American Lung
[1749]

Dillard T, Moores L, Bilello K, Phillips Y: The pre-flight evaluation:
a comparison of the hypoxic inhalation test with hypobaric

Hnatiuk O: Adherence to established guidelines for preoperative
pulmonary function testing. Proceedings of the 10th Army Regional
Meeting of the American College of Physicians, Orlando, FL,
November, 1993. [1761]

Hnatiuk O: Adherence to established guidelines for preoperative
pulmonary function testing. 10th Army Regional Meeting of the
[1761]

period during provocation with eucapnic hyperventilation and

Knutson S, Dillard T, Berg B, Mehm W: Impact of exercise on severity
[1749]

Knutson S: Effect of upright and supine posture on hypoxemia during
air transport. 10th Army Regional Meeting of the American College
of Physicians, Orlando, FL, November, 1993. [1749]

Knutson S: Effect of upright and supine posture on hypoxemia during
air transport. 59th Annual International Scientific Assembly of
the American College of Chest Physicians, Orlando, FL, October,
1993. [1749]

* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*  

DEPARTMENT OF MEDICINE  
Pulmonary Disease Service (continued)


Lepler L: Utility of capnography in the assessment of obstructive lung disease. 10th Army Regional Meeting of the American College of Physicians, Orlando, FL, November, 1993. [1760]


Parker J: Impact of stated versus measured height on screening spirometry. 10th Army Regional Meeting of the American College of Physicians, Orlando, FL, November, 1993. [1753]


* Number in [] is the protocol number.  
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION

DEPARTMENT OF MEDICINE
Pulmonary Disease Service (continued)


DEPARTMENT OF MEDICINE
Rheumatology Service


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation

116


Tsokos G: Lymphocytes, cytokines, inflammation, and immune trafficking in SLE. Curr Opin in Rheumatol 1994;6:461-7. [3711]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF MEDICINE
Rheumatology Service (continued)


NEUROLOGY SERVICE


Davis D, Jabbari B: Significant improvement of Stiffperson-person syndrome after paraspinal administration of botulinum toxin A. Movement Disord 1993;8:371-3. [7150]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
NEUROLOGY SERVICE (continued)


Polo K, Jabbari B: Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord 1994;March 9(2):233-5. [7150]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

NEUROLOGY SERVICE (continued)


Salazar A: Acute pathogenesis of traumatic brain injury. Department of Veterans Affairs Vocational Rehabilitation and Counseling Head Injury Symposium, Milwaukee, WI, 1993. [7144]


DEPARTMENT OF NURSING


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION


Sarnecky M: From whence we came: a story of the predecessors of the Army Nurse Corps. 11th Annual Conference on Nursing History, Chicago, IL, September, 1994. [7533]

Shotkin J, Lombardo F: Use of an indwelling peripheral catheter for 3-5 days sequential chemotherapy dosing in the outpatient setting. Proceedings of the Eighth Biennial Phyllis J. Verhonick Research Course, Fitzsimmons Army Medical Center, Aurora, CO, June, 1994. [7527]

Shotkin J: Use of an indwelling peripheral catheter for 3-5 days sequential chemotherapy dosing in the outpatient setting. Eight Biennial Phyllis J. Verhonick Research Course, Fitzsimmons Army Medical Center, Aurora, CO, June, 1994. [7527]

DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES


* Number in [ ] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
DEPARTMENT OF PEDIATRICS (continued)


DEPARTMENT OF PEDIATRICS
Pediatric Hematology-Oncology Service


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
Beattie B: Descriptive analysis of a collaborative practice model developed by the Physical Medicine Therapy and Occupational Therapy Sections at Walter Reed Army Medical Center in response to Desert Shield/Storm contingencies. 9th Annual Physical Medicine and Rehabilitation Short Course, Washington, DC, 1993. [9623]


Braverman S: Intern perceptions of Physical Medicine and Rehabilitation. Clinical Investigator Recognition Seminar, Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, January, 1994. [9616]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION

PHYSICAL MEDICINE AND REHABILITATION SERVICE (continued)


DEPARTMENT OF PSYCHIATRY


Lande R: The art of crime. 7th MEDCOM Conference, Garmisch, Germany, April, 1994. [7249]

DEPARTMENT OF SURGERY

Anesthesia-Operative Service


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation

126
DEPARTMENT OF SURGERY
Anesthesia-Operative Service (continued)


DEPARTMENT OF SURGERY
Army Audiology and Speech Center


Beamer S: Hearing aid benefit in patients with high frequency hearing loss. Military Audiology Short Course, Richmond, VA, April, 1994. [2525]


Grant K, Walden B: Evaluating the articulation index for auditory-visual consonant recognition. Fall Meeting of the Acoustical Society of America, Denver, CO, October, 1993. [2528]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation

127


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

**CITATION**

DEPARTMENT OF SURGERY
Army Audiology and Speech Center (continued)


DEPARTMENT OF SURGERY
Ophthalmology Service


* Number in [] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

DEPARTMENT OF SURGERY
Orthopaedic Surgery Service


* Number in [] is the protocol number.

** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF SURGERY
Orthopaedic Surgery Service (continued)

DeVries W, Popovic N, Xenos J, Chang A, Mulligan M, Hopkinson W:
Evaluation of lateral ankle ligaments and effectiveness of ankle
braces during rotational force across the tibiotalar joint.
Meeting of the Society of Military Orthopaedic Surgeons, Bethesda,
MD, December, 1993. [2441]

DeVries W, Popovic N, Xenos J, Hopkinson W: Evaluation of the lateral
ankle ligaments during rotational forces across the ankle joint.
Orthopaed Trans 1994;18(1):186. [2441]

DeVries W, Xenos J, Popovic N, Mulligan M, Hopkinson W: Evaluation of
the lateral ankle ligaments and effectiveness of ankle braces
during rotational forces across the ankle joint. 3rd Annual
Orthopaedic Research Day, Walter Reed Army Medical Center,
Washington, DC, June, 1994. [2441]

DeVries W: Subtalar arthrodesis in the pediatric population, a long
term follow-up study. Residents' Night Competition, Washington
Orthopaedic Society, Washington, DC, 1993. [2447]

Deffer P, Popovic N, DeVries W, Cook J, Smith A: Carpal ligament
injuries associated with fractures of the distal radius: a cadaver
study. 3rd Annual Orthopaedic Research Day, Walter Reed Army
Medical Center, Washington, DC, June, 1994. [2451]

Hansen M, Polly D, McHale K, Asplund L: A prospective evaluation of
orthopedic patients evacuated from Operation Desert Shield and
Desert Storm: the Walter Reed experience. Military Med
1994;159(5):376. [2457]

Johnson K, Popovic N, Linden C, Wilhelm G, McKinney L, Hollinger J:
The osteoconductive potential of a polycaprolactone foam in the
rat tibia. 3rd Annual Orthopaedic Research Day, Walter Reed Army
Medical Center, Washington, DC, June, 1994. [2452]

Kilkelly F, Popovic N, Choma T, Miller D, Johnstone F, Sweet D: Tendon
repair by laser welding: a biomechanical and histologic comparison
of suture repair with CO2 and argon lasers. 3rd Annual
Orthopaedic Research Day, Walter Reed Army Medical Center,
Washington, DC, June, 1994. [2454]

* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION*

DEPARTMENT OF SURGERY
Orthopaedic Surgery Service (continued)


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation

132
DEPARTMENT OF SURGERY
Orthopaedic Surgery Service (continued)


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
Xenos J: The tibiofibular syndesmosis: evaluation of the ligamentous structures, methods of fixation and radiographic assessment. Hufnagel Award recipient, Uniformed Services University of the Health Sciences, Bethesda, MD, 1993. [2432]

DEPARTMENT OF SURGERY
Urology Service


Lewis D: Immunohistochemical expression of p53 tumor suppressor gene protein in adult germ cell tests tumors. Clinical Investigator Recognition Seminar, Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, December, 1993. [2873]


Lewis D: P53 tumor suppressor gene expression in germ cell testis tumors. 13th Annual Surgical Associates Day of the Uniformed Services University of the Health Sciences, Bethesda, MD, 1993. [2873]


* Number in [] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*

DEPARTMENT OF SURGERY
Urology Service (continued)

Lewis D: Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. Meeting of the Mid-Atlantic Section of the American Urological Association, Palm Beach, FL, 1993. [2873]


Moul J: Cathepsin-D expression in prostate cancer. 51st Mid-Atlantic American Urological Association Meeting, Palm Beach, FL, 1993. [2877]

Moul J: Cathepsin-D expression in clinically localized adenocarcinoma of the prostate. 41st James C. Kimbrough Urological Seminar, San Diego, CA, October, 1993. [2877]


IRELAND AH, FORT KNOX, KY


* Number in [ ] is the protocol number.
** P = publication, Ab = abstract, Pr = presentation
CITATION*  

DEPARTMENT OF MEDICINE  
Cardiology Service  


DEPARTMENT OF MEDICINE  
Endocrine-Metabolic Service  


* Number in [ ] is the closed protocol number  
** P = publication, Ab = abstract, Pr = presentation  
136
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-94

CITATION* Type**

DEPARTMENT OF MEDICINE
Gastroenterology Service

Cremins J, Salata K, Kikendall J, Hershey J, Nair P, Wong R:
Colonocyte expression of CD and HLA markers in patients with

Cremins J, Salata K, Kikendall J, Hershey J, Nair P, Wong R: PNA-
binding to isolated colonocytes may diagnose colon carcinoma.
Gastro 1994;106(4):A379. [1414]

Cremins J, Salata K, Kikendall J, Hershey J, Nair P, Wong R: PNA
binding to isolated colonocytes may diagnose colon carcinoma.
95th Annual Meeting of the American Gastroenterologic

Gilchrist W, Burkhalter E, Eaton C, Schaudies R, Maydonovitch C,
Andrada F, Abdel-Rahim M, Wong R: The effect of indomethacin
on the secretion of human salivary epidermal growth factor.
Am J Gastro 1994;89(1):97-100. [1496]

Kikendall J, Glass A, Sobin L, Bowen P: Serum gastrin is not higher
in subjects with colonic neoplasia. Am J Gastroenterol 1994;
87(10):1394-7. [1414]

Moses F: Gastrointestinal bleeding and the athlete. Am J
Gastroenterol 1993;88(8):1157-9. [2031]

Moses F, Stamm C, Peller P, Larsen B, Peller T, Brewer T: Oral
low-dose pulse methotrexate in primary sclerosing
cholangitis: an open-label trial. American College of
[1419]

Murphy J, Maydonovitch C, Phillips R, Luk G, Tang D, Wong R:
Omeprazole-induced hypergastrinemia does not increase colonic
proliferation. American Gastroenterology Association Annual
Meeting, Boston, MA, 1993. [1401]

Murphy J, Maydonovitch C, Phillips R, Luk G, Tang D, Wong R:
Omeprazole-induced hypergastrinemia does not increase colonic
proliferation. 21st Annual William Beaumont Gastrointestinal
Symposium of the Army Regional American College of Physicians,
Orlando, FL, November, 1993 [1401]

* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation

137
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-94

CITATION*

DEPARTMENT OF MEDICINE
Gastroenterology Service (continued)


DEPARTMENT OF MEDICINE
General Medicine Service


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation

138
<table>
<thead>
<tr>
<th>Citation</th>
<th>Type**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
</tr>
<tr>
<td>General Medicine Service (continued)</td>
<td></td>
</tr>
<tr>
<td>Reed W, Herbers J, Noel G: Cholesterol-lowering therapy: what patients</td>
<td>P</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
<td></td>
</tr>
<tr>
<td>Hematology-Oncology Service</td>
<td></td>
</tr>
<tr>
<td>R, Cooper M, Barlogie B, Trump D, Doroshow J, Aisner J, Pugh R,</td>
<td></td>
</tr>
<tr>
<td>study of doxorubicin and dacarbazine with or without ifosfamide and</td>
<td></td>
</tr>
<tr>
<td>1276-85. [1564]</td>
<td></td>
</tr>
<tr>
<td>Peters W, Ross M, Vredenburgh J, Meisenberg B, Marks L, Winer E,</td>
<td>P</td>
</tr>
<tr>
<td>High-dose chemotherapy and autologous bone marrow support as</td>
<td></td>
</tr>
<tr>
<td>consolidation after standard dose adjuvant therapy for high-risk</td>
<td></td>
</tr>
<tr>
<td>Reid T, Greilich P, Carr M, Alving B: Quantitative clot retraction:</td>
<td>Ab</td>
</tr>
<tr>
<td>a method for assessing the function of fresh and stored platelets and</td>
<td></td>
</tr>
<tr>
<td>GPIIb/IIa receptors. Blood 1994;99:A100. [2072A]</td>
<td></td>
</tr>
<tr>
<td>Vukelja S, Krishnan J, Diehl L: Mean platelet volume improves upon the</td>
<td>P</td>
</tr>
<tr>
<td>megathrombocyte index but cannot replace the blood film examination in</td>
<td></td>
</tr>
<tr>
<td>the evaluation of thrombocytopenia. Am J Hematol 1993;44:89-94. [1647]</td>
<td></td>
</tr>
<tr>
<td>phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B</td>
<td></td>
</tr>
</tbody>
</table>

* Number in [ ] is the closed protocol number

** P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-94

CITATION*

DEPARTMENT OF MEDICINE
Pulmonary Disease Service

Argyros G: Presentation of carcinoma metastatic to the thorax and diagnosis with fiberoptic bronchoscopy. Department of Clinical Investigation Recognition Seminar, Walter Reed Army Medical Center, Washington, DC, 1993. [1756]


Eisenhauer M: Risk and incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Department of Clinical Investigation Recognition Seminar, Walter Reed Army Medical Center, Washington, DC, 1993. [1738]


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation

140
CITATION*  

DEPARTMENT OF MEDICINE  
Pulmonary Disease Service (continued)


NEUROLOGY SERVICE


DEPARTMENT OF NURSING


* Number in [ ] is the closed protocol number  
** P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-94

CITATION*

DEPARTMENT OF PEDIATRICS
Pediatric Hematology/Oncology Service


DEPARTMENT OF RADIOLOGY


DEPARTMENT OF SURGERY
Anesthesiology-Operative Service


DEPARTMENT OF SURGERY
Army Audiology and Speech Center


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation

142
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-94

CITATION* Type**

DEPARTMENT OF SURGERY
Otolaryngology/Head and Neck Surgery Service


DEPARTMENT OF SURGERY
Urology Service

Moul J: Molecular biology of prostate cancer. University of Iowa, Iowa City, IA, 1993. [2860]


* Number in [ ] is the closed protocol number
** P = publication, Ab = abstract, Pr = presentation

143
CITATION

ALLERGY-IMMUNOLOGY SERVICE


Carpenter G, Oster C. Adverse drug reactions to rifampin and tolmetin presenting as sepsis syndrome. American Academy of Allergy and Immunology, Chicago, IL, March, 1993.


* P = publication, Ab = abstract, Pr = presentation
CITATION

ALLERGY-IMMUNOLOGY SERVICE (continued)


Salata K, Berger T: Anti-inflammatory action of N-(fluorenyl-9-methoxy carbonyl)-leucine, effect on neutrophil and lymphocyte activation. American Association of Allergy and Immunology, Chicago, IL, March, 1993.

* P = publication, Ab = abstract, Pr = presentation

145
<table>
<thead>
<tr>
<th>Citation</th>
<th>Type*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALLERGY-IMMUNOLOGY SERVICE (continued)</strong></td>
<td></td>
</tr>
<tr>
<td>Salata K, Berger T: Anti-inflammatory action of N-(fluorenyl-9-</td>
<td>Ab</td>
</tr>
<tr>
<td>methoxycarbonyl)-L-leucine, effect on neutrophil and</td>
<td></td>
</tr>
<tr>
<td>Selzer J, Findlay S, Morgan J, Salata K, Zeiger R: Multicenter trial</td>
<td>Pr</td>
</tr>
<tr>
<td>comparing potency of different D farinae extracts with prick</td>
<td></td>
</tr>
<tr>
<td>puncture. American Association of Allergy and Immunology,</td>
<td></td>
</tr>
<tr>
<td>Chicago, IL, March, 1993.</td>
<td></td>
</tr>
<tr>
<td>Selzer J, Findlay S, Morgan J, Salata K, Zeiger R: Multicenter trial</td>
<td>Ab</td>
</tr>
<tr>
<td>comparing potency of different D farinae extracts with prick</td>
<td></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF CLINICAL INVESTIGATION</strong></td>
<td></td>
</tr>
<tr>
<td>Chan C, Strickman D, Kelly D, Weddle J, Dasch G, Paxton H:</td>
<td>Pr</td>
</tr>
<tr>
<td>Laboratory validations of dot blot immunoassays (dipsticks)</td>
<td></td>
</tr>
<tr>
<td>for murine, epidemic, and scrub typhus. American Society of</td>
<td></td>
</tr>
<tr>
<td>Rickettsiology and Rickettsial Diseases, St. Simon's Island,</td>
<td></td>
</tr>
<tr>
<td>Corwin A, Olson J, Habib M, Dasch G, Kelly D, Darwish M, Botros B,</td>
<td>Pr</td>
</tr>
<tr>
<td>Watts D, Arthur R: Community-based profiles of rickettsial</td>
<td></td>
</tr>
<tr>
<td>infections in the Nile river delta of Egypt. American Society of</td>
<td></td>
</tr>
<tr>
<td>Tropical Medicine and Hygiene 42nd Meeting, Atlanta, GA,</td>
<td></td>
</tr>
<tr>
<td>A serological survey for evidence of infection with pathogenic</td>
<td></td>
</tr>
<tr>
<td>rickettsiae in humans and animals of Indonesia. American Society for</td>
<td></td>
</tr>
<tr>
<td>Dasch G, Kelly D, Richards A, Sanchez J, Rives C: Western blotting</td>
<td>Pr</td>
</tr>
<tr>
<td>analysis of sera from military personnel exhibiting serological</td>
<td></td>
</tr>
<tr>
<td>reactivity to spotted fever group rickettsiae. American Society of</td>
<td></td>
</tr>
<tr>
<td>Tropical Medicine and Hygiene 42nd Meeting, Atlanta, GA, October-November, 1993.</td>
<td></td>
</tr>
<tr>
<td>Pridham K, Chang A, Chiu Y-M: Influences on mothers' use of clinician</td>
<td>P</td>
</tr>
<tr>
<td>help in the infants' first three months. Public Health Nursing</td>
<td></td>
</tr>
<tr>
<td>1994;11(2)80-9.</td>
<td></td>
</tr>
<tr>
<td>Pridham K, Chang A, Chiu Y-M: Mothers' parenting self-appraisal: the</td>
<td>P</td>
</tr>
<tr>
<td>contribution of perceived infant temperament. Research in</td>
<td></td>
</tr>
<tr>
<td>Nursing and Health 1994;17:381-92.</td>
<td></td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF CLINICAL INVESTIGATION (continued)


DEPARTMENT OF MEDICINE
Cardiology Service


* P = publication, Ab = abstract, Pr = presentation
CITATION

DEPARTMENT OF MEDICINE
Cardiology Service (continued)


Kovach J, Nearing B, Thurnher M, Verrier R: Effect of aggressive arousal on precordial T-wave alternans magnitude in the normal and ischemic canine heart with and without β-adrenergic blockade with metoprolol. JAM Coll Cardiol 1994;329A.


DEPARTMENT OF MEDICINE
Dermatology Service


* P = publication, Ab = abstract, Pr = presentation
ADDITIONAL PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Dermatology Service (continued)

Beard J, Smith K, Skelton H: Combination chemotherapy with
5-fluorouracil, folinic acid, and alpha-interferon producing
histologic features of graft-versus-host disease. J Am Acad
P
Beard J, Sperling L: Picture of the month. Congenital cartilaginous
P
P
Dunn C, James W: The role of magnetic resonance imaging in the
diagnostic evaluation of dermatomyositis. Arch Dermatol 1993;
129:1104-6.
P
P
Harrington A, Stasko T: Radiation-induced adiposis of the parotid
P
In: Lillegard, ed. Handbook of Sports Medicine. Stoneham, MA:
P
Montemarano A, Benson P, James W, Crowe M: Acute paronychia
apparently caused by Candida albicans in a healthy female.
Arch Dermatol 1993;129:786-7.
P
Montemarano A, James W: Staphylococcus aureus as a cause of perianal
P
bed and periungual area. A clinicopathologic analysis of
P
Schwab R, Giblin W, James W, Lupton G: Multiple cutaneous
P
absorbable collagen hemostatic sponges in cutaneous surgery in
P
Smack D, Korge B, James W: Keratins and keratinization. JAAD 1994;
P

* P = publication, Ab = abstract, Pr = presentation

149
ADDENDUM

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Dermatology Service (continued)

and immunohistochemical findings associated with inflammatory
dermatoses in human immunodeficiency virus type 1 disease and
their correlation with Walter Reed stage. J Am Acad Dermatol
1993;28:174-84.


Sperling L, Whiting D: Disorders of the hair shaft. In: Demis D, ed.
Clinical Dermatology. Philadelphia: J.P. Lippincott, 1994:
vol. 1, Unit 2-2, 1-29.

Trakimas C, Sperling L, Skelton H, Smith K: Temporal triangular

Clinical Dermatology. Philadelphia: J.P. Lippincott, 1993:
Unit 4-31, 1-9.

Vogel P, Heimer W, Sau P, Benson P: Primary cutaneous nocardia
infection due to Nocardia asteroides. Int J Dermatol 1993;32:
811-2.

lesions of Herpes simplex in HIV-1+ patients. Int J Dermatol

120-2.

features in inflammatory linear verrucous epidermal nevi
suggest a distinctive pattern of clonal dysregulation of

DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service

Jossart G: P53 mutations in thyroid tumors: evaluation of the
ability of SSCP to detect abnormalities. American Thyroid
Association, Chicago, IL, September, 1994.

* P = publication, Ab = abstract, Pr = presentation

150
CITATION

DEPARTMENT OF MEDICINE
Endocrine-Metabolic Service (continued)


* P = publication, Ab = abstract, Pr = presentation

151


McCormick S, Sjogren M: A case of markedly elevated α fetoprotein and a nonneoplastic liver mass. Amer J Gastro 1994;89(9):1741.


* P = publication, Ab = abstract, Pr = presentation
CITATION

DEPARTMENT OF MEDICINE
Gastroenterology Service (continued)


DEPARTMENT OF MEDICINE
General Medicine Service


* P = publication, Ab = abstract, Pr = presentation
CITATION

DEPARTMENT OF MEDICINE
General Medicine Service (continued)


* P = publication, Ab = abstract, Pr = presentation

154
CITATION

DEPARTMENT OF MEDICINE

General Medicine Service (continued)


DEPARTMENT OF MEDICINE

Hematology-Oncology Service


* P = publication, Ab = abstract, Pr = presentation

155
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Hematology-Oncology Service (continued)

Babcock J, Hartman K, Pederson A, Murphy M, Alving B: Rodenticide-
induced coagulopathy in a young child: a case of Munchausen
P
Baker W, Vukelja S, Weiss R: Multicentric angiofollicular lymph node
P
Bolan C, Krishnamurti C, Tang F, Alving B: Protein S deficiency in a
kindred with thrombosis previously attributed to elevated levels
of plasminogen activator inhibitor 1. International Society of
Haemostasis and Thrombosis XIVth Congress, New York, NY, July,
1993.
Pr
Bolan C, Krishnamurti C, Tang F, Alving B: Protein S deficiency in a
kindred with thrombosis previously attributed to elevated levels
of plasminogen activator inhibitor 1. Thromb Haemost 1993;69:
119.
Ab
Byrd J, Hargis J, Kester K, Hospenthal D, Weidner S, Diehl L:
Fludarabine therapy for lymphoid malignancies is associated
with a high number of opportunistic pulmonary infections.
Blood 1993;82:A539.
Ab
Byrd J, Weiss R: Recurrent granulocytic sarcoma: an unusual variation
of acute myelogenous leukemia associated with 8';21 chromosomal
translocation and blast expression of the neural cell adhesion
P
Byrd J, Weiss J, Kweeder S, Diehl L: Fludarabine therapy for lymphoid
malignancies is associated with hemolytic anemia. Proc Ann
Ab
Dawson N: Treatment of hormone-refractory metastatic prostate cancer.
P
Dawson N, Kobayashi K, Vogelzang N: Advances in the treatment of
"hormone-refractory" metastatic prostate cancer. In: Prostate
P
Dawson N, Sartor O, Gigg D, Headlee D, Tompkins A, Myers C: Suramin
response in patients with hormone-refractory prostate cancer
(HRPC) who have progressed after hydrocortisone and withdrawal
Ab

* P = publication, Ab = abstract, Pr = presentation

156
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Hematology-Oncology Service (continued)


Krishnamurti C, Boan C, Colleton C, Reilly T, Alving B: Comparison of the thrombogenic effects of ancord and thrombin on renal fibrin deposition in rabbits with elevated levels of plasminogen activator inhibitor (PAI-1). Throm Haem 1993;69:163.


Ladwig M, Giangeruso E, Reid T III: The effect of subcutaneous anti-Rh0(D) in adult patients with immune thrombocytopenic purpura. Transfusion 1993.


La Russa V, Mosca J, Cutting M, Kessler S, Reid T: CD34+ stromal cell precursors are possible targets for HIV. Blood 1993;82:414a.


* P = publication, Ab = abstract, Pr = presentation

157
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Hematology-Oncology Service (continued)


Reid T III, Alving B: A quantitative thrombin time for determining levels of hirudin and hirulog. Thromb Haemost 1993;70:608-16.


Reid T III, Alving B: The quantitative thrombin time (QTT): a simple, rapid method for monitoring levels of hirulog or r-hirudin in patient plasmas or whole blood. Thromb Haemost 1993;69:1306.


* P = publication, Ab = abstract, Pr = presentation

158
CITATION

DEPARTMENT OF MEDICINE
Hematology-Oncology Service (continued)


* P = publication, Ab = abstract, Pr = presentation
<table>
<thead>
<tr>
<th>Type*</th>
<th>CITATION</th>
</tr>
</thead>
</table>

* P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Infectious Disease Service (continued)


* P = publication, Ab = abstract, Pr = presentation

161
Addendum
Publications/Presentations by Department/Service and Author Not Related to Approved Clinical Investigation Protocols

Citation

Department of Medicine
Infectious Disease Service (continued)


Ockenhouse C: Molecular cloning of malaria sequestration ligands. VIIIth International Conference on Parasitology, Izmir, Turkey, October, 1994.

Ockenhouse C: NYVAC-Pf7, a multivalent Plasmodium falciparum vaccine expressed in vaccinia virus. VIIIth International Conference on Parasitology, Izmir, Turkey, October, 1994.


* P = publication, Ab = abstract, Pr = presentation
ADDITIONAL PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

**CITATION**

DEPARTMENT OF MEDICINE
Infectious Disease Service (continued)


*P = publication, Ab = abstract, Pr = presentation*
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Nephrology Service


DEPARTMENT OF MEDICINE
Pulmonary Disease Service


* P = publication, Ab = abstract, Pr = presentation

164
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF MEDICINE
Pulmonary Disease Service (continued)

Elsayed N, Dodd K, Fitzpatrick T: Biochemical alterations associated
with pulmonary contusion injury resulting from exposure to air
blast. American Thoracic Society and American Lung Association

Glass K, Dillard T, Dennis G, Dacey M, Dwyer T: Pyogenic arthritis
complicating varicella infection, Southern Med J 1994;87(8):
857-9.


smoking exposure. American Lung Association/American Thoracic

Hatch R, Parker J, Engler R: Wheezing, hypoxia, and dyspnea in a

Mayorga M, Januszkiewicz A, Fitzpatrick T: Platelet-activating factor
and leukotriene production following acute high-level nitrogen

Moores L: Evaluation of internist's screening spirometry
interpretations. American College of Physicians Army Regional

Murphy F, Manoun T, Knutson S, Eliasson A: Epinephrine-induced lactic
lactic acidosis in the setting of status asthmaticus. American
College of Physicians Washington Metropolitan Regional

Parker J, Torrington K, Phillips Y: Chylothorax complicating

Phillips Y: Clinical practice guidelines in the ATS. Symposium at
the American Lung Association/American Thoracic Society 1994

Phillips Y: Exercise-induced asthma and eucapnic voluntary
hyperventilation. Pulmonary Grand Rounds, Brown University,

Phillips Y: Staging of COPD. Symposium at the American Lung
Association/American Thoracic Society 1994 International

* P = publication, Ab = abstract, Pr = presentation
Addendum
Publications/Presentations by Department/Service and Author Not Related to Approved Clinical Investigation Protocols

Citation

Department of Medicine
Pulmonary Disease Service (continued)

Poropatich R: Atlantic telemedicine projects: field hospital applications in Somalia, Croatia, and Macedonia. Pacific Military Medical Conference, Honolulu, HI, April, 1994. Pr


Rayburn D, Fitzpatrick T, Van Albert S: Neural network evaluation of slopes from sequential volume segments of expiratory carbon dioxide curves. IEEE World Congress on Computational Intelligence, Orlando, FL, June, 1994. Pr


* P = publication, Ab = abstract, Pr = presentation

166
CITATION

DEPARTMENT OF MEDICINE
Pulmonary Disease Service (continued)


DEPARTMENT OF MEDICINE
Rheumatology Service


NEUROLOGY SERVICE


Koski K: Treatment of symptomatic square wave jerks. NONOS.


* P = publication, Ab = abstract, Pr = presentation

167
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

NEUROLOGY SERVICE (continued)

Salazar A: Acute pathogenesis of traumatic brain injury: long-term
gain recovery from penetrating brain wounds in Vietnam War Veterans,
Poly-ICLC in malignant gliomas, First Congress of Neurosurgeons
of the Ukraine, Kiev, November, 1993.

Salazar A: Biological response modifiers in neurologic diseases.

Salazar A: Developing therapies for acute head injuries: Post-
traumatic seizures. Traumatic Brain Injury Conference,
Brantree Hospital, Cambridge, MA, September, 1994.

Salazar A: First course for investigation in the neurologic sciences,

Salazar A: Head trauma. Osler Institute Neurology and Neurological

Salazar A: Mild brain injury in sports summit. National Athletic
Trainers’ Association Research and Education Foundation,
Atlanta, GA, April, 1994.

Salazar A: Pathogenesis of acute head injury. AAN Head Injury
Course, American Academy of Neurology Annual Meeting,
Washington, DC, April, 1994.

Salazar A: Post-traumatic epilepsy. Investigators’ Workshop of the

Salazar A: Post-traumatic epilepsy, Investigators’ Workshop of the
Foundation 12th Annual National Symposium, Orlando, FL,

Salazar A: TBI 2000: building the network. National Head Injury
Foundation 12th Annual National Symposium, Orlando, FL,

Guidelines for drug trials in memory disorders. New York:
Raven, 1993, 31-49.

The 5-minute clinical consult. Philadelphia: Lea and Febiger,
1993, 120-1.

Shafrir Y: Persistent nonprogressive chorea: an unusual presentation

* P = publication, Ab = abstract, Pr = presentation

168
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF NURSING


Reeder J: Families, grief and trauma. Trauma Nursing Grand Rounds, Beth Israel Hospital, Boston, MA, September, 1994.


Reeder J, King C: Societal and ethical challenges have impact on perioperative trauma nursing. Int J Trauma Nursing 1994;11-14.


* P = publication, Ab = abstract, Pr = presentation
<table>
<thead>
<tr>
<th>Citation</th>
<th>Type*</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPARTMENT OF NURSING</td>
<td></td>
</tr>
<tr>
<td>Anesthesia Nursing Service</td>
<td></td>
</tr>
<tr>
<td>Pollack G: Access to health care. 10th Annual Mary Kline Lecture Series, West Chester University, West Chester, PA, October, 1993.</td>
<td>Pr</td>
</tr>
<tr>
<td>Pollack G: Communicating with difficult colleagues. Annual Post-Graduate Anesthesia Practice Seminar, San Antonio, TX, May, 1994.</td>
<td>Pr</td>
</tr>
<tr>
<td>Pollack G: Women's health issues and health promotion. 7th Medical Command Nursing Conference, Passau, Germany, January, 1994.</td>
<td>Pr</td>
</tr>
<tr>
<td>Porter C: Communicating with difficult colleagues. Annual Post-Graduate Anesthesia Practice Seminar, San Antonio, TX, May, 1994.</td>
<td>Pr</td>
</tr>
<tr>
<td>Rutkowski D: Anesthesia nursing under combat conditions in Somalia. Nursing Education Grand Rounds, Walter Reed Army Medical Center, Washington, DC, April, 1994.</td>
<td>Pr</td>
</tr>
<tr>
<td>Rutkowski D: Army nursing and CRNA's. Lower Alabama Association of Nurse Anesthetists, Gulf Shores, AL, April, 1994.</td>
<td>Pr</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</th>
<th></th>
</tr>
</thead>
</table>

* P = publication, Ab = abstract, Pr = presentation
**ADDENDUM**

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

**CITATION**

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Title</th>
<th>Journal/Conference</th>
<th>Year</th>
<th>Page(s)</th>
</tr>
</thead>
</table>

**DEPARTMENT OF PATHOLOGY AND AREA LABORATORY SERVICES**

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Title</th>
<th>Journal/Conference</th>
<th>Year</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dow N, Gallasch K</td>
<td>Comparison of CD45/CD13 gated results vs CD45/CD14 gated results in lymphocyte subset testing</td>
<td>Clinical Cytometry Society 9th Annual Meeting, September 1994</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fielding C, et al</td>
<td>Recently described entities in oral maxillofacial pathology, Part I: Lesions of odontogenic and salivary origin</td>
<td>Naval Dental Corps Clinical Update</td>
<td>1994</td>
<td>16(4)</td>
</tr>
<tr>
<td>Griffin G, Lippert L, Dow N, Berger T, Hickman M, Salata K</td>
<td>A flow cytometric method for phenotyping recipient red cells following transfusion</td>
<td>Transfusion</td>
<td>1994</td>
<td>34:233-7</td>
</tr>
<tr>
<td>Ladwig M</td>
<td>Subcutaneous administration of Rho gam (anti-D)</td>
<td>American Association of Blood Banks Annual Meeting, Los Angeles, CA, October, 1993</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mellen P</td>
<td>Renal cell carcinoma in a 3 year old</td>
<td>J Neurol Orthopaedic Med Surg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract, Pr = presentation

171
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF PATHOLOGY AND AREA LABORATORY SERVICES (continued)


DEPARTMENT OF PEDIATRICS
Pediatric Gastroenterology and Nutrition


* P = publication, Ab = abstract, Pr = presentation
CITATION

DEPARTMENT OF PEDIATRICS
Pediatric Gastroenterology and Nutrition (continued)


* P = publication, Ab = abstract, Pr = presentation
CITATION

DEPARTMENT OF PEDIATRICS
Pediatric Gastroenterology and Nutrition (continued)


DEPARTMENT OF PEDIATRICS
Pediatric Hematology/Oncology Service


* P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF PEDIATRICS
Pediatric Hematology/Oncology Service (continued)

Herden M, De Bauche D: Detection of the MbcR-abl rearrangement of the
rearrangement by interphase-fluorescent in-situ hybridization in

Herden M, De Bauche D: Detection of the MbcR-abl rearrangement by
interphase-fluorescent in-situ hybridization in Philadelphia
chromosome positive leukemia. Proceedings of the Greenwood
Genetics Center 1994;13.

Lentz L, Grayson M, North E, Herden M, Bock H, DeBauche D: A case of
9p+ syndrome due to a 45,XY,–9/46,XY,r(9)(p22q34) karyotype.

Morrison F, Herden M, Lee D: Pediatric therapeutic hemapheresis.
Transfusion Med 1993; 3(suppl 1):34.

Mosijczuk A: Methods of clinical trials in pediatric oncology.
Proceedings of the 5th Annual Congress of the World Federation of
Ukrainian Medical Association 1994;A504.

Mosijczuk A: Methods of clinical trials in pediatric oncology.
World Federation of Ukrainian Medical Association 5th Annual

PHARMACY SERVICE

Howe J, Green D: A pharmacoeconomic analysis of doxicurium chloride
in extended cardiothoracics surgical procedures. Eastern States
Pharmacy C Conference, Baltimore, MD, April, 1994.

Strickland W: A DUE of filgrastim (G-CSF) in the adult oncology
outpatient setting. Eastern States Pharmacy Conference,
Baltimore, MD, April, 1994.

PHYSICAL MEDICINE AND REHABILITATION SERVICE

Henderson N, Metzger D: U.S. Army rehabilitation advisors in El

Marin R, Bryant P, Eng G: Lumbosacral plexopathy temporally related

* P = publication, Ab = abstract, Pr = presentation

175
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

PHYSICAL MEDICINE AND REHABILITATION SERVICE (continued)


DEPARTMENT OF PSYCHIATRY


Labbate L: Outcome of one versus two weeks phototherapy in SAD. American Psychiatric Association Annual Meeting, 1994; NR174.


* P = publication, Ab = abstract, Pr = presentation

176
ADDITIONAL PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF PSYCHIATRY (continued)


* P = publication, Ab = abstract, Pr = presentation

177
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF PSYCHIATRY (continued)


Wong N: The military psychologists' psychopharmacology prescribing program. University of South Dakota Psychiatric Association and Department of Psychiatry, South Dakota, September, 1994. Pr

* P = publication, Ab = abstract, Pr = presentation

178
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF PSYCHIATRY (continued)

Wong N: Trance possession and dissociative disorders. University
of South Dakota Psychiatric Association and Department of

Wong N: Transcultural psychiatry: its relevance to mental health
practice and training in the Washington-Baltimore region. Pan
American Health Organization Symposium, Washington, DC, March,
1994.

Wong N, Klein R, Bernard H, Singer D: Handbook of contemporary group
psychotherapy: contributions from object relations, self
psychology, and social systems theories. J of Psychotherapy

Young S: Electroconvulsive therapy for depression in a liver

Young S: Use of methylphenidate in a case of mild, inoperative,
idiopathic, normal pressure hydrocephalus. General Hospital

DEPARTMENT OF RADIOLOGY
Nuclear Medicine Service

Balingit A, Anderson J: Clinical application of captopril renal
(9):742-5.

Hagan M, et al: Erythroid progenitor (BFUe, CFUe) proliferation as
inferred from 5'-bromodeoxyuridine labeling. Exp Hematol 1994;

radiotherapy on vascular grafts in a canine model. Int J

Tochner, Sprague M, et al.: Intrathoracic photodynamic therapy: a
canine normal tissue tolerance study and early clinical

DEPARTMENT OF SOCIAL WORK

Cartwright, J: Mental health consultation services to the 10th
mountain division. Peace Keeping Operations Workshop.
University of Maryland, College Park, MD, February, 1994.

* P = publication, Ab = abstract, Pr = presentation

179
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SOCIAL WORK (continued)


Mays R, Jr.: The future is now. How big is your tool kit? A historical perspective of the army quality of life programs for the United States Army Europe and 7th Army. The 1994 Army Medical Department Symposium, Garmisch, Germany, April, 1994.


Mays R, Jr.: The Gulf War syndrome and the role of army social work. Presented to Department of Veteran Affairs via live national telecast with telephone link to 273 sites in the Regional Education and Training Center (REMC), Birmingham, AL, August, 1994.


DEPARTMENT OF SURGERY
Anesthesia-Operative Service


* P = publication, Ab = abstract, Pr = presentation
CITATION

DEPARTMENT OF SURGERY
Anesthesia-Operative Service (continued)

Boedecker B: Preparation, properties, and pharmacokinetics of
tetracaine, bupivacaine, propofol, isoflurane and dantrolene in
lecithin-coated microcrystal or microdroplet form. American

Bolt S: Laser-Doppler flowmetry measurement of subcortical blood flow
after fluid percussion brain injury in rats. American Society

Burnham K, Boedecker B, Kline M, Mattix M, Long J, Calkins M, Rapacki
T, Haynes D: Spinal cord toxicity of lecithin-coated
tetracaine microcrystals in the rat. American Society of
Regional Anesthesia Meeting, Chicago, IL, April, 1994.

Casinelli P, Reynolds P: Use of the drawover anesthesia machine at
Womack Army Medical Center: our experience. Mil Med 1994;
159(9):600-2.

Edwards S: The effect of internal mammary harvest on
post-operative pain and pulmonary function. Ann Thor Surg

Foley E, O’Neill B, Chang A: The effect of duration of LMA exposure
on the incidence of postoperative pharyngeal complaints.
International Anesthesia Research Society.

Fontana J, Welborn L, Sturm L, Bunger R: Recommended clinical
transfusion practice and experimental limits of hemodilution in

Fontana J, Welborn L, Sturm L, Bunger R: Recommended clinical
transfusion practice and experimental limits of hemodilution in

Greilich P: Effect of cardiopulmonary bypass on platelet force
development and its association with early bypass hemorrhage.
Society of Cardiovascular Anesthesiologists meeting, Montreal,
Canada, April, 1994.

Greilich P, Carr M: Reductions in platelet force development by
cardiopulmonary bypass are associated with hemorrhage.
American Society of Anesthesiologists Annual Meeting, October,
1994.

* P = publication, Ab = abstract, Pr = presentation

181
CITATION

DEPARTMENT OF SURGERY
Anesthesia-Operative Service (continued)


* P = publication, Ab = abstract, Pr = presentation

182
CITATION

DEPARTMENT OF SURGERY
Anesthesia-Operative Service (continued)


DEPARTMENT OF SURGERY
Army Audiology and Speech Center


* P = publication, Ab = abstract, Pr = presentation
## DEPARTMENT OF SURGERY

**Army Audiology and Speech Center (continued)**


## DEPARTMENT OF SURGERY

**Critical Care Medicine Service**


---

*P = publication, Ab = abstract, Pr = presentation*
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Critical Care Medicine Service (continued)


* P = publication, Ab = abstract, Pr = presentation

185
A D D E N D U M
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Critical Care Medicine Service (continued)


* P = publication, Ab = abstract, Pr = presentation
<table>
<thead>
<tr>
<th>Citation</th>
<th>Department of Surgery</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayorga M, Janusikiewicz A, Fitzpatrick T: Platelet-activating factor</td>
<td>Critical Care Medicine Service (continued)</td>
<td>Ab</td>
</tr>
<tr>
<td>and leukotriene production following acute high-level nitrogen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayorga M, Janusikiewicz A, Fitzpatrick T: Platelet-activating factor</td>
<td></td>
<td>Pr</td>
</tr>
<tr>
<td>and leukotriene production following acute high-level nitrogen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dioxide exposure. American Thoracic Society and American Lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maniscalco-Theberge M: The evaluation of the trauma. U.S. Army Oral</td>
<td></td>
<td>Pr</td>
</tr>
<tr>
<td>and Maxillofacial Surgery Post-Graduate Dental Course, October, 1993.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parker J, et al.: The impact of using stated versus measured height on</td>
<td></td>
<td>Pr</td>
</tr>
<tr>
<td>screening spirometry. Am Lung Association International Meeting, May,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1993.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parker J, et al.: The impact of using stated versus measured height on</td>
<td></td>
<td>Ab</td>
</tr>
<tr>
<td>Powell C, Schultz S, Burris D, Drucker W, Malcolm D: Subcutaneous oxygen</td>
<td></td>
<td>Pr</td>
</tr>
<tr>
<td>tension: a useful adjunct in assessment of perfusion status measured by</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randle D: Metabolic alkalosis. Citywide Combined Critical Care</td>
<td></td>
<td>Pr</td>
</tr>
<tr>
<td>Randle D: Supraventricular tachydysrhythmias. Citywide Combined Critical</td>
<td></td>
<td>Pr</td>
</tr>
<tr>
<td>Care Conference, San Antonio, TX, 1993.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ries M: Survey of ACCM Fellowship Directors. American Society of</td>
<td></td>
<td>Pr</td>
</tr>
<tr>
<td>Critical Care Anesthesiologists, October, 1993.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ries M: Uncommon neurologic and neuromuscular disorders in the ICU,</td>
<td></td>
<td>Pr</td>
</tr>
<tr>
<td>October 1993.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodriguez A, Elliott D: Blunt traumatic rupture of the thoracic aorta.</td>
<td></td>
<td>P</td>
</tr>
<tr>
<td>In: Maull et al., eds. Advances in trauma and critical care, vol. 8. St.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Critical Care Medicine Service (continued)

Shaver T, Maniscalco-Theberge M, Swanson S, Kosanderle: Internal
marsupilization after laparoscopy for lymphoceles after renal

Verma A, Carver J, Kazacs E, Guzzi L: Endotoxemia differentially
modifies rat hepatic and renal calcium pools. Society of

DEPARTMENT OF SURGERY
General Surgery Service

Alijani T, Johnson C, Jaques D: Tumors associated with familial
polyposis: case presentation. All-City Grand Rounds,

Bamberger P, Maniscalco-Theberge M, Pearl R, Jaques D: Death and
dollars: the cost of death in the ICU. American College of
Physicians, Army 10th Annual Scientific Meeting, Orlando, FL,

Bamberger P, Molloy M: Batzri S, Hale D, Goldberg W, Harmon J:
Transient, bile salt-induced, intracellular hypercalcemia: a
recurring challenge for gastrointestinal mucosal cells. Gary P.
Wratten Military Surgical Symposium, Cloudcraft, NM, April,
1994.

Batty D, Hale D, Molloy M, Pearl R, Jaques D: Appendectomy: a
current community standard. Gary P. Wratten Military Surgical
Symposium, Cloudcraft, NM, April, 1994.

Cunningham J, Fong Y, Shriver C, Melendez J, Marx W, Blumgart L: One
hundred consecutive hepatic resections: blood loss, transfusion,

D'Addio V, Gomez E, Jackson R: The value of early postoperative
carotid duplex ultrasonography. Gary P. Wratten Military
Surgical Symposium, Cloudcraft, NM, April, 1994.

D'Addio V, Jackson R, Gomez E: Selective management of isolated iliac
artery aneurysms. Gary P. Wratten Military Surgical Symposium,
Cloudcraft, NM, April, 1994.

Elliott D: Hypocholesterolemia among trauma patients: marker for
mortality and organ failure. American Association for Surgery
of Trauma. 1994.

* P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
General Surgery Service (continued)


* P = publication, Ab = abstract, Pr = presentation

189
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
General Surgery Service (continued)


Lane B: Management of a chemical casualty during ODS. 12th Annual USUHS Trauma Day, Bethesda, MD, October, 1993.


* P = publication, Ab = abstract, Pr = presentation

190
### ADDENDUM

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

<table>
<thead>
<tr>
<th>CITATION</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEPARTMENT OF SURGERY</strong></td>
<td></td>
</tr>
<tr>
<td>General Surgery Service (continued)</td>
<td></td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract, Pr = presentation
<table>
<thead>
<tr>
<th>DEPARTMENT OF SURGERY</th>
<th>Type*</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Surgery Service (continued)</td>
<td></td>
</tr>
<tr>
<td>Pearl R: Surgical care in Operation Desert Storm: mobility and medicine, the challenge of desert warfare. Children's Medical Center, Dayton, OH and Wright Patterson AFB Medical Center, Dayton, OH, April, 1994.</td>
<td>Pr</td>
</tr>
<tr>
<td>Shriver C, Kim B, Jaques D: Treatment choices for breast carcinoma in Walter Reed Army Medical Center. WRAMC Cancer Report.</td>
<td>P</td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract, Pr = presentation
ADDITIONAL PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Neurosurgery Service


* P = publication, Ab = abstract, Pr = presentation

193
CITATION

DEPARTMENT OF SURGERY
Neurosurgery Service (continued)


Osenbach R: Diagnosis and management of spinal subdural empyema and intramedullary spinal cord abscess. Luncheon Seminar, Congress of Neurological Surgeons, Chicago, IL, October, 1994.


* P = publication, Ab = abstract, Pr = presentation
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Ophthalmology Service


DEPARTMENT OF SURGERY
Orthopaedic Surgery Service


Cockerill D, Polly D, Ondra S: Use of the harm’s titanium mesh cage graft for cervical and thoracolumbar corpectomies with fusion. American Association of Neurological Surgeons Annual Meeting, San Diego, CA, April, 1994. Pr


* P = publication, Ab = abstract, Pr = presentation
### ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

<table>
<thead>
<tr>
<th>CITATION</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEPARTMENT OF SURGERY</strong></td>
<td></td>
</tr>
<tr>
<td>Orthopaedic Surgery Service (continued)</td>
<td></td>
</tr>
<tr>
<td>Hansen M, Polly D: Orthopaedic injuries in Operation Desert Shield/</td>
<td>Pr</td>
</tr>
<tr>
<td>Storm: a two-year follow-up. Society of Military Orthopaedic Surgeons</td>
<td></td>
</tr>
<tr>
<td>Hansen M, Polly D, McHale K, Asplund L: A prospective evaluation of</td>
<td>P</td>
</tr>
<tr>
<td>orthopaedic patients evacuated from Operation Desert Shield and</td>
<td></td>
</tr>
<tr>
<td>Hopkinson W: Porous coated anatomic total hip arthroplasty: seven to</td>
<td>Pr</td>
</tr>
<tr>
<td>nine year results of a prospective consecutive series. American</td>
<td></td>
</tr>
<tr>
<td>Academy of Orthopaedic Surgeons 61st Annual Meeting, New Orleans, LA,</td>
<td></td>
</tr>
<tr>
<td>Hopkinson W: Thigh pain in uncemented total hip arthroplasty.</td>
<td>Pr</td>
</tr>
<tr>
<td>American Academy of Orthopaedic Surgeons 61st Annual Meeting, New</td>
<td></td>
</tr>
<tr>
<td>Kilkerly F, Lenhart M, Temple H: Tumoral calcinosis: a clinical and</td>
<td>Pr</td>
</tr>
<tr>
<td>radiographic review. American Academy of Orthopaedic Surgeons 61st</td>
<td></td>
</tr>
<tr>
<td>Kilkerly F, Lenhart M, Temple H: Tumoral calcinosis: a clinical and</td>
<td>Pr</td>
</tr>
<tr>
<td>radiographic review. Society of Military Orthopaedic Surgeons 35th</td>
<td></td>
</tr>
<tr>
<td>Kilkerly F, McHale K: Acute rupture of the peroneal longus tendon: a</td>
<td>Pr</td>
</tr>
<tr>
<td>case report and review of the literature. Society of Military Orthopaedic</td>
<td></td>
</tr>
<tr>
<td>Kim C, McHale K: Immediate correction of cavus deformity. American</td>
<td>Pr</td>
</tr>
<tr>
<td>Academy of Orthopaedic Surgeons 61st Annual Meeting, New Orleans, LA,</td>
<td></td>
</tr>
<tr>
<td>McHale K: Abnormal foot muscles in clubfoot deformity. American</td>
<td>Pr</td>
</tr>
<tr>
<td>Academy of Orthopaedic Surgeons 61st Annual Meeting, New Orleans, LA,</td>
<td></td>
</tr>
<tr>
<td>McHale K: Anomalous foot muscles in clubfoot deformity. Pediatric</td>
<td>Pr</td>
</tr>
<tr>
<td>McHale K: Circular fixation for combat and training injuries. Society</td>
<td>Pr</td>
</tr>
<tr>
<td>of Military Orthopaedic Surgeons 35th Annual Meeting, Bethesda, MD,</td>
<td></td>
</tr>
<tr>
<td>December, 1993.</td>
<td></td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract, Pr = presentation
CITATION

DEPARTMENT OF SURGERY
Orthopaedic Surgery Service (continued)


* P = publication, Ab = abstract, Pr = presentation
### ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

<table>
<thead>
<tr>
<th>CITATION</th>
<th>Type*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEPARTMENT OF SURGERY</strong></td>
<td></td>
</tr>
<tr>
<td>Orthopaedic Surgery Service (continued)</td>
<td></td>
</tr>
<tr>
<td>Ogilvie J, Polly D, Ista C: Spinal implant sensitivity to airport</td>
<td>Pr</td>
</tr>
<tr>
<td>metal detectors. North American Spine Society, San Diego, CA, October,</td>
<td></td>
</tr>
<tr>
<td>1993.</td>
<td></td>
</tr>
<tr>
<td>Ogilvie J, Polly D, Ista C: Spinal implant sensitivity to airport</td>
<td>Pr</td>
</tr>
<tr>
<td>metal detectors. Society of Military Orthopaedic Surgeons 35th Annual</td>
<td></td>
</tr>
<tr>
<td>Meeting, Bethesda, MD, December, 1993.</td>
<td></td>
</tr>
<tr>
<td>Olson E: Soft tissue allografts in sports medicine. Maryland Orthopaedic</td>
<td>Pr</td>
</tr>
<tr>
<td>Society, Frederick, MD, November, 1993.</td>
<td></td>
</tr>
<tr>
<td>Olson E: The unstable shoulder: an international consensus. Eighth</td>
<td>Pr</td>
</tr>
<tr>
<td>Ondra S, Polly D, Carter T, Monacci W: Clinical and Ct analysis of 100</td>
<td>Pr</td>
</tr>
<tr>
<td>consecutively placed lateral mass screws. Techniques of Spinal Surgery</td>
<td></td>
</tr>
<tr>
<td>Polly D: Orthopaedic injuries in Operation Desert Shield/Storm: a</td>
<td>Pr</td>
</tr>
<tr>
<td>two-year follow-up. Society of Military Orthopaedic Surgeons 35th Annual</td>
<td></td>
</tr>
<tr>
<td>Polly D, Ondra S, Armonda R: Anterior salvage of late problems</td>
<td>Pr</td>
</tr>
<tr>
<td>following thoracolumbar trauma. Techniques of Spinal Surgery 2nd Annual</td>
<td></td>
</tr>
<tr>
<td>Polly D, Ondra S, Donovan D: Extraction of a malpositioned pedicle</td>
<td>Pr</td>
</tr>
<tr>
<td>screw transgressing neural elements at the level of the conus medullaris.</td>
<td></td>
</tr>
<tr>
<td>Techniques of Spinal Surgery 2nd Annual Symposium, New York, NY,</td>
<td></td>
</tr>
<tr>
<td>December, 1993.</td>
<td></td>
</tr>
<tr>
<td>Pope R, Popovic N, McKinney L, Berrey B: The effect of extracorporeal</td>
<td>Pr</td>
</tr>
<tr>
<td>shockwaves on the compartments in the rabbit leg. Society of Military</td>
<td></td>
</tr>
<tr>
<td>Popovic N: Infants: ethical, legal, and social aspects of medical</td>
<td>Pr</td>
</tr>
<tr>
<td>care. Uniformed Services University of the Health Sciences, Bethesda,</td>
<td></td>
</tr>
<tr>
<td>MD, August, 1994.</td>
<td></td>
</tr>
<tr>
<td>Popovic N: Microvascular Surgery Course. Uniformed Services University</td>
<td>Pr</td>
</tr>
<tr>
<td>of the Health Sciences, Bethesda, MD, October, 1993.</td>
<td></td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract, Pr = presentation

198
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Orthopaedic Surgery Service (continued)


* P = publication, Ab = abstract, Pr = presentation

199
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Otolaryngology-Head and Neck Surgery Service


Mann E, Sidman J: Results of cleft palate with the double reverse Z-plasty performed by residents. Academy of Otolaryngology-Head and Neck Surgery, Minneapolis, MN, October, 1993.


DEPARTMENT OF SURGERY
Plastic Surgery Service


* P = publication, Ab = abstract, Pr = presentation

200
ADDENDUM
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

CITATION

DEPARTMENT OF SURGERY
Urology Service


* P = publication, Ab = abstract, Pr = presentation

201
## Addendum

Publications/Presentations by Department/Service and Author Not Related to Approved Clinical Investigation Protocols

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEPARTMENT OF SURGERY</strong></td>
<td></td>
</tr>
<tr>
<td>Urology Service (continued)</td>
<td></td>
</tr>
</tbody>
</table>

* P = publication, Ab = abstract, Pr = presentation
AUTHOR INDEX*

Abdel-rahim M, (I) 39, 40; (II) 325, 333
Aessopos A, (I) 35; (II) 251
Almirez R, (I) 16; (II) 118
Anderson D, (I) 12, 13; (II) 44
Anthony B, (I) 40; (II) 328
Antoine J, (I) 43; (II) 453
Argyroso J, (I) 7; (II) 57
Argyros G, (I) 29, 30, 31, 33; (II) 235
Aroni I, (I) 3; (II) 31
Aronson A, (I) 4; (II) 62
Aronson N, (I) 9; (II) 53
Ascher D, (I) 4, 9, 13; (II) 46
Ashton W, (I) 39; (II) 323
Asplund L, (I) 48, 49; (II) 515, 524
Atkinson J, (I) 4, 6, 8, 9, 10, 12; (II) 48
Atolagbe T, (I) 24; (II) 204
Bahn S, (I) 17; (II) 142
Bailey L, (I) 14; (II) 116
Baraf H, (I) 2, 3; (II) 32
Barnes S, (I) 17; (II) 142
Baxter D, (I) 10; (II) 54
Beamer S, (I) 44; (II) 474
Beattie B, (I) 42; (II) 432
Beckett L, (I) 7; (II) 57
Belandres P, (I) 42, 43; (II) 427, 428, 429, 430, 433
Benson P, (I) 5; (II) 54
Bent R, (I) 41; (II) 331
Benton R, (I) 14; (II) 118
Berg B, (I) 18, 30, 31; (II) 146, 233
Berger T, (I) 1; (II) 22, 26
Berman J, (I) 27; (II) 206
Bermas B, (I) 35; (II) 251
Bernet V, (I) 16; (II) 165
Berrey B, (I) 49; (II) 512
Bethke F, (I) 13; (II) 59
Bettencourt J, (I) 43; (II) 453
Bhatia S, (I) 17; (II) 133
Bilello K, (I) 31; (II) 233
Billups L, (I) 1; (II) 28, 29
Birx D, (I) 4, 8, 9, 10, 13; (II) 53, 58, 59, 62
Biselli R, (I) 4; (II) 53
Bishoff J, (I) 52; (II) 546
Blake S, (I) 12; (II) 48
Boedecker B, (I) 43; (II) 453
Boedecker B, (I) 43, 44; (II) 453
Bohen E, (I) 27, 28, 29; (II) 215, 219, 222

* Reference is to page numbers in Volumes I & II.

203
AUTHOR INDEX*

Boki K, (I) 35; (II) 251
Borden P, (I) 49, 50; (II) 508
Bowen P, (I) 20; (II) 176
Boxer L, (I) 26; (II) 204
Brailman J, (I) 35; (II) 260, 264
Brandt U, (I) 5, 8, 10, 12; (II) 48
Braverman S, (I) 42; (II) 428
Brewer T, (I) 21; (II) 173
Brinker J, (I) 15; (II) 116
Brody D, (I) 24; (II) 188
Brown A, (I) 4; (II) 46
Brown D, (I) 6, 36, 37; (II) 48, 258
Brown H, (I) 36; (II) 258
Brown M, (I) 47; (II) 503
Brundage J, (I) 9; (II) 53
Bryan M, (I) 52; (II) 546
Burch H, (I) 17, 19; (II) 133, 142, 152, 157
Burge R, (I) 47; (II) 503
Burgess D, (I) 1; (II) 29
Burgess M, (I) 20; (II) 176
Burke D, (I) 4, 7, 8, 9, 13, 25; (II) 53, 57, 62, 204
Burman K, (I) 16, 17, 18, 19; (II) 133, 142, 145, 152, 154, 157, 165
Burnham K, (I) 43; (II) 453
Burrell L, (I) 5, 9; (II) 60
Byrd J, (I) 21, 22, 26; (II) 191, 203
Calkins M, (I) 43; (II) 453
Campbell L, (I) 8; (II) 58
Cantilena L, (I) 14, 15, 16; (II) 118
Capra J, (I) 35; (II) 251
Carone M, (I) 28, 29; (II) 219, 222
Carpenter G, (I) 1; (II) 18, 24
Carr F, (I) 17, 18, 19; (II) 135, 157, 159
Carregal V, (I) 1; (II) 22
Carter A, (I) 14, 15, 16; (II) 116
Cavallaro B, (I) 46; (II) 491
Chaired J, (I) 12; (II) 48
Chandler J, (I) 4, 6, 8, 9, 10, 12; (II) 48
Chang A, (I) 18, 42, 43, 47, 48; (II) 145, 427, 429, 430, 509
Chang G, (I) 7, 8; (II) 53
Charalamopoulos S, (I) 3, 34; (II) 32, 251
Chernier M, (I) 6; (II) 48
Chima T, (I) 48; (II) 521
Choremi H, (I) 3; (II) 32
Christian M, (I) 13; (II) 87

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

Chung R, (I) 2, 7; (II) 35, 57
Cieslak T, (I) 4, 13; (II) 46
Clasby S, (I) 6; (II) 48
Clay J, (I) 45, 46; (II) 469, 470, 478
Clerici M, (I) 35; (II) 251
Coates J, (I) 12, 13; (II) 44
Cobb J, (I) 43; (II) 453
Colling C, (I) 16; (II) 112
Conner D, (I) 15, 16; (II) 118
Cook J, (I) 47, 48, 49; (II) 518
Cookfair D, (I) 35, 36; (II) 257
Cooper L, (I) 1; (II) 29
Cord M, (I) 45, 46; (II) 466, 469, 471
Cranston T, (I) 16; (II) 165
Cremins J, (I) 20; (II) 183
Cross A, (I) 27; (II) 207
Crowell M, (I) 38, 39; (II) 322
Crumpacker C, (I) 7; (II) 57
Cryz S, (I) 27; (II) 207
Cutting M, (I) 25; (II) 204
D'Arcy L, (I) 8; (II) 53
Daniell F, (I) 10; (II) 48
Darling B, (I) 39; (II) 341
Davis C, (I) 4; (II) 62
Davis D, (I) 35; (II) 264
Davis J, (I) 14, 41; (II) 116, 331
Davis P, (I) 13; (II) 87
Davis W, (I) 1; (II) 22
DeGruy F, (I) 24; (II) 188
DeMarkles M, (I) 20; (II) 182
Devries W, (I) 47, 48, 49; (II) 509, 514, 518
Deedwania P, (I) 16; (II) 112
Deffer P, (I) 48, 49; (II) 518
Del Bono V, (I) 4; (II) 53
Derderian S, (I) 30, 31, 32; (II) 233, 237
Diehl L, (I) 26; (II) 203
Dillard T, (I) 30, 31; (II) 233
Dillingham T, (I) 42, 43; (II) 427, 429, 430, 433
Dobek A, (I) 2; (II) 35
Donovon D, (I) 36; (II) 258
Dopler B, (I) 6; (II) 48
Dougherty D, (I) 35, 36, 37; (II) 258, 259
Dow N, (I) 1; (II) 26
Doyle M, (I) 35; (II) 264
Drabick J, (I) 5, 10, 27; (II) 54, 207
Dubowy R, (I) 41; (II) 363

* Reference is to page numbers in Volumes I & II.

205
AUTHOR INDEX*

Duncan W, (I) 18; (II) 145
Dunn D, (I) 43; (II) 453
Dykstra K, (I) 39; (II) 323, 325
Ehrenberg P, (I) 7, 8; (II) 53
El-Mohandes A, (I) 33; (II) 250
Eliasson A, (I) 29, 31, 33; (II) 235
Engler R, (I) 1, 5, 6, 7; (II) 18, 52
Erbe E, (I) 43; (II) 441
Farb A, (I) 14, 15, 16; (II) 116
Fattom A, (I) 28; (II) 218
Fields S, (I) 13; (II) 87
Figg W, (I) 13; (II) 87
Filby C, (I) 4; (II) 42
Finelli M, (I) 33; (II) 242
Fischer G, (I) 4, 40; (II) 46, 328
Fisher C, (I) 17, 18; (II) 135
Fisher S, (I) 16; (II) 112
Fitzpatrick T, (I) 33; (II) 240
Fletcher R, (I) 16; (II) 112
Francis G, (I) 39, 40, 41; (II) 323, 325, 333
Francis M, (I) 9; (II) 60
Franke E, (I) 27; (II) 206
Froelich E, (I) 43; (II) 453
Gallagher K, (I) 39; (II) 341
Gardner L, (I) 7; (II) 57
Gartner S, (I) 25, 26; (II) 204
Gasser R, (I) 27; (II) 206
Glass K, (I) 26; (II) 203
Goldberg D, (I) 9, 13; (II) 46
Goldstein J, (I) 2; (II) 27
Gordon J, (I) 43; (II) 453
Gorny M, (I) 13; (II) 59
Grabenstein J, (I) 4; (II) 42
Grafman J, (I) 36; (II) 259
Grant I, (I) 6, 8, 9, 10, 12; (II) 48
Grant K, (I) 44; (II) 474, 476
Graves M, (I) 36, 37; (II) 258
Greenhouse J, (I) 26; (II) 204
Greenwall S, (I) 20; (II) 182
Greenwell H, (I) 52; (II) 556
Griffin G, (I) 1; (II) 26
Grogel M, (I) 27; (II) 206
Gurney C, (I) 37; (II) 271
Hahn S, (I) 21, 24; (II) 188
Hall E, (I) 25, 26; (II) 204
Hamm C, (I) 31, 32; (II) 237

* Reference is to page numbers in Volumes I & II.

206
AUTHOR INDEX*

Hammer S, (I) 7; (II) 57
Hansen M, (I) 48; (II) 524
Hargis J, (I) 13; (II) 87
Harris T, (I) 4; (II) 42
Hartman K, (I) 24; (II) 200, 204
Hawkins A, (I) 1; (II) 28
Haynes D, (I) 43, 44; (II) 453
Heaton R, (I) 6; (II) 48
Heimer W, (I) 10; (II) 54
Hemming V, (I) 40; (II) 328
Herndon R, (I) 35, 36; (II) 257
Hershey J, (I) 1, 20, 38; (II) 18, 22, 28, 183, 322
Heyes M, (I) 6; (II) 48
Hickman M, (I) 1; (II) 26
Hicks C, (I) 7, 21, 22; (II) 57, 191
Hinson R, (I) 39, 40; (II) 350
Hnatiuk O, (I) 31; (II) 241
Hollifield R, (I) 46; (II) 491
Hollinger J, (I) 48; (II) 519
Holt W, (I) 1; (II) 18
Holtzmuller K, (I) 20, 21; (II) 180
Hong T, (I) 40; (II) 333
Honig P, (I) 14, 15, 16; (II) 118
Hoover D, (I) 9, 25; (II) 60, 204
Hopkinson W, (I) 47, 48, 49, 50; (II) 500, 508, 509
Hospenthal D, (I) 21, 22, 26; (II) 191, 203
Howard R, (I) 26; (II) 203
Hull R, (I) 15; (II) 118
Hurwitz K, (I) 29, 31, 33; (II) 235
Huston C, (I) 42; (II) 430
Inscoe K, (I) 20, 21; (II) 180
Isenbarger D, (I) 21, 22; (II) 191
Jabbari B, (I) 35, 36, 37; (II) 260, 264
Jacobs L, (I) 35, 36; (II) 257
Japur A, (I) 7; (II) 57
Jenkins P, (I) 5, 10; (II) 48
Jenkins R, (I) 5, 8; (II) 48
Jesteadt W, (I) 44; (II) 483
Johnson C, (I) 5, 8, 10, 12; (II) 48
Johnson J, (I) 22; (II) 188
Johnson K, (I) 48; (II) 519
Johnson L, (I) 33; (II) 250
Johnson S, (I) 4, 9, 27; (II) 53, 62, 206
Johnstone F, (I) 48; (II) 521
Kadakia S, (I) 20, 21; (II) 180
Kaklanianis P, (I) 35; (II) 251

* Reference is to page numbers in Volumes I & II.

207
AUTHOR INDEX*

Kaplan R, (I) 9; (II) 48
Kapsimali V, (I) 35; (II) 251
Katona I, (I) 33; (II) 250
Kauhal S, (I) 25, 26; (II) 204
Kelly P, (I) 43; (II) 453
Kendall S, (I) 8; (II) 48
Kende M, (I) 36, 37; (II) 258
Kenney R, (I) 26; (II) 204
Kepczyk T, (I) 20, 21; (II) 180
Kerns H, (I) 52; (II) 556
Kessler S, (I) 9, 25, 26; (II) 60, 204
Kiang J, (I) 18; (II) 135
Kikendall J, (I) 20; (II) 176, 183
Kilkelly F, (I) 48; (II) 521
Kim C, (I) 49; (II) 514
Kim J, (I) 9, 25, 26; (II) 53, 204
King N, (I) 47; (II) 503
Kleinman D, (I) 12; (II) 52
Kline M, (I) 43, 44; (II) 453
Klippel G, (I) 2, 24, 34; (II) 32, 204, 251, 252
Knutson S, (I) 31; (II) 233
Kobylerz E, (I) 36; (II) 262
Koch W, (I) 6, 9; (II) 48
Kohn E, (I) 13; (II) 87
Kohn L, (I) 19; (II) 157
Konzelman J, (I) 5, 6, 7, 12; (II) 52
Kosisky S, (I) 1; (II) 24
Kosugi S, (I) 19; (II) 157
Krober M, (I) 4, 9, 13; (II) 46
Kroenke K, (I) 21, 22, 23, 24; (II) 187, 188, 190
Kufes W, (I) 14, 15, 16; (II) 116
Kumke K, (I) 31, 32; (II) 237
Kuppers R, (I) 17; (II) 133
Kurnot R, (I) 52; (II) 546
Kushner J, (I) 18; (II) 146
Kuzma P, (I) 43, 44; (II) 453
La Russa V, (I) 24, 25, 26; (II) 204
Lahir S, (I) 19, 20; (II) 162
Laird J, (I) 14, 16; (II) 116
Lande R, (I) 43; (II) 437
Landry F, (I) 32; (II) 238
Lane J, (I) 7, 13; (II) 57
Langenberg P, (I) 20; (II) 176
Larid J, (I) 15; (II) 116
Larsen B, (I) 21; (II) 173
Lauder T, (I) 42; (II) 430

* Reference is to page numbers in Volumes I & II.

208
Law W, (I) 5, 6; (II) 48
Lazzeri D, (I) 16; (II) 112
Ledsy R, (I) 10; (II) 54
Leek H, (I) 44, 45, 46; (II) 467, 473, 478, 482, 483
Leiby D, (I) 25, 26; (II) 204
Lennox J, (I) 4, 7, 9; (II) 53, 57, 62
Leone L, (I) 35; (II) 260
Lepler L, (I) 32, 33; (II) 240
Levandowski D, (I) 45; (II) 466, 469
Levy H, (I) 36, 37; (II) 258
Lewis D, (I) 16, 51, 52; (II) 112, 546
Linden C, (I) 48; (II) 519
Ling G, (I) 6; (II) 48
Link C, (I) 13; (II) 87
Linzer M, (I) 24; (II) 188
Lipnick R, (I) 2, 34; (II) 32, 251
Lippert L, (I) 1; (II) 26
Liu Y, (I) 26; (II) 204
Lojeski E, (I) 43; (II) 453
Lombardo F, (I) 38; (II) 273
Long J, (I) 43; (II) 453
Loomis L, (I) 4, 9; (II) 53
Lu X, (I) 16; (II) 118
Lucas C, (I) 22, 23; (II) 187
Lucas M, (II) 363
Lucey C, (I) 22, 23; (II) 187
Lukes Y, (I) 17, 19; (II) 133, 157
Magill A, (I) 5, 27; (II) 54, 206
Magnetti C, (I) 20; (II) 176
Mahoney D, (I) 28; (II) 219
Malech H, (I) 26; (II) 204
Manca F, (I) 9, 10; (II) 53
Manly J, (I) 6; (II) 48
Mapou R, (I) 5, 6; (II) 48
Marin R, (I) 42; (II) 427
Marple R, (I) 22, 23; (II) 187
Martin A, (I) 6; (II) 48
Martin B, (I) 18; (II) 146
Martinez M, (I) 6, 7; (II) 52
Massie B, (I) 16; (II) 112
Mathias B, (I) 43; (II) 429
Mattix M, (I) 43; (II) 453
Maybee D, (I) 1, 41; (II) 29, 363
Maydonovitch C, (I) 20; (II) 182
Mayers D, (I) 7, 12, 13, 25; (II) 44, 57, 204
McCarthy W, (I) 10; (II) 54

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

McClain D, (I) 18; (II) 135
McClain J, (I) 27; (II) 207
McClellan M, (I) 45; (II) 466, 469, 470
McCune B, (I) 3; (II) 31
McCutchan J, (I) 8, 9, 10, 12; (II) 48
McGovern T, (I) 20, 21; (II) 180
McHale K, (I) 48, 49; (II) 514, 524
McKinney L, (I) 48, 49; (II) 512, 519
McLeod G, (I) 7; (II) 57
Mehm W, (I) 30, 31; (II) 233
Melcher G, (I) 4; (II) 62
Melcher W, (I) 33; (II) 250
Meltzer M, (I) 9; (II) 60
Mena H, (I) 37; (II) 258
Merritt T, (I) 41; (II) 331
Meyer G, (I) 9, 13; (II) 46
Michael N, (I) 7, 8, 9, 13; (II) 53
Miller A, (I) 13; (II) 87
Miller D, (I) 48, 49; (II) 515, 518, 521
Mondy W, (I) 43; (II) 453
Moore J, (I) 27, 28; (II) 215, 218, 219
Moore M, (I) 49; (II) 518
Mores L, (I) 31; (II) 233
Moores R, (I) 40; (II) 333
Horiarty R, (I) 4, 9, 13; (II) 46
Morris E, (I) 20, 21; (II) 180
Mosca J, (I) 8, 25; (II) 53, 204
Moses F, (I) 21; (II) 173
Mostofi F, (I) 52; (II) 546
Moul J, (I) 51, 52; (II) 546, 550
Mullen J, (I) 15; (II) 118
Mulligan M, (I) 47, 48, 50; (II) 500, 509
Mullin J, (I) 16; (II) 118
Murphy J, (I) 20, 21; (II) 180, 182
Musio F, (I) 28, 29; (II) 219, 222
Nagy E, (I) 17, 19; (II) 133, 142, 157
Nair P, (I) 20; (II) 183
Nannis E, (I) 5, 8, 10, 12; (II) 48
Nau M, (I) 12, 13; (II) 44
Newby J, (I) 5, 12; (II) 48
Newman R, (I) 40; (II) 325
Nicholson D, (I) 19, 20; (II) 162
Nutman T, (I) 5; (II) 54
O'Connor F, (I) 4; (II) 41
O'Leary A, (I) 8; (II) 48
O'Malley P, (I) 23, 24; (II) 190

* Reference is to page numbers in Volumes I & II.
<table>
<thead>
<tr>
<th>Author</th>
<th>Volume I</th>
<th>Page(s)</th>
<th>Volume II</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>O'Neill J</td>
<td>I</td>
<td>39, 341</td>
<td>II</td>
<td>204</td>
</tr>
<tr>
<td>Oette D</td>
<td>I</td>
<td>26</td>
<td>II</td>
<td>188</td>
</tr>
<tr>
<td>Oglesby R</td>
<td>I</td>
<td>3, 33, 34</td>
<td>II</td>
<td>32, 251</td>
</tr>
<tr>
<td>Olson E</td>
<td>I</td>
<td>50</td>
<td>II</td>
<td>500</td>
</tr>
<tr>
<td>Oman C</td>
<td>I</td>
<td>24</td>
<td>II</td>
<td>188</td>
</tr>
<tr>
<td>Ondra S</td>
<td>I</td>
<td>36, 37</td>
<td>II</td>
<td>258</td>
</tr>
<tr>
<td>Oster C</td>
<td>I</td>
<td>4, 9, 27</td>
<td>II</td>
<td>53, 62, 206</td>
</tr>
<tr>
<td>Otto M</td>
<td>I</td>
<td>13</td>
<td>II</td>
<td>57</td>
</tr>
<tr>
<td>Ottolini M</td>
<td>I</td>
<td>4, 9, 13</td>
<td>II</td>
<td>46</td>
</tr>
<tr>
<td>Pacicco T</td>
<td>I</td>
<td>18</td>
<td>II</td>
<td>146</td>
</tr>
<tr>
<td>Panagiotidis P</td>
<td>I</td>
<td>35</td>
<td>II</td>
<td>251</td>
</tr>
<tr>
<td>Parker J</td>
<td>I</td>
<td>32</td>
<td>II</td>
<td>236, 238</td>
</tr>
<tr>
<td>Pascual V</td>
<td>I</td>
<td>35</td>
<td>II</td>
<td>251</td>
</tr>
<tr>
<td>Patterson T</td>
<td>I</td>
<td>4, 6, 8, 9, 10, 12</td>
<td>II</td>
<td>48</td>
</tr>
<tr>
<td>Payne A</td>
<td>I</td>
<td>39, 40</td>
<td>II</td>
<td>325, 333, 341</td>
</tr>
<tr>
<td>Payne M</td>
<td>I</td>
<td>40</td>
<td>II</td>
<td>325, 333</td>
</tr>
<tr>
<td>Peabody S</td>
<td>I</td>
<td>41</td>
<td>II</td>
<td>331</td>
</tr>
<tr>
<td>Pedersen A</td>
<td>I</td>
<td>40</td>
<td>II</td>
<td>333</td>
</tr>
<tr>
<td>Pelli K</td>
<td>I</td>
<td>2</td>
<td>II</td>
<td>27</td>
</tr>
<tr>
<td>Peller P</td>
<td>I</td>
<td>21</td>
<td>II</td>
<td>173</td>
</tr>
<tr>
<td>Peller T</td>
<td>I</td>
<td>21</td>
<td>II</td>
<td>173</td>
</tr>
<tr>
<td>Perera L</td>
<td>I</td>
<td>25, 26</td>
<td>II</td>
<td>204</td>
</tr>
<tr>
<td>Petrov J</td>
<td>I</td>
<td>38</td>
<td>II</td>
<td>272</td>
</tr>
<tr>
<td>Pettet T</td>
<td>I</td>
<td>39</td>
<td>II</td>
<td>341</td>
</tr>
<tr>
<td>Phillipson J</td>
<td>I</td>
<td>8</td>
<td>II</td>
<td>48</td>
</tr>
<tr>
<td>Phillips Y</td>
<td>I</td>
<td>29, 30, 31, 32, 33</td>
<td>II</td>
<td>233, 235, 237, 238</td>
</tr>
<tr>
<td>Piskontaki I</td>
<td>I</td>
<td>3</td>
<td>II</td>
<td>32</td>
</tr>
<tr>
<td>Podraza B</td>
<td>I</td>
<td>46</td>
<td>II</td>
<td>478</td>
</tr>
<tr>
<td>Pollock B</td>
<td>I</td>
<td>41</td>
<td>II</td>
<td>363</td>
</tr>
<tr>
<td>Polly D</td>
<td>I</td>
<td>48, 49</td>
<td>II</td>
<td>515, 524</td>
</tr>
<tr>
<td>Polo K</td>
<td>I</td>
<td>36</td>
<td>II</td>
<td>264</td>
</tr>
<tr>
<td>Polonis V</td>
<td>I</td>
<td>8, 13</td>
<td>II</td>
<td>58, 59</td>
</tr>
<tr>
<td>Poldiselli T</td>
<td>I</td>
<td>25</td>
<td>II</td>
<td>204</td>
</tr>
<tr>
<td>Pope R</td>
<td>I</td>
<td>49</td>
<td>II</td>
<td>512</td>
</tr>
<tr>
<td>Popham S</td>
<td>I</td>
<td>29</td>
<td>II</td>
<td>222</td>
</tr>
<tr>
<td>Popovic N</td>
<td>I</td>
<td>47, 48, 49, 50</td>
<td>II</td>
<td>500, 503, 505, 509, 512, 518, 519, 521</td>
</tr>
<tr>
<td>Poth M</td>
<td>I</td>
<td>41</td>
<td>II</td>
<td>325</td>
</tr>
<tr>
<td>Prewitt K</td>
<td>I</td>
<td>14, 15, 16</td>
<td>II</td>
<td>116</td>
</tr>
<tr>
<td>Pitezbylik J</td>
<td>I</td>
<td>1</td>
<td>II</td>
<td>29</td>
</tr>
<tr>
<td>Pulliam M</td>
<td>I</td>
<td>37</td>
<td>II</td>
<td>258</td>
</tr>
<tr>
<td>Putnak R</td>
<td>I</td>
<td>25, 26</td>
<td>II</td>
<td>204</td>
</tr>
<tr>
<td>Pyne M</td>
<td>I</td>
<td>35, 37</td>
<td>II</td>
<td>259</td>
</tr>
<tr>
<td>Quintero-Sheely E</td>
<td>I</td>
<td>37</td>
<td>II</td>
<td>259</td>
</tr>
<tr>
<td>Rajagopal K</td>
<td>I</td>
<td>31, 32</td>
<td>II</td>
<td>237</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX*

Rapacki T, (I) 43; (II) 453
Rappaport J, (I) 8; (II) 53
Raszka W, (I) 9, 13; (II) 46
Ratto S, (I) 9, 10; (II) 53
Rayburn D, (I) 33; (II) 240
Redfield R, (I) 4, 7, 8, 9, 10, 13, 26; (II) 53, 58, 59, 62, 204
Reed E, (I) 13; (II) 87
Reichman R, (I) 7; (II) 57
Reid T, (I) 25; (II) 204
Remsey K, (I) 27; (II) 207
Ries L, (I) 12; (II) 52
Ritchey D, (I) 25, 26; (II) 204
Roach J, (I) 29, 31, 33; (II) 235
Robb M, (I) 4, 8, 9, 13; (II) 46, 53, 58
Robbins J, (I) 28; (II) 218
Roberts C, (I) 7; (II) 57
Robles H, (I) 37; (II) 264
Roller T, (I) 6; (II) 48
Rose N, (I) 17; (II) 133
Rosenberg M, (I) 36; (II) 262
Rossetti R, (I) 34; (II) 251
Roth P, (I) 12; (II) 48
Rothenberg M, (I) 13; (II) 87
Rothman S, (I) 2; (II) 35
Rothwell S, (I) 24, 26; (II) 204
Rowton E, (I) 26; (II) 204
Roy M, (I) 23, 24; (II) 190
Rubin H, (I) 9; (II) 48
Rudick R, (I) 35, 36; (II) 257
Ruiz N, (I) 4, 7; (II) 57, 62
Rundell J, (I) 6; (II) 48
Salata K, (I) 1, 2, 4, 20, 38; (II) 18, 22, 26, 27, 28, 29, 32, 183, 322
Salazar A, (I) 6, 35, 36, 37; (II) 48, 257, 258, 259
Salzberg D, (I) 21, 22, 28, 29; (II) 191, 219, 222
Sarnecky M, (I) 38; (II) 276
Sarosy G, (I) 13; (II) 87
Sarnati H, (I) 13; (II) 57
Scherokman B, (I) 36, 37; (II) 258
Schlangen K, (I) 10; (II) 48
Schneerson R, (I) 28; (II) 218
Schwab K, (I) 36, 37; (II) 258
Schwartz G, (I) 9; (II) 60
Sciolla A, (I) 4; (II) 48
See A, (I) 20, 21; (II) 180

* Reference is to page numbers in Volumes I & II.

212
AUTHOR INDEX*

Sellitti D, (I) 17; (II) 142
Semple S, (I) 6, 8, 10, 12; (II) 48
Sesterhenh I, (I) 51, 52; (II) 546
Sfikakis P, (I) 2, 3, 33, 34; (II) 32, 251, 252
Sfikakis PP, (I) 3, 34, 35; (II) 31, 32, 251
Shaeter E, (I) 39; (II) 350
Sharp-Breslau E, (I) 10, 12; (II) 48
Shearer G, (I) 35; (II) 251
Sherman K, (I) 20, 21; (II) 180
Shotkin J, (I) 38; (II) 273
Sigmon J, (I) 28; (II) 218
Singh B, (I) 16; (II) 112
Singh S, (I) 16; (II) 112
Sitz K, (I) 9, 10, 26; (II) 53, 204
Sjogren M, (I) 20, 21; (II) 180, 182
Skelton H, (I) 10; (II) 54
Slayter M, (I) 41; (II) 331
Smallridge R, (I) 17, 18, 34; (II) 135, 251
Smith A, (I) 47, 48, 49; (II) 518
Smith J, (I) 15, 16; (II) 118
Smith K, (I) 5, 10, 11; (II) 54
Smith L, (I) 1; (II) 24
Smith M, (I) 18, 20, 21; (II) 146, 180
Smith S, (I) 18; (II) 146
Solomon B, (I) 16, 17, 18, 19; (II) 145, 146, 152, 154, 165
Spellman N, (I) 42; (II) 433
Spitzer R, (I) 21, 22, 24, 35; (II) 188, 251
St. Louis D, (I) 25, 26; (II) 204
Stacewicz-Sapuntzakis M, (I) 20; (II) 176
Stamm C, (I) 21; (II) 173
Staudenmeier J, (I) 37; (II) 259
Stevens H, (I) 35; (II) 260
Stitzel A, (I) 35; (II) 251
Stoltzfus D, (I) 29; (II) 223
Stott D, (I) 18; (II) 145
Straits-Troster K, (I) 12; (II) 48
Stuart J, (I) 49, 50; (II) 505, 508
Summers W, (I) 44, 45, 46; (II) 467, 473, 482, 483
Sun W, (I) 27; (II) 206
Surr R, (I) 46; (II) 471
Swango P, (I) 5, 12; (II) 52
Sweet D, (I) 48; (II) 521
Taylor B, (I) 40; (II) 333
Temoshok L, (I) 5, 6, 8, 10, 12; (II) 48
Tencer H, (I) 41; (II) 340

* Reference is to page numbers in Volumes I & II.

213
AUTHOR INDEX*

Tesar J, (I) 2, 34; (II) 32, 252
Theocaris S, (I) 3, 34; (II) 32, 251, 252
Theune S, (I) 52; (II) 546
Thyphronitis G, (I) 33; (II) 250
Toro L, (I) 25; (II) 204
Toro-Lopez L, (I) 26; (II) 204
Torrington K, (I) 33; (II) 242
Tseng Y, (I) 19, 20; (II) 162
Tsokos G, (I) 2, 3, 4, 33, 34, 35; (II) 31, 32, 251, 252
Tsokos M, (I) 3; (II) 31
Turmicky R, (I) 4, 6, 12, 13; (II) 44, 46, 48
Uhorchak J, (I) 49, 50; (II) 508
Urban E, (I) 37; (II) 264
Vahey M, (I) 7, 8, 9, 13, 26; (II) 46, 53, 57, 204
Van Cott T, (I) 8, 13; (II) 58, 59
Van Dam B, (I) 47, 49; (II) 503, 515
Vassilopoulos D, (I) 2, 4, 34; (II) 32, 251
Vauter R, (I) 42
Vayiopoulos G, (I) 3; (II) 32
Vayopoulos G, (I) 3, 34, 35; (II) 31, 251
Velin R, (I) 6; (II) 48
Via C, (I) 3, 35; (II) 32, 251
Victor K, (I) 35; (II) 251
Viglis V, (I) 3; (II) 32
Virmani R, (I) 14, 15; (II) 116
Waecker N, (I) 4, 9, 13; (II) 46
Wagner K, (I) 4, 7, 10; (II) 54, 57, 62
Wahl L, (I) 33; (II) 250
Walden B, (I) 44, 46; (II) 471, 474, 476
Ward F, (I) 24; (II) 204
Ward T, (I) 46; (II) 491
Warden D, (I) 35, 37; (II) 259
Wartofsky L, (I) 17, 18, 19, 20; (II) 145, 152, 154, 162
Watson M, (I) 40, 41; (II) 325, 333
Wei-Sing C, (I) 10; (II) 54
Weinstein H, (I) 41; (II) 363
Weislow O, (I) 7; (II) 57
Weisman L, (I) 40; (II) 328
Weiss R, (I) 13; (II) 87
Welch C, (I) 41; (II) 325
Welch P, (I) 28; (II) 218
Wertz F, (I) 46; (II) 491
Whippo P, (I) 49; (II) 505
White F, (I) 7; (II) 57

* Reference is to page numbers in Volumes I & II.
AUTHOR INDEX

Wiesen A, (I) 21, 22, 26; (II) 191, 203
Wilder J, (I) 22, 23; (II) 187
Wilhelm G, (I) 48; (II) 519
Williams C, (I) 18; (II) 146
Williams J, (I) 6, 21, 22, 24; (II) 48, 188
Wilson J, (I) 4; (II) 42
Winslow D, (I) 7, 13; (II) 57
Wiswell T, (I) 41; (II) 331, 340
Wong M, (I) 23; (II) 190
Wong N, (I) 18; (II) 159
Wong P, (I) 23; (II) 190
Wong R, (I) 20, 21, 23, 24; (II) 180, 182, 183, 190
Wong T, (I) 8; (II) 48
Woosley R, (I) 14; (II) 118
Wortham D, (I) 14, 15, 16; (II) 116, 118
Wright D, (I) 26; (II) 204
Xauschal S, (I) 25; (II) 204
Xenos J, (I) 47, 48, 50, 51; (II) 500, 509
Xu J, (I) 25, 26; (II) 204
Yancey J, (I) 52; (II) 556
Yang S, (I) 16; (II) 118
Yeager J, (I) 10; (II) 54
Yeun J, (I) 27; (II) 215
Young P, (I) 43; (II) 453
Yu Z, (I) 25, 26; (II) 204
Yuan C, (I) 27, 28, 29; (II) 215, 219, 222
Zamani K, (I) 14, 15, 16; (II) 118
Zeigler D, (I) 43; (II) 429
Zhang X, (I) 25; (II) 204
Zhao F, (I) 12, 13; (II) 44
Zhou S, (I) 7; (II) 57
Zografou E, (I) 3; (II) 32
Zolla-Pazner S, (I) 13; (II) 59
Zuehlke R, (I) 52; (II) 556
Zurier R, (I) 34; (II) 251

* Reference is to page numbers in Volumes I & II.
ADDENDUM
AUTHOR INDEX*
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-94

Abdel-Rahim M, (I) 137
Aisner J, (I) 139
Allen S, (I) 139
Alving B, (I) 139
Andrada F, (I) 137
Antman K, (I) 139
Argyros G, (I) 140
Ascher D, (I) 142
Baker J, (I) 139
Baker L, (I) 139
Balcerzak S, (I) 139
Barlogie B, (I) 139
Bast R, (I) 139
Becker J, (I) 142
Bowen P, (I) 136, 137, 138
Brewer T, (I) 137
Brown H, (I) 141
Browning S, (I) 139
Burger P, (I) 142
Burgess L, (I) 143
Burkhalter E, (I) 137
Burman K, (I) 139
Busacco D, (I) 142
Campos-Esteve M, (I) 136
Carr F, (I) 136, 139
Carr M, (I) 142, 143
Chang A, (I) 142
Clamon G, (I) 139
Coats M, (I) 141
Colon E, (I) 142
Coniglio D, (I) 139
Cooper B, (I) 139
Cooper M, (I) 139
Cord M, (I) 142
Cremins J, (I) 137
Crowley J, (I) 139
Dadakia S, (I) 138
Davis C, (I) 142
Davis F, (I) 138
Diehl L, (I) 139
Dillard T, (I) 140
Doroshow J, (I) 139
Duggan D, (I) 139
Duncan W, (I) 136
Earls J, (I) 142
Eaton C, (I) 137
Eisenhauer M, (I) 140
Elias A, (I) 139

* Reference is to page number(s) in Volume I

216
ADDENDUM

AUTHOR INDEX*
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-94

Eliasson A, (I) 140, 141
Fabry D, (I) 142
Fajardo J, (I) 142
Fein H, (I) 136
Fischer G, (I) 142
Fishbach N, (I) 140
Fisher C, (I) 136
Foley E, (I) 142
Gary-Stephens M, (I) 141
Gilbert C, (I) 139
Gilchrist W, (I) 137
Glass A, (I) 136, 137
Grafman J, (I) 141
Greilich P, (I) 142
Hart M, (I) 141
Henderson I, (I) 139
Herbers J, (I) 139
Heroman W, (I) 142
Hershey J, (I) 137
Heyes M, (I) 141
Hnatuik O, (I) 140
Hurd D, (I) 139
Hurwitz K, (I) 140
Jabbari B, (I) 141
Jones R, (I) 139
Kern J, (I) 141
Kikendall J, (I) 136, 137, 138
Kraft J, (I) 141
Krishnan J, (I) 139
Kroenke K, (I) 138
Kufs W, (I) 136
Kurtzburg J, (I) 139
Lahiri S, (I) 136
Laird J, (I) 136
Landry F, (I) 138
Lane W, (I) 140
Larsen B, (I) 137
Law W, (I) 141
Leek M, (I) 142
Lepler L, (I) 140
Livermore G, (I) 143
Lucas C, (I) 138
Luk G, (I) 137, 138
Mapou R, (I) 141
Marks L, (I) 139
Martin A, (I) 141
Mathias B, (I) 139
Maydonovitch C, (I) 137, 138

* Reference is to page number(s) in Volume I
ADDENDUM
AUTHOR INDEX*
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
FROM PROTOCOLS CLOSED PRIOR TO FY-94

McAdams H, (I) 142
McNally P, (I) 138
Meisenberg B, (I) 139
Mendiola J, (I) 142
Montgomery A, (I) 142
Moses F, (I) 137
Mosiejczuk A, (I) 142
Moul J, (I) 143
Murphy J, (I) 137, 138
Nair P, (I) 137
Natale R, (I) 139
Nelson R, (I) 138
Nicholson D, (I) 136
Nigro M, (I) 142
Noel G, (I) 139
Norton L, (I) 139
O'Neili B, (I) 142
Parker J, (I) 138
Peele M, (I) 139
Peller P, (I) 137
Peller T, (I) 137
Peters W, (I) 139
Peterson B, (I) 139
Petros W, (I) 139
Phillips Y, (I) 137, 138, 140, 141
Pickett B, (I) 143
Pike J, (I) 140
Price R, (I) 138
Pugh R, (I) 139
Reed W, (I) 139
Reeder J, (I) 141
Reid A, (I) 139
Reid T, (I) 143
Rivkin S, (I) 139
Roach J, (I) 140, 141
Rosenberg M, (I) 138
Rosner G, (I) 139
Ross M, (I) 139
Salata K, (I) 137
Salazar A, (I) 141
Schaaf M, (I) 136, 138
Schaudies R, (I) 137
Scherokman B, (I) 138, 141
Schiffer C, (I) 139
Schwab K, (I) 141
Shpall E, (I) 139
Snoiff S, (I) 141
Smallridge R, (I) 136

* Reference is to page number(s) in Volume I

218
ADDENDUM
AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR FROM PROTOCOLS CLOSED PRIOR TO FY-94

Smith M, (I) 138
Sobin L, (I) 136, 137, 138
Solomon B, (I) 136
Stacewicz-Sapuntzakis M, (I) 138
Stamm C, (I) 137
Stoltzfus D, (I) 140
Sutter E, (I) 138
Swartz A, (I) 141
Tang D, (I) 137, 138
Taylor A, (I) 140
Thomas P, (I) 142
Tijerina M, (I) 141
Torrington K, (I) 140, 141
Trump D, (I) 139
Tseng Y, (I) 136
Tzikas T, (I) 143
Vougough V, (I) 143
Vredenburgh J, (I) 139
Vukelja S, (I) 139
Vaecker N, (I) 142
Walden B, (I) 142
Wartofsky L, (I) 136
Weiss R, (I) 139
Weisse M, (I) 142
Wessendorf M, (I) 136
Williams J, (I) 141
Willis S, (I) 138
Winer E, (I) 139
Wong N, (I) 136
Wong R, (I) 137, 138
Wortham D, (I) 136
Wu K, (I) 139
Yoder B, (I) 142
Zekert S, (I) 142

* Reference is to page number(s) in Volume I

219
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Abbondanza S, (I) 172
Acheson D, (I) 173
Aikawa M, (I) 161
Alessio M, (I) 160
Alijani T, (I) 188
Allan A, (I) 148
Allegra C, (I) 157, 158
Alving B, (I) 155, 156, 157, 158, 159, 200
Amundson D, (I) 153
Andejeski T, (I) 157
Anderson J, (I) 150, 158
Anderson M, (I) 177
Andrews J, (I) 163, 179
Agritt P, (I) 150, 163
Antoine G, (I) 200
Antoine J, (I) 180
Arbuck S, (I) 157
Arduino J, (I) 162
Argyros G, (I) 166, 184, 185
Armonda R, (I) 171, 193, 198
Armstrong S, (I) 176
Aronson N, (I) 161
Arthur D, (I) 158
Arthur R, (I) 146
Asplund L, (I) 196
Atoloagbe T, (I) 174
Babcock J, (I) 156
Bachinski M, (I) 152
Badger G, (I) 161
Baker W, (I) 156
Bales J, (I) 160
Balingit A, (I) 179
Bamberger F, (I) 185, 188
Barker J, (I) 174
Barr C, (I) 157
Battin L, (I) 153
Batty D, (I) 188, 189
Batzri S, (I) 188, 190, 191
Bauer F, (I) 148, 167
Baxter D, (I) 163
Beadle C, (I) 161
Beard J, (I) 148, 149
Becker H, (I) 169
Beckett L, (I) 162
Beier J, (I) 160, 161
Belman M, (I) 164
Benedek D, (I) 177
Benson P, (I) 144, 145, 148, 149, 150, 160

* Reference is to page number(s) in Volume I

220
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berg B</td>
<td>(I) 151</td>
</tr>
<tr>
<td>Bergen R</td>
<td>(I) 158</td>
</tr>
<tr>
<td>Berger T</td>
<td>(I) 145, 146, 171</td>
</tr>
<tr>
<td>Bergman W</td>
<td>(I) 193</td>
</tr>
<tr>
<td>Berman J</td>
<td>(I) 160, 161, 163</td>
</tr>
<tr>
<td>Bernard H</td>
<td>(I) 179</td>
</tr>
<tr>
<td>Berrey B</td>
<td>(I) 195, 198</td>
</tr>
<tr>
<td>Bettencourt J</td>
<td>(I) 180</td>
</tr>
<tr>
<td>Beveridge R</td>
<td>(I) 157</td>
</tr>
<tr>
<td>Bilello J</td>
<td>(I) 190</td>
</tr>
<tr>
<td>Bilello K</td>
<td>(I) 164</td>
</tr>
<tr>
<td>Billups L</td>
<td>(I) 174</td>
</tr>
<tr>
<td>Binder R</td>
<td>(I) 157</td>
</tr>
<tr>
<td>Bix D</td>
<td>(I) 160</td>
</tr>
<tr>
<td>Biswas R</td>
<td>(I) 172</td>
</tr>
<tr>
<td>Blair E</td>
<td>(I) 200</td>
</tr>
<tr>
<td>Blanck R</td>
<td>(I) 155</td>
</tr>
<tr>
<td>Blatt S</td>
<td>(I) 153</td>
</tr>
<tr>
<td>Bloomfield C</td>
<td>(I 158)</td>
</tr>
<tr>
<td>Blumenthal D</td>
<td>(I) 153, 155</td>
</tr>
<tr>
<td>Blumenthal R</td>
<td>(I) 147, 148</td>
</tr>
<tr>
<td>Blumgart L</td>
<td>(I) 188, 189</td>
</tr>
<tr>
<td>Boan C</td>
<td>(I) 157</td>
</tr>
<tr>
<td>Bock H</td>
<td>(I) 175</td>
</tr>
<tr>
<td>Bodihidata D</td>
<td>(I) 147</td>
</tr>
<tr>
<td>Boedecker B</td>
<td>(I) 173, 181, 182</td>
</tr>
<tr>
<td>Bolan C</td>
<td>(I) 156</td>
</tr>
<tr>
<td>Boley T</td>
<td>(I) 170</td>
</tr>
<tr>
<td>Bolger W</td>
<td>(I) 200</td>
</tr>
<tr>
<td>Bolls C</td>
<td>(I) 173</td>
</tr>
<tr>
<td>Bolt S</td>
<td>(I) 181</td>
</tr>
<tr>
<td>Botet J</td>
<td>(I) 189</td>
</tr>
<tr>
<td>Botros B</td>
<td>(I) 146</td>
</tr>
<tr>
<td>Boyd E</td>
<td>(I) 200</td>
</tr>
<tr>
<td>Brabyn C</td>
<td>(I) 158</td>
</tr>
<tr>
<td>Braida L</td>
<td>(I) 184</td>
</tr>
<tr>
<td>Brainerman J</td>
<td>(I) 167</td>
</tr>
<tr>
<td>Braverman S</td>
<td>(I) 176</td>
</tr>
<tr>
<td>Brengman M</td>
<td>(I) 186</td>
</tr>
<tr>
<td>Brennan M</td>
<td>(I) 190, 192</td>
</tr>
<tr>
<td>Brewer T</td>
<td>(I) 163</td>
</tr>
<tr>
<td>Brinker J</td>
<td>(I) 147, 148</td>
</tr>
<tr>
<td>Brown A</td>
<td>(I) 161</td>
</tr>
<tr>
<td>Brown K</td>
<td>(I) 189</td>
</tr>
<tr>
<td>Bruderer B</td>
<td>(I) 191</td>
</tr>
<tr>
<td>Brundage J</td>
<td>(I) 160, 161</td>
</tr>
<tr>
<td>Brunetto V</td>
<td>(I) 158</td>
</tr>
<tr>
<td>Bryant P</td>
<td>(I) 175</td>
</tr>
</tbody>
</table>

* Reference is to page number(s) in Volume I

221
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Bunda M, (I) 148
Bunger R, (I) 181, 183
Burch H, (I) 150
Burgess D, (I) 174
Burke D, (I) 160, 162, 163
Burman K, (I) 150, 151
Burnham K, (I) 181, 182
Burrell L, (I) 158, 189
Burris D, (I) 164, 166, 187
Burt M, (I) 190, 192
Butzin C, (I) 153
Buzard G, (I) 201
Byrd J, (I) 156, 159, 160
Byron J, (I) 170, 171
Cail W, (I) 200
Calkins M, (I) 181, 182
Callaghan J, (I) 195
Canpos-Estve M, (I) 147
Carpenter G, (I) 144, 145, 159, 160
Carr M, (I) 181, 182
Carregal V, (I) 144, 145
Carter A, (I) 147, 148
Carter R, (I) 181
Carter T, (I) 192, 194, 198
Carver J, (I) 188
Cartwright J, (I) 179
Case S, (I) 151
Casinelli P, (I) 181
Casler J, (I) 200
Caspar E, (I) 190
Castello P, (I) 193
Celleon D, (I) 173
Chadduck W, (I) 193
Chambers S, (I) 171
Chan C, (I) 146, 147
Chandler D, (I) 183
Chang A, (I) 146, 151, 181, 183
Chapman R, (I) 151
Chapman W, (I) 192
Chen B, (I) 157, 164
Chiu Y-M, (I) 146
Christian M, (I) 159
Christopherson R, (I) 151
Chumo D, (I) 160
Chung R, (I) 155, 160, 161, 162, 163
Church C, (I) 146
Ciraulo D, (I) 185
Citrin C, (I) 193

* Reference is to page number(s) in Volume I

222
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Clawson L, (I) 176
Clement S, (I) 151
Close H, (I) 200
Cobb J, (I) 182
Cockerham G, (I) 195
Cockerhill D, (I) 195
Cohen A, (I) 181
Coit D, (I) 190
Cole F, (I) 164
Colleton C, (I) 157, 174
Collins H, (I) 158
Colon E, (I) 189
Coombs V, (I) 147, 148
Cooper L, (I) 174
Cooper M, (I) 158
Cortese L, (I) 160
Corwin A, (I) 146
Coster T, (I) 148
Cowan D, (I) 195
Cowan K, (I) 159
Cozza K, (I) 176
Cremins J, (I) 152
Crespo I, (I) 152
Crowe M, (I) 149
Crowl F, (I) 182
Crumpacker C, (I) 162
Cucinell S, (I) 192
Cunningham J, (I) 188
Cuozzo D, (I) 149, 150
Cutting M, (I) 157
Dalal J, (I) 147, 148
Dacey M, (I) 165
D'Addio V, (I) 188
D'Alessandro M, (I) 151
Darwish M, (I) 146
Dasch G, (I) 146, 147, 163
Davey F, (I) 158
Davis W, (I) 144
Dawson N, (I) 156, 157, 159
De Bauche D, (I) 175
Deffer P, (I) 195
Dennis G, (I) 165, 167
Dent R, (I) 182
Devoid D, (I) 172
Di Bisceglie A, (I) 172
Diehl L, (I) 156, 157, 159, 160
Diggs C, (I) 160
Dillard T, (I) 165

* Reference is to page number(s) in Volume I

223
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Djuh Y-Y, (I) 150
Dodd K, (I) 164, 165
Donovan D, (I) 193, 198
Dons B, (I) 151
Dougherty D, (I) 176, 177
Dow N, (I) 171
Doyle M, (I) 176
Drobick J, (I) 160
Drucker W, (I) 187
Dryzer T, (I) 200
Duggan D, (I) 158
Duncan W, (I) 151
Dunn C, (I) 149
Dwyer T, (I) 165
Dykes E, (I) 192
Eamsila C, (I) 147
Earls J, (I) 189
Edison D, (I) 176
Edwards J, (I) 155
Elias S, (I) 199
Elissass A, (I) 164, 165, 185
Ellenbogen R, (I) 193, 194
Elliott D, (I) 185, 186, 187, 188, 189
Elliott J, (I) 199
Elsayed N, (I) 164, 165
Endy T, (I) 160, 162
Eng G, (I) 175
Engel C, (I) 153
Engler R, (I) 144, 145, 160, 165, 186
Erickson M, (I) 167
Erer A, (I) 189
Evans D, (I) 151
Ferrell R, (I) 153
Fielding C, (I) 171
Figg W, (I) 158
Finder K, (I) 149
Findlay S, (I) 146
Finger M, (I) 201
Finkelman F, (I) 172, 173, 174
Fitzpatrick T, (I) 164, 165, 166, 187
Fleckenstein L, (I) 163
Fleischer G, (I) 186
Foley E, (I) 181, 183
Foley K, (I) 193
Fong Y, (I) 188
Fontana J, (I) 181, 182
Franke E, (I) 160, 161
Frei E, (I) 159

* Reference is to page number(s) in Volume I

224
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Friedman K, (I) 150
Frishberg D, (I) 148, 174
Frisman D, (I) 150, 163
Froelich E, (I) 180
Furnia A, (I) 153
Gachihi G, (I) 163
Gaddipati J, (I) 201, 202
Gafni A, (I) 154
Gaither N, (I) 183
Galapon D, (I) 189
Gallasch K, (I) 171
Galvin M, (I) 150
Gamble W, (I) 195
Garrett M, (I) 189
Gasch G, (I) 146
Gasser R Jr, (I) 160, 161, 162
Gavigan M, (I) 159
Gemmill R, (I) 161
Ghigo D, (I) 160
Giangreco E, (I) 157
Giblin W, (I) 149
Gigg D, (I) 156
Gilbert G, (I) 166
Glass K, (I) 159, 165
Gloth S, (I) 147, 148
Goedert J, (I) 172
Goldberg W, (I) 188, 191
Goldhill J, (I) 172, 173, 174
Goldspiel B, (I) 157, 195
Gomez E, (I) 157, 166, 167, 188, 192
Gordon J, (I) 180
Graham R, (I) 146
Grant K, (I) 184
Grantham D, (I) 183
Graves E, (I) 171
Grayson M, (I) 175
Greco N, (I) 160
Greilich P, (I) 181, 182
Green D, (I) 175, 187
Greenman P, (I) 186
Greenstein F, (I) 202
Grem J, (I) 157
Grieger T, (I) 176
Griffin G, (I) 171
GrogI M, (I) 160, 161, 162
Gurney C, (I) 169
Guzzi L, (I) 186, 188
Habib M, (I) 146

* Reference is to page number(s) in Volume I

225
ADDENDUM
AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Haddy F, (I) 164
Hadro N, (I) 189
Hagan M, (I) 179
Hakim F, (I) 159
Hale D, (I) 188, 189, 190, 191, 192
Hallett M, (I) 167
Hamblet J, (I) 169
Hamelink J, (I) 157
Hamilton J, (I) 157, 163
Hamlyn J, (I) 164
Hammer S, (I) 162
Hann L, (I) 189
Hansen M, (I) 156, 196
Hargis J, (I) 157, 160
Harmon J, (I) 188, 191
Harrington A, (I) 148, 149
Hartigan P, (I) 163
Hartman K, (I) 156, 174
Harviel J, (I) 192
Hatch R, (I) 165, 186
 Hathaway T, (I) 192
Hawley-Bowland C, (I) 171
Haynes D, (I) 181, 182
Hays M, (I) 151
Headlee D, (I) 156, 158, 159
Heidenberg H, (I) 200
Heimer W, (I) 150
Henderson N, (I) 175
Hendrix C, (I) 153
Henson K, (I) 148
Heppner D Jr, (I) 161
Herbers J, (I) 154
Herden M, (I) 175
Hershey J, (I) 144, 145, 147
Hesslink R, (I) 151
Hickman M, (I) 171
Hilsenbeck S, (I) 154
Hirotani W, (I) 166
Ho C, (I) 172, 202
Hoffman S, (I) 160, 161
Holcomb J, (I) 189
Hollifield R, (I) 195
Holm C, (I) 171
Holt W, (I) 144, 145
Hom R, (I) 202
Hopkinson W, (I) 196, 199
Hospenthal D, (I) 156, 159, 160
Howard R, (I) 159, 195

* Reference is to page number(s) in Volume I

226
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Howe J, (I) 175
Hudak J, (I) 169
Hugh M, (I) 144
Huh M, (I) 145
Hume R, (I) 192
Huntley D, (I) 155
Hurwitz K, (I) 185
Ilstrup D, (I) 191
Isenbarger D, (I) 161
Ista C, (I) 198
Jabbari B, (I) 167, 176
Jackson M, (I) 157
Jackson R, (I) 188, 192
Jaffin J, (I) 164, 166, 192
James W, (I) 148, 149, 150, 160, 163
Jamieson G, (I) 160
Janssen D, (I) 163
Januszkiewicz A, (I) 165, 187
Japour A, (I) 162
Jacques D, (I) 150, 185, 186, 188, 189, 190, 192
Javier J, (I) 148
Jeffers D, (I) 153, 154
Johnson A, (I) 163
Johnson C, (I) 188
Johnson J, (I) 200
Johnson L, (I) 152
Johnson S, (I) 161, 162, 163
Johnstone W, (I) 179
Jones B, (I) 195
Jones C, (I) 181
Jones D, (I) 153, 154
Jordon E, (I) 157
Jordon M, (I) 192
Jossart G, (I) 150
Joy R, (I) 153, 154
Kahn D, (I) 202
Kahn K, (I) 202
Kales A, (I) 157
Kaplan R, (I) 186
Karan S, (I) 182
Kark J, (I) 157
Karpa M, (I) 182
Karpeh M, (I) 192
Kasili S, (I) 163
Katon W, (I) 153
Katz R, (I) 149
Kaushal S, (I) 157
Kazacs E, (I) 188

* Reference is to page number(s) in Volume I

227
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Kelly D, (I) 146, 147, 163
Kennedy D, (I) 200
Kent K, (I) 148
Kessler S, (I) 157
Kester K, (I) 156, 160
Kikendall J, (I) 152
Kilkelly P, (I) 196
Killen A, (I) 169
Kim B, (I) 192
Kim C, (I) 195
King A, (I) 160
King C, (I) 169
Kirig i G, (I) 163
Klein R, (I) 179
Klimstra D, (I) 189
Kline M, (I) 181, 182
Knutson S, (I) 165
Kobayashi K, (I) 156
Kobrine A, (I) 163
Koech D, (I) 160
Kohler D, (I) 158, 159
Koppelman J, (I) 170
Korge B, (I) 149
Kosanderle, (I) 188
Koski K, (I) 167
Kovach J, (I) 148
Kramer K, (I) 195
Krishnamurti C, (I) 156, 157
Krivda S, (I) 149
Kroenke K, (I) 153, 154, 155
Kushner J, (I) 151
Kryzer T, (I) 200
Kufs W, (I) 147
Kumke K, (I) 186
Kushner J, (I) 151
Kuzma P, (I) 182
Kweeder S, (I) 156
La Russa V, (I) 157
Labbate L, (I) 176, 177
Labutta R, (I) 167
Ladwig M, (I) 157, 171
Lafer B, (I) 176, 177
Laird J, (I) 147
Lambert P, (I) 200
Landry F, (I) 153, 154
Lane B, (I) 190
Lane J, (I) 162
Larson K, (I) 160

* Reference is to page number(s) in Volume I
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Latimer M, (I) 145
Lauwers D, (I) 192
Lawrence V, (I) 154
Lazas D, (I) 152
Ledsky R, (I) 160
Lee D, (I) 175
Leek M, (I) 183
Leff M, (I) 177
Lenhart M, (I) 196, 197
Lentz L, (I) 175
Leon M, (I) 148
Lepler L, (I) 164, 166
Levin L, (I) 161
Lewis D, (I) 202
Lieberman M, (I) 190
Lindstrom J, (I) 163
Lineham W, (I) 158
Lippert L, (I) 171
Lojeski E, (I) 182, 183
Long J, (I) 181
Longfield J, (I) 161
Lucas C, (I) 177
Lucas D, (I) 158
Lucey C, (I) 153, 154
Lucey D, (I) 153
Luk G, (I) 152
Lupkus R, (I) 181
Lupton G, (I) 149, 160
Macarthy P, (I) 160
Madigan W, (I) 195
Maeno Y, (I) 161
Magglo M, (I) 172
Magill A, (I) 160, 161, 162
Magruder C, (I) 161
Maher P, (I) 202
Malavesi M, (I) 160
Malcolm D, (I) 164, 166, 187
Mangan K, (I) 158
Maniscalco-Theberge M, (I) 185, 186, 187, 188, 191
Mann E, (I) 200
Manoun T, (I) 165
Mansfield J, (I) 160
Manunta P, (I) 164
Marin R, (I) 175
Markenson G, (I) 170
Martin B, (I) 151, 185
Marx W, (I) 188
Maslow A, (I) 170

* Reference is to page number(s) in Volume I
ADDENDUM
AUTHOR INDEX*
PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Mason J, (I) 193, 199
Mattix M, (I) 181, 182
Maybee D, (I) 174
Maydonovitch C, (I) 152, 153
Maygarden S, (I) 202
Mayer A, (I) 171
Mayer M, (I) 193, 200
Mayer R, (I) 158
Mayers D, (I) 162, 163
Mayorga M, (I) 165, 187
Mays R, (I) 180
Mbugua J, (I) 163
McAleer I, (I) 190
McAttee N, (I) 157
McCormack E, (I) 145
McCormick S, (I) 152
McElroy P, (I) 161
McHale K, (I) 196, 197, 199
McIntyre O, (I) 158, 159
McKinney L, (I) 198, 199
McLeod D, (I) 162
McLeod G, (I) 201, 202
McLoughlin T, (I) 183
McMarlin S, (I) 149
McQueen C, (I) 152
Mellen P, (I) 171
Melendez J, (I) 188
Mena H, (I) 172
Menezes A, (I) 193, 194
Meter J, (I) 196
Metzger D, (I) 175
Meyer G, (I) 153, 154, 155
Milazzo M, (I) 161
Miles R, (I) 167
Millard F, (I) 158
Miller A, (I) 157, 158
Miller D, (I) 196
Miller J, (I) 157
Milnor W, (I) 196
Mills L, (I) 182, 183, 186
Mills W, (I) 151
Miner T, (I) 181
Minkoff H, (I) 172
Mintz G, (I) 148
Mitchell K, (I) 185
Miyazawa K, (I) 170
Molloy M, (I) 188, 189, 190, 191, 192
Monacci W, (I) 193, 194, 198

* Reference is to page number(s) in Volume I

230
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Mondragon D, (I) 155
Mongan P, (I) 183
Montemarano A, (I) 149
Moore P, (I) 181
Moores L, (I) 165, 194
Morgan J, (I) 146
Morgan K, (I) 148
Morris S, (I) 172, 173, 174
Morrison F, (I) 175
Mosca J, (I) 157
Moses F, (I) 152
Mosijczuk A, (I) 175
Moss F, (I) 152
Mostofi F, (I) 201
Moul J, (I) 172, 201, 202
Mugo M, (I) 163
Muigai R, (I) 163
Muldoon S, (I) 182
Mullaney M, (I) 158
Mullet C, (I) 173
Mulvey K, (I) 158
Murphy F, (I) 165
Murphy J, (I) 152
Murphy K, (I) 152
Murphy M, (I) 156
Myers C, (I) 156, 158, 159
Myhand R, (I) 158, 159
Nearing B, (I) 148
Nelson B, (I) 171
Nelson H, (I) 191
Newman R, (I) 158
Nicely E, (I) 172
North E, (I) 175
Noone M, (I) 159
Nowlin J, (I) 200
Nutman T, (I) 160
Nguyen H, (I) 166
O’Hair K, (I) 199
O’Neill B, (I) 181, 183
O’Shaughnessy J, (I) 159
Ockenhousey C, (I) 160, 161, 162
Ogilvie J, (I) 198
Ohi C, (I) 167
Oloo A, (I) 161
Olson E, (I) 198, 199
Olson J, (I) 146
Ondra S, (I) 177, 193, 194, 195, 197, 198, 200
Onyango F, (I) 160

* Reference is to page number(s) in Volume I

231
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Ordas D, (I) 177
Osenbach R, (I) 193, 194
Oster C, (I) 144, 160, 161, 162, 163
Otchy D, (I) 191
Otto M, (I) 176
Pacicco T, (I) 151
Painter J, (I) 148
Pamnani M, (I) 164
Panasci L, (I) 159
Pangaro L, (I) 154, 177
Paparello S, (I) 167
Parenti D, (I) 163
Park R, (I) 171
Parker J, (I) 165, 186, 187
Parson D, (I) 200
Paxton H, (I) 146, 147
Pearl R, (I) 185, 188, 189, 190, 191, 192
Pederson A, (I) 156
Peele K, (I) 195
Peele M, (I) 151
Perkins P, (I) 160
Peterson B, (I) 158, 159
Phelps J, (I) 171
Phillips Y, (I) 164, 165, 166, 185
Richard A, (I) 148
Pickett B, (I) 200
Pineiro-Carrero V, (I) 172, 173, 174
Pinyopornpanit V, (I) 147
Place H, (I) 193
Pollack G, (I) 170
Pollack M, (I) 176, 177
Pollner J, (I) 163
Polly D, (I) 193, 194, 195, 196, 197, 198
Polo K, (I) 167
Pope R, (I) 198
Popek E, (I) 170
Popma J, (I) 148
Popovic N, (I) 197, 198, 199
Poropatich R, (I) 166, 167
Porter C, (I) 164, 170
Powell C, (I) 166, 187
Prewitt K, (I) 148
Pridham K, (I) 146
Primo L, (I) 160
Pryzbylik J, (I) 174
Puckett T, (I) 195
Pyne M, (I) 176, 177
Quesada M, (I) 151

* Reference is to page number(s) in Volume I

232
ADDENDUM

AUTHOR INDEX

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Radford B, (I) 145
Radulovic S, (I) 163
Randle D, (I) 187
Rapacki T, (I) 181
Rashid J, (I) 163
Ratelle S, (I) 155
Ray K, (I) 161
Rayburn D, (I) 166
Read J, (I) 170
Redfield R, (I) 160
Redmond J, (I) 158
Reed N, (I) 151
Reed S, (I) 162
Reeder J, (I) 169
Reich P, (I) 202
Reichman R, (I) 162
Reid T, (I) 157, 158
Reilly T, (I) 157
Renn R, (I) 184
Resar J, (I) 148
Reynolds H, (I) 186
Reynolds P, (I) 181
Rhoads J, (I) 160
Rhooms P, (I) 150
Ribas J, (I) 172
Richards A, (I) 146
Ries M, (I) 187
Rimm W, (I) 195
Ritchie E, (I) 177
Rives C, (I) 146
Roach J, (I) 185
Roberts C, (I) 160, 161, 162, 163
Robinson J, (I) 195
Robinson M, (I) 176
Robels H, (I) 167, 174
Robson M, (I) 157
Rodriguez A, (I) 187
Rodriguez R, (I) 144, 145
Rosenbaum J, (I) 176, 177
Ross A, (I) 202
Roy M, (I) 155
Royston I, (I) 158
Ruck D, (I) 177
Rueda-Pedraza E, (I) 172
Ruiz P, (I) 180
Rutkowski D, (I) 170
Salata K, (I) 145, 146, 147, 171, 174
Salazar A, (I) 167, 168, 176, 177, 193

* Reference is to page number(s) in Volume I

233
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Sanchez J, (I) 146
Sandler D, (I) 158
Sanes J, (I) 167
Sartell K, (I) 159
Sartor O, (I) 156, 159
Satler L, (I) 148
Sau P, (I) 148, 149, 150
Sawson N, (I) 158
Sayles J, (I) 192
Schaaf M, (I) 152
Schaefer K, (I) 163
Schenkman N, (I) 172, 202
Scherockman B, (I) 193
Schiffer C, (I) 158
Schneider E, (I) 159
Schultz A, (I) 154
Schultz S, (I) 164, 166, 187
Schuster B, (I) 163
Schutt D, (I) 189, 192
Schwab R, (I) 149
Schwartz A, (I) 163, 182
Schwartz P, (I) 171
Scrogan A, (I) 151
Selzer J, (I) 146
Sesterhenn I, (I) 202
Shannon M, (I) 193
Shafrir Y, (I) 168
Shaver T, (I) 188
Shea-Donohue T, (I) 172, 173, 174
Sheeley E, (I) 177
Sherr T, (I) 147
Sherwood J, (I) 160, 161, 163
Shore D, (I) 158
Shriver C, (I) 188, 189, 190, 192
Sidman J, (I) 200
Sie A, (I) 146
Silver R, (I) 158
Simberkoff M, (I) 163
Simon G, (I) 163
Simonds G, (I) 193, 194
Simmons T, (I) 193
Singer D, (I) 155, 179
Sirisanthana T, (I) 147
Sirisanthana V, (I) 147
Sizemore D, (I) 160
Sjogren M, (I) 152
Sjogren R, (I) 172, 173, 174
Skelton H, (I) 149, 150, 163

* Reference is to page number(s) in Volume I

234
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Skillman D, (I) 163
Skillman L, (I) 148
Smack D, (I) 149
Smith A, (II) 195
Smith B, (I) 202
Smith C, (I) 161
Smith G, (I) 195
Smith K, (I) 149, 150, 160, 163
Smith L, (I) 160
Smith M, (I) 151, 152
Smith S, (I) 151
Smolin M, (I) 148
Solomon B, (I) 151
Sorensen G, (I) 149
Southby J, (I) 169
Sover E, (I) 157
Speer K, (I) 195
Sperling L, (I) 149, 150
Sprague M, (I) 179
Spritzer C, (I) 195
Squire E, (I) 144, 145, 160
Srivastava S, (I) 201, 202
St. Clair M, (I) 163
St. Pierre P, (I) 199
Stachelski S, (I) 192
Stambaugh K, (I) 200
Starnes B, (I) 192
Stasko T, (I) 148, 149
Staudenmeier J, (I) 177
Steinbaum S, (I) 192
Steinberg S, (I) 157
Stern T, (I) 177
Stojadinovic A, (I) 192
Stolte A, (I) 182
Stoltzfus D, (I) 187
Stoute J, (I) 160
Strickland W, (I) 175
Strickman D, (I) 146, 147
Stuart J, (I) 199
Stuifbergen A, (I) 169
Sturm L, (I) 181
Sullivan M, (I) 160
Sullivan N, (I) 167
Swanson S, (I) 188
Swartz G, (I) 159
Szigeti J, (I) 171
Tandon N, (I) 160
Tang D, (I) 152, 156, 157

* Reference is to page number(s) in Volume I

235
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Tang F, (I) 156
Tanskul P, (I) 147
Tegoshi T, (I) 161
Temple H, (I) 196
Tesar G, (I) 176, 177
Thach A, (I) 195
Theroux J, (I) 154
Thibault A, (I) 159
Thompson J, (I) 157, 166
Thompson K, (I) 147
Thurnher M, (I) 148
Tibbetts G, (I) 151
Tochner, (I) 179
Tolcher A, (I) 159
Tomic D, (I) 153
Tompkins A, (I) 156, 159
Toro L, (I) 157
Torrington K, (I) 164, 166, 185
Trakimas C, (I) 150
Tramont E, (I) 162
Trotter J, (I) 202
Trump D, (I) 158
Truwit J, (I) 166
Tseng P, (I) 171
Tseng L, (I) 173
Tsou H, (I) 148
Tuley M, (I) 154
Turiansky G, (I) 149
Turner B, (I) 151
Uhorchak J, (I) 199
Uruburu A, (I) 169
Vahey M, (I) 162, 163
Van Albert S, (I) 166
van Heerden J, (I) 191
Vavro C, (I) 163
Vennos L, (I) 150
Verma A, (I) 188
Vernalis M, (I) 148
Verrier R, (I) 148
Vire D, (I) 161
Vogel P, (I) 150
Vogelgesang S, (I) 167
Vogelzang N, (I) 156, 157, 159
Vukelja S, (I) 156, 157
Wagner K, (I) 162, 163
Walden B, (I) 184
Walker D, (I) 163
Wallier P, (I) 169

* Reference is to page number(s) in Volume I
ADDENDUM

AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Ward F, (I) 157
Ward J, (I) 171
Warden D, (I) 176, 177
Ware J, (I) 202
Wartofsky L, (I) 151
Wassef N, (I) 159
Wasunna K, (I) 163
Watt G, (I) 147
Watts D, (I) 146
Weaver A, (I) 191
Weddle J, (I) 146, 147
Weghorst C, (I) 201
Weidner S, (I) 156, 160
Weinberger B, (I) 158
Weinberger M, (I) 159
Weislow O, (I) 162, 163
Weiss J, (I) 156
Weiss R, (I) 156, 157, 158, 159
Weissman J, (I) 200
Weitzel M, (I) 169
Welborn L, (I) 181
Welch M, (I) 150
Were J, (I) 163
Wertz D, (I) 195
Whiting D, (I) 150
Whitmire R, (I) 160
Wierzba T, (I) 160
Wiesen A, (I) 159
Wiles C, (I) 186
Williams C, (I) 151
Williams G, (I) 182
Williams S, (I) 192
Williams W, (I) 163
Wilson R, (I) 172
Winquist R, (I) 199
Winslow D, (I) 162
Winter L, (I) 191
Wiswell T, (I) 192
Wolff B, (I) 191
Wong N, (I) 177, 178, 179
Wong R, (I) 152, 153
Wortham D, (I) 147, 148
Wurster-Hill D, (I) 158
Yager J, (I) 154
Yamada T, (I) 194
Yavorski R, (I) 152, 153
Yeager J, (I) 150, 163
Yee L, (I) 183

* Reference is to page number(s) in Volume I

237
ADDENDUM
AUTHOR INDEX*

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR
NOT RELATED TO APPROVED CLINICAL INVESTIGATION PROTOCOLS

Young B, (I) 151
Young P, (I) 182
Young S, (I) 179
Yuan C, (I) 164
Zajtchuk J, (I) 166, 167
Zeiger R, (I) 146
Zekert S, (I) 182
Zhou S, (I) 162, 163
Zurcher R, (I) 181, 183

* Reference is to page number(s) in Volume I

238
<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel-rahim, M.</td>
<td>333</td>
</tr>
<tr>
<td>Abt, M.</td>
<td>545</td>
</tr>
<tr>
<td>Adebonojo, S.</td>
<td>239</td>
</tr>
<tr>
<td>Alving, B.</td>
<td>197, 201, 464</td>
</tr>
<tr>
<td>Anderson, D.</td>
<td>44</td>
</tr>
<tr>
<td>Anderson, J.</td>
<td>446</td>
</tr>
<tr>
<td>Argyros, G.</td>
<td>244</td>
</tr>
<tr>
<td>Aronson, N.</td>
<td>485</td>
</tr>
<tr>
<td>Ashton, W.</td>
<td>348</td>
</tr>
<tr>
<td>Atwa, M.</td>
<td>157</td>
</tr>
<tr>
<td>Bailey, L.</td>
<td>37</td>
</tr>
<tr>
<td>Barry, M.</td>
<td>487</td>
</tr>
<tr>
<td>Baumgartner, J.</td>
<td>39</td>
</tr>
<tr>
<td>Beamer, S.</td>
<td>474</td>
</tr>
<tr>
<td>Beard, J.</td>
<td>130</td>
</tr>
<tr>
<td>Beattie, B.</td>
<td>432</td>
</tr>
<tr>
<td>Becker, G.</td>
<td>227</td>
</tr>
<tr>
<td>Belandres, P.</td>
<td>428</td>
</tr>
<tr>
<td>Belliveau, P.</td>
<td>440</td>
</tr>
<tr>
<td>Benedek, D.</td>
<td>434</td>
</tr>
<tr>
<td>Berg, B.</td>
<td>225</td>
</tr>
<tr>
<td>Berger, T.</td>
<td>11</td>
</tr>
<tr>
<td>Bernet, V.</td>
<td>158, 165</td>
</tr>
<tr>
<td>Bettencourt, J.</td>
<td>458</td>
</tr>
<tr>
<td>Bilello, J.</td>
<td>234</td>
</tr>
<tr>
<td>Billups, L.</td>
<td>29, 30</td>
</tr>
<tr>
<td>Birx, D.</td>
<td>45, 53, 58, 59</td>
</tr>
<tr>
<td>Biskey, V.</td>
<td>271</td>
</tr>
<tr>
<td>Blaydon, S.</td>
<td>493</td>
</tr>
<tr>
<td>Bley, J.</td>
<td>534</td>
</tr>
<tr>
<td>Bohen, E.</td>
<td>214, 216, 217, 219</td>
</tr>
<tr>
<td>Brandt, U.</td>
<td>48</td>
</tr>
<tr>
<td>Braverman, S.</td>
<td>428</td>
</tr>
<tr>
<td>Brousseau, S.</td>
<td>40</td>
</tr>
<tr>
<td>Brown, A.</td>
<td>254</td>
</tr>
<tr>
<td>Brown, J.</td>
<td>438</td>
</tr>
<tr>
<td>Brown, M.</td>
<td>503</td>
</tr>
<tr>
<td>Burch, H.</td>
<td>136, 142, 151, 152, 167, 255</td>
</tr>
</tbody>
</table>

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Burrell, L, 60, 195, 196, 198, 199, 332, 513
Byrd, J, 191, 191, 203
Cambier, P, 114
Campos, M, 123
Cantilena, L, 118, 124, 125
Carome, M, 211, 213, 219, 220, 221, 222
Carpenter, G, 24
Carr, F, 135
Carregal, V, 2, 22
Carter, A, 113, 116
Carvill, K, 452
Cavallaro, B, 491, 492
Chang, A, 145, 427, 434, 437, 464
Cheney, C, 170
Choma, T, 521
Chung, R, 43, 50, 51, 61
Clay, J, 469, 470, 475, 476, 478
Clement, S, 137, 140, 144, 221
Collier, E, 126
Colon, E, 448, 449
Cook, J, 518
Cooper, L, 29
Cord, M, 466, 471, 475, 476
Cortese, L, 55
Costabile, R, 354
Cremins, J, 186
Cross, A, 207
Crowell, M, 322
Cukier, A, 531
Curley, M, 334
Darling, B, 341
Davis, W, 22, 495
Dawson, N, 193
DeCesare, E, 278
DeMarkles, M, 174
DeVries, W, 509, 510, 514, 520
Degnan, B, 344
Dennis, G, 243, 250, 254
Derdener, S, 224, 237, 245
Diehl, L, 164
Dillard, T, 225, 229, 231, 236
Dillingham, T, 426, 427, 429, 431, 433
Dobek, A, 35, 36
Doyle, J, 232, 243
Drabick, J, 207
Duester, P, 161

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Duncan, W, 145, 148, 150, 155
Earls, J, 448, 449
Edwards, F, 456
Ellasson, A, 230, 243, 244
Engler, R, 1, 2, 5, 13, 23, 130, 495
Erbe, E, 441
Esposito, M, 436
Farley, J, 280
Febo, M, 445
Finelli, M, 242
Fisher, C, 135
Fontana, J, 457, 459
Francis, G, 323, 324, 325, 333, 334
Francis, T, 141
Garrett, M, 448
Gasser, R, 206
Giangeruso, E, 201, 202
Glass, A, 132, 166
Glenn, R, 39
Gold, P, 161
Gordon, J, 458
Gorman, P, 115, 121, 122, 127
Grabenstein, J, 42
Grant, K, 465, 474, 476
Graumlich, J, 125
Greenwell, H, 556
Greilich, P, 464
Grosso, N, 507
Gurczak, P, 119
Gurevich-Uvera, J, 530
Gurney, C, 271, 277
Guzzi, L, 451, 462
Hale, D, 488, 489, 490
Hall, D, 434
Hall, E, 239
Hamm, C, 38, 237
Harrington, G, 486
Harris, T, 42
Hartman, K, 200, 202, 249
Hawkes, C, 49, 63, 64, 65
Hayda, R, 501

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Herden, M, 418, 419, 422
Hershey, J, 3, 4, 6, 7, 8, 10, 11, 12, 14, 15, 16, 17, 18, 19, 21, 322
Hetzler, N, 487
Hicks, C, 43, 56, 191
Hiner, W, 55
Hinson, R, 350
Hnatiuk, O, 231, 232, 241
Hollinger, J, 532, 533, 534
Hopkins, T, 234
Hopkinson, W, 499, 500, 502, 508
Hospenthal, D, 203
Howard, R, 431
Howie, P, 437
Huh, M, 20
Hull, R, 112, 117, 120
Hurwitz, K, 235, 244
Irby, P, 555
Isaac, J, 67
Jabbari, B, 260, 261, 263, 264
Jacob, E, 505
James, W, 128, 130, 168
Johnson, S, 53, 56, 58, 59, 206, 208
Jones, F, 445
Jones, K, 274
Joslin, S, 439
Kapur, J, 30, 438
Karan, S, 456, 461, 463
Katona, I, 250
Kerns, D, 556
Keslar, P, 163
Kester, K, 208
Kiandoli, L, 212, 214
Kikendall, J, 1, 176, 183
Kilkelly, F, 523
Kishbaugh, D, 431
Kleinman, D, 52
Kline, M, 453, 455
Klipple, G, 200, 246, 247, 248, 249, 253
Knutson, S, 233
Kobydarz, E, 265, 266
Konzelman, J, 52
Kosisky, S, 24
Kroenke, K, 187, 188, 189
Kufs, W, 123
Kunke, K, 231, 237

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Kushner, J, 146
La Russa, V, 205
Lahiri, S, 139, 162
Laird, J, 121, 122, 123, 156
Lande, R, 437, 444
Landry, F, 189
Lasswell, W, 155, 156
Latimer, J, 336, 345
Lauder, T, 430
Leek, M, 467, 472, 473, 478, 479, 480, 481, 482, 483
Leone, L, 260
Lepler, L, 240
Lewis, D, 546
Ling, G, 266
Lojeski, E, 453
Longer, C, 485
Lower, R, 501
Lucas, C, 189
Lucey, C, 187
Lukes, Y, 157
Magill, A, 206
Maldonado, J, 269
Mann, E, 44, 530
Marlowe, S, 41
Marple, R, 187
Martin, B, 146
Martinez, M, 1
Mateski, D, 176
Matson, M, 460
Maybee, D, 327, 352, 353, 354, 355, 356, 357, 358, 359,
360, 361, 362, 363, 364, 365, 366, 367, 368, 369,
370, 371, 372, 373, 374, 375, 376, 377, 378, 379,
380, 381, 382, 383, 384, 385, 386, 387, 388, 389,
390, 391, 392, 393, 394, 395, 396, 397, 398, 399,
400, 401, 403, 404, 405, 406, 407, 408, 409, 410,
411, 412, 413, 414, 415, 416, 417, 418, 419, 420,
421, 422, 423
Maydonovitch, C, 171, 172, 178, 184, 186
Mayer, A, 282, 283, 284, 285, 286, 287, 288, 289, 290,
291, 292, 293, 294, 295, 296, 297, 298, 299, 300,
301, 302, 303, 304, 305, 306, 307, 308, 309, 310,
311, 312, 313, 314, 315, 316, 317, 318, 319, 320,
321
Mayer, M, 532, 533, 534
Mayers, D, 57
McAdams, H, 449

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Mcclain, J, 207
Mcclean, M, 466, 468, 469, 470, 477
Mccormack, E, 2, 5
Mcevoy, P, 35, 208
McFarland, J, 369
McHale, K, 496, 501, 514, 524
McKenzie, P, 530
Mcleod, D, 537, 538, 539, 540, 542, 544, 545, 547, 548, 554
Mewshaw, B, 246, 247, 248
Miller, J, 339
Moore, J, 209, 211, 212, 213, 216, 218
Moore, R, 329, 331, 340, 342, 346
Moses, F, 169, 173, 179
Moul, J, 540, 542, 545, 548, 549, 550
Murphy, J, 176
Nagy, E, 133
Nannis, E, 48
Nelson, B, 424
Nicholson, D, 148, 150, 438
O'connor, F, 41
O'Malley, P, 190
O'Neill, T, 341
Oleshansky, M, 435
Olson, E, 500
Osenbach, R, 263
Oster, C, 43, 50, 55, 57, 60
Pacisco, T, 185
Pampani, M, 217
Parker, J, 229, 236, 238
Patterson, A, 39
Payne, M, 36, 157, 333, 341, 477
Pearl, R, 336
Pearson, C, 119, 122
Peller, T, 173
Petrov, J, 272
Phillips, W, 456
Phillips, Y, 228, 233, 235, 236, 245
Pierce, J, 330

* Reference is to page numbers in Volume II.

244
INVESTIGATOR INDEX*

Pineiro, V, 336, 345
Podraza, B, 478
Polly, D, 497, 513, 515, 516, 526, 527
Polly, S, 495
Popham, S, 222
Popovic, N, 505, 511, 512, 517, 518, 519, 522, 523, 525, 528, 529
Poropatich, R, 223, 228
Poth, M, 323, 335, 338, 343, 344
Prewitt, K, 114, 121
Radford, B, 25
Rajagopal, K, 224, 226, 227, 245
Raszka, W, 347, 349
Rayburn, D, 240
Redfield, R, 45, 53, 58, 59, 62, 66
Reeder, J, 272
Reid, T, 201, 202, 204, 205
Rich, I, 270, 275
Ries, M, 487
Robb, M, 46, 47
Robinson, C, 337, 351
Rock, D, 466
Rogers, P, 344, 345
Rosenberg, M, 262
Rothberg, J, 445
Rothman, S, 35
Roy, M, 190
Salata, K, 3, 4, 6, 7, 8, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21, 25, 26, 27, 28, 29, 30, 322
Salazar, A, 256, 257, 258, 259, 268
Salvado, A, 205
Sarnecky, M, 271, 276
Schaaf, M, 134
Schaudies, P, 34
Schempp, C, 277
Schwartz, G, 60
Sfikakis, P, 252
Shaver, T, 494
Shay, S, 177
Shotkin, J, 273
Siheinlik, S, 541, 543, 551, 552
Sinoff, S, 267
Sjogren, M, 175, 180, 181, 182
Sjogren, R, 174, 177
Skelton, H, 54
Smallridge, R, 135

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Smith, A, 518
Smith, K, 54, 129
Smith, L, 5
Smith, S, 146, 279
Solimando, D, 425
Solomon, B, 131, 143, 145, 151, 154, 165
Squire, E, 9
Stamos, J, 450, 454
Stewart, F, 442
Stoltzfus, D, 223, 484
Striker, L, 211
Stuart, J, 505, 506, 508
Summers, W, 467, 468, 473, 479, 480, 483
Surr, R, 471
Taylor, T, 149
Temple, T, 498
Teneriello, M, 281
Tesar, J, 253, 255
Thompson, P, 468
Thwaites, B, 484
Tomoshok, L, 48
Torrens, J, 153
Torrington, K, 232, 233, 234, 239, 242
Tseng, Y, 209
Tsokos, G, 31, 32, 33, 251, 252, 253
Turiansky, G, 129
Turnicky, R, 44
Uhochak, J, 508
Vauter, R, 42
Verma, A, 266
Vernalis, M, 484
Wagner, K, 57
Wain, H, 443
Walden, B, 471, 474
Ward, F, 199, 200
Ward, T, 491, 492
Wartofsky, L, 131, 154, 167
Watson, R, 555
Weisman, L, 328
Weiss, R, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78,
  79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,
  91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102,
  103, 104, 105, 106, 107, 108, 109, 110, 111, 192,
  194
Welch, M, 129
Welch, P, 218, 221

* Reference is to page numbers in Volume II.
INVESTIGATOR INDEX*

Wertz, F, 491, 492
Whatmore, D, 485, 486
Wiesen, A, 203
Wiley, T, 117
Williams, S, 447
Winn, D, 52
Wiswell, T, 340
Wong, P, 190
Wong, R, 171, 172, 174, 178, 184, 185
Wortham, D, 114, 118, 124, 125
Wray, H, 150, 155
Wright, D, 249
Xenos, J, 500, 502, 504
Yavorski, R, 184
Yee, L, 457
Yin-Ying, D, 163
Yuan, C, 210, 212, 214, 215, 216, 217, 219, 222
Zeigler, D, 429
Zorn, B, 553
Zuehike, R, 556
Zurcher, R, 535, 536
vanDam, B, 507

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

1,25-Dihydroxyvitamin D, 155
111 In-CYT-356, 547, 548
24 hr pH monitoring, 172
3NP, 209
5-alpha-reductase, 323
5-fluorouracil, 129, 299
5-FU/leucovorin, 312
5FU, 305
5FU control arm, 95
ablation, 152
ABMT, 332
ABVE, 416
Acadesine, 457
accessory pathway, 120
accrual, 399
achalasia, 171
acoustic analyses, 468
activation, 6
acute leukemia, 81
acute myelocytic leukemia, 365
acyclovir, 63
adaptation, 271
adenocarcinoma, 95, 296, 309
adhesion molecules, 32
adjuvant, 100
adjuvant chemotherapy, 72
adjuvant radiotherapy, 540
adjuvant therapy, 79, 85
adolescent medicine, 337
adolescents, 351
adrenal imaging, 446
adult, 502
adult acute leukemia, 192
adult dysarthria, 468
advance directives, 189
advanced, 96, 288, 289, 300
advanced stage, 401
adverse reactions, 5
aeroallergen, 22, 24
AIDS, 50, 51, 64, 398
airway hyperreactivity, 235, 243
ALL, 104, 105, 382, 383, 384, 403
allergens, 3, 18
allergy, 8
allergy immunotherapy, 5
altitude, 233

* Reference is to page numbers in Volume II.
SUBJECT INDEX *

ambivalence, 270
ambulatory, 441
aminothiadiazole, 285
AML, 73
AML/CML, 74
amonafide, 301
amphotericin B, 485
amputees, 431
anaphylaxis, 14
androgen, 323
androgen blockage, 542
anesthesia, 454
anesthetic, 462
angina pectoris, 119
angioplasty, 113
angiotensin II, 217
ankle, 500, 509
ANLL, 368
ANP, 147, 210
anti-D, 202
anti-lymphocyte, 494
antiarrhythmic therapy, 112
antibacterial agent, 36
antibiotics, 505
antibody, 27, 230, 250
antifungal drugs, 191
antigen, 107
antiphospholipid, 253
antiproliferative, 148
antisense, 220
Ara-C, 417
ARC, 49
Arginine, 160
Army, 278
Army Nurse Corps, 276
art, 437
arthroplasty, 502
aspirin, 25, 127
assay, 35
assessment, 437
asthma, 9, 235, 237, 244
astrocytoma, 395
atherectomy, 123
auditory, 478
auditory models, 481
auditory-visual, 465, 476

* Reference is to page numbers in Volume II.
autoantibodies, 249
autoimmunity, 200, 252, 254
autologous, 195, 196, 326
autologous bone marrow, 365
azithromycin, 61
AZT resistance, 57
B lymphocyte, 250
B-adrenergic, 493
B-cell ALL, 419
B2-glycoprotein-I, 253
back pain, 496
bacteremia, 208
balloon, 113, 121
balloon angioplasty, 122
benefit, 474
beta-interferon, 257
bile acid, 489
biofeedback, 442
biology, 167, 371
biopsy, 449
biostator therapy, 334
bird, 21
bladder, 545
bladder cancer, 538
bleomycin, 295
blockers, 493
blood, 444
blood donors, 175
blood flow, 185
blood loss, 499
blood transfusion, 29
blood type, 27
bone, 145, 505, 506, 511, 520, 529, 532, 533
bone healing, 523
bone marrow, 60, 195, 196
bone mineral density, 153
bone substitute, 525
botulinum toxin-A, 264
bowel, 555
Bowen’s disease, 129
BPH, 551, 552
braces, 513
brain damage, 341
brain irradiation, 359
brain tumor, 396, 406, 407, 421
brain tumors, 374

* Reference is to page numbers in Volume II.

250
SUBJECT INDEX* 

brainstem, 269
breast, 103, 155, 278
breast cancer, 78, 79, 83, 107, 148, 520
breast masses, 447
breast milk, 2
bronchoalveolar lavage, 242
bronchodilators, 226
bronchoprovocation, 235
BTOPS, 541
Burkitt’s lymphoma, 417, 419
bursitis, 248
buspirone, 237
c-erbB-2 oncogene, 549
c-reactive protein, 327
C. difficile, 35
CA15-3 antigens, 68
CABC, 459
caffeine, 444, 461
calcium, 489
calcium metabolism, 158
cAMP, 350
cancer, 103, 154, 163, 278, 293, 313, 488, 531, 539, 545, 547, 548, 549, 550
cancer pain, 450
candidiasis, 485
capnography, 240
capsaicin, 429
carbocyanine (DIO), 16
carbonate, 174
carboplatin, 372, 397
carcinoma, 136, 155, 287, 288, 294, 297, 316, 387
cardiac outcomes, 457
cardiac repolarization, 118, 124, 125
cardiolipin antibody, 197
cardiopulmonary bypass, 456
carpal ligament injuries, 518
carpal tunnel syndrome, 67
cartilage, 510
casodex, 544
cathepsin D, 550
caudal epidural steroid, 463
causal models, 271
CCNU, 258
CD69, 16
celiac disease, 344
cervical, 315

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

cervix, 287, 297, 300, 304, 311, 316, 321
changes, 152
chemoprotective agent, 86
chemoradiation, 313
chemotherapy, 82, 88, 100, 103, 110, 195, 196, 319,
   368, 384, 386, 391, 392, 393, 397, 401, 402, 404,
   406, 413, 418, 419, 422
chest radiography, 232
child, pre-school, 406
childhood, 369, 370, 383, 388, 389, 390, 396, 400, 402,
   403, 413
childhood cancer, 378
childhood leukemia, 354
childhood tumor, 367
children, 47, 345, 371, 372, 373, 374, 377, 379, 382,
   391, 392, 393, 394, 395, 398, 405, 407, 408, 409,
   410, 411, 415
chlorambucil, 70
cholangitis, 173
cholecaldiferol, 150
cholecystectomy, 234
cholesterol, 115
cholesteramine, 143
CHOPE, 108
chromic phosphate, 294
chromosome 10, 141
chronic myeloid, 363
cirrhosis, 266
cis-platinum, 283, 302
cis-retinoic acid, 410
Cisapride, 177, 186
cisplatin, 214, 295, 299, 305, 310, 314, 381, 538
clinical isolate, 36
clophilene, 132
CML, 77
CNS relapse, 380
coccygectomy, 507
coccygodynia, 507
cognition, 256
colitis, 169
collagen, 39, 213
collection, 317
colon cancer, 92
colon polyps, 176
colonic adenocarcinoma, 183
combat injuries, 524

* Reference is to page numbers in Volume II.
combination therapy, 102
combined, 151
companion study, 77
compliance, 440
compressive nonlinearity, 482
computed tomography, 448, 449
computer modeling, 262, 470
concentration-controlled, 435
condylar measurements, 40
consolidation, 89
contamination, 508
contingency, 432
continuous infusion, 111
contrasuppressor, 10
COPD, 225, 229, 486
coping, 271
cord, 455
coronary artery disease, 464
coronary mapping, 120
coronary vascular injury, 116
corticosteroid, 130
Gorynebacteria, 208
coumadin, 127
critical care, 238
crossover, 89
crossover therapy, 70
cryopreserved human valve, 535, 536
Cushing's syndrome, 134
cyanacrylate, 492
cycllical etidronate, 153
cyclophosphamide, 302
cyclosporin A, 212, 412, 420
cystectomy, 538
cytogenetics, 81, 91, 375, 376
cytokines, 162, 333
cytoprotection, 219
cytotoxicity, 7
Cytoxan, 417
data base, 55
decision making, 274
DEMO, 545
density, 145
dependent, 161
depression, 188, 434, 435
dermatology, 54
dermis, 130

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

Desert Shield/Storm, 432
Desert Storm casualties, 524
developmental regulation, 346
diabetes, 140, 144, 216, 217, 335
diabetes mellitus, 137, 221, 334, 338
diabetic gastroparesis, 177
diagnosis, 378, 445
dialysis, 218
diaminedichloroplatinum, 283
diarrhea, 1
differentiation, 205
diffuse liver disease, 179
dihydroxyanthracenedione, 284
DIO, 11
direction atherectomy, 122
disease progression, 43
disinfectants, 523
disinfection, 508
distal radius fractures, 518
diuretic, 458
diving reflex, 260
DNA, 307, 308, 309
dose, 161, 503
dose comparison, 97, 194
downregulation, 15
drug combination, 111
drug level, 92
drug use, 55
dust mite, 3
early HIV disease, 48
echocardiography, 484
ectopic, 17
EGF, 34
EGF-R, 168
electrocardiogram, 260
electrocardiographs, 117
electroencephalography, 261
electromyography, 430
ELISA, 18
embryonal tumor, 388
emphysema, 225, 229, 233
enalapril, 216
endometrial, 296, 319
endometrium, 288
endoscopy, 190
endothelin, 139, 212, 214, 215

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

endothelin-1, 255
eosinophilia, 159
epidemiology, 43, 46, 52, 99, 369, 400
epidermal growth factor, 168
epidural, 450
epilepsy, 261
equilibration, 203
erectile, 554
ethics, 189
evoked potentials, 263
Ewing’s sarcoma, 367
ex-vivo purge, 332
excitatory amino acids, 341
exercise, 227, 229
extracorporeal, 528, 529
extravascular lung water, 487
failure, 554
fat, 176
Fazarabine, 306
fetus, 346
fiber, 176
fiberoptic device, 460
fibrillation, 117
fibrinogen, 464
fibromyalgia, 429
fibrosis, 224
first relapse, 366
fixation, 506, 534
flow cytometry, 6, 7, 10, 11, 15, 19, 26, 28, 29, 307, 308, 309, 322
fludarabine, 70
Fludarabine Phosphate, 198
fluorescence, 4
fluoxetine, 435
flutamide, 537
FMOC-Leu, 19
foot and ankle, 501
foot length, 329
fractures, 131
free, 151
frequency discrimination, 473
frequency resolution, 467, 481, 483
frequency transition, 473
frontal lobe, 256
function testing, 241
fungal, 24

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

funguria, 191
G-CSF, 192, 318
GABA, 266
gallium nitrate, 298
gastric emptying, 174
gastritis, 170, 178
gastroesophageal reflux, 172, 184, 336
gelatinase, 211
gene, 133, 135, 163
gene expression, 221
genetics, 374
gentamicin, 215
germ cell, 292
gestation, 17
gestational age, 329
ginger, 348
gingival, 556
glaucoma, 493
glipizide, 144
glipizide GITS, 137
glomerulonephritis, 213
glomerulosclerosis, 211
glucocorticoids, 147
glycosidase, 27
glycosylated, 140
GME, 428
gonad, 325
gp120, 59
gp160 vaccine, 62
graft, 508
Graves’ disease, 143, 152, 164
group, 282
growth, 343
growth factor, 73, 490
growth factor priming, 74
guaiac, 555
gynecologic, 282
gynecologic cancer, 283
gynecologic cancers, 281
halothane, 461
harmonics, 480
head injury, 268, 478
headache, 452, 462
health care, 337
hearing aid, 471, 474
hearing impairment, 479

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

hearing loss, 472, 474, 475, 481
hearing-impaired, 465, 467, 473, 483
heart failure, 112
heart rate, 260
heat shock, 219, 222
height, 236
helicobacter pylori, 170
hemodynamic responses, 451
hemoglobin, 203
Hemophilia A, 30
hepatitis B, 345, 351
hepatitis C, 180, 181
hepatitis C antibody, 175, 182
hepatoblastoma, 373, 422
hepatocellular carcinoma, 373
Heplocks, 273
herpes zoster, 63
Hexabrix, 156
high-dose, 108
high-dose cytosine, 90
high-dose interferon, 84
hip, 502
Hispanic, 445
history, 276
HIV, 43, 47, 49, 50, 51, 52, 53, 54, 56, 57, 65, 66, 349
HIV infection, 58, 59, 62, 242, 277
HIV risk behaviors, 48
HIV RNA, 44
HIV seropositive, 45
HIV viral load, 44
HIV-1, 60
HLA, 166
HLA-DQ, 30
hoarseness, 184, 530
Hodgkin's disease, 110, 164, 355, 364, 369, 370, 401, 416
Holter monitor, 114
homoharringtonine, 362
honey, 36
human, 139
humoral immunity, 250
hydrocortisone, 147
hydroxyurea, 304
hypercortisolemia, 134
hypersensitivity, 21, 130

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

hypertension, 216, 217
hyperventilation, 244
hypnotic capacity, 443
hypocortisolemia, 134
hypogammaglobulinemia, 1
hypoglycemia, 341
hypothyroidism, 255
hypoxia, 225, 233
I-131 NP-59, 446
ibuprofen, 178
ICAM-1, 12
ICE, 423
idarubicin, 394, 409
idiopathic scoliosis, 515, 527
ifosfamide, 290, 291, 303
IgE, 8
IGF-1, 490
immune response, 23
immunization, 495
immunodeficiency, 13, 23
immunoglobulin, 1, 2, 21, 105, 207
immunohistochemistry, 546
immunologic, 17
immunological changes, 20
immunology, 25, 75, 106
immunosuppression, 16
immunotherapy, 10, 22
inactivation, 201
IND, 206
indices, 556
indomethacin, 185
induction, 89
induction study, 74
infant, 386
infant brain tumor, 359
infant leukemia, 380
infection, 339, 505
inflammation, 280
information-processing, 478
infrared, 339
inhibitor, 30
injuries, 501
insane, 437
inspiration, 226
insufficiency, 161
insulin, 140

* Reference is to page numbers in Volume II.
integrins, 249
intensity, 479
interferon, 321, 345, 363
interferon alpha, 181
interleukin-1, 12
interleukin-6, 350
intermediate markers, 183
interstitial cystitis, 553
intervention, 272
interview, 99
intracoronary stents, 116
intracranial pressure, 458
intraocular, 491
intravenous, 202
intravenous catheter, 460
investigational, 94
iodide, 162
iodine 131, 138
iontophoresis, 129, 246, 247, 248
irradiation, 322, 416
irritable bowel syndrome, 186
isoniazid, 556
IVIG, 20, 328
JCML, 410
ketamine, 37
kidney, 209, 210, 220
Klebsiella, 207, 230
knowledge, 272
kyphoscoliosis, 245
L-tryptophan, 159
L5, 427
labor, 333
laboratory analysis, 382
laceration, 492
large cell, 358
large cell lymphoma, 97
laser, 504, 510
laser Doppler, 185
laser welding, 521
late phase response, 244
lateral ligaments, 509
leishmaniasis, 206
leucovorin, 83
leukemia, 69, 75, 106, 360, 362, 363, 386, 405, 408, 413
leukotriene B4, 15

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

leuprolide, 537
level, 444
Levothyroxine, 158, 165
ligaments, 500
limited chemotherapy, 71
lipid, 37, 330
lipid peroxidation, 335
lithium, 174
lithotripsy, 512, 555
liver enzymes, 454
local anesthetic, 453
localized, 379, 411
long-term culture, 204
long-term effects, 370
low back pain, 41
low grade lymphoma, 96
low-dose, 485
low-dose interferon, 84
lumbar epidural steroid, 463
lumbar lordosis, 516
lung, 488
lung cancer, 82
lung mechanics, 227
lupus, 32
lupus anticoagulant, 197
Lupus erythematosus, 33
lymph node biopsy, 44
lymph node positive, 80
lymph nodes, 315
lymphocyte, 4, 22, 75, 251
lymphocytic leukemia, 198, 354
lymphoma, 98, 108, 358, 411
MAC, 347
magnesium, 477
magnetic stimulation, 263
malignancy, 291, 301, 306, 312, 320, 398
malignant germ cell tumor, 377, 379
malignant glioma, 388
malignant ovarian tumors, 286
malnutrition, 146
mammary arteries, 149
mandibular movement, 40
marrow transplantation, 326
masking, 483
mast cell, 14
materials, 532, 533

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

maturation, 28
maximum dose, 111
MCH, 157
mechanical ventilation, 223, 486
mechanics, 226
meconium, 340
meconium aspiration, 331, 342
medical castration, 544
medical discharge, 436
medical therapy, 551, 552
medulloblastoma, 359, 381
MEN II, 141
meniscus, 510
mesangium, 222
Mesna, 290, 291
metabolic parameters, 33
metastatic, 83, 193, 194, 422, 520
metastatic breast cancer, 68
methotrexate, 9, 12, 173, 354, 361
MicroGeneSys rgp160, 47
microscopic/collagenous, 169
military, 337, 426
military performance, 48
milk, 34
MLC, 11
moderate head injury, 259
molecular, 167
monoclonal, 8
mononuclear cells, 438
mood variance, 434
MOPP/ABVD, 355, 364
morphine, 425
motor nerve conduction, 433
MRI, 498
mRNA, 150
mucosal immunity, 13
mucosal injury, 178
multi-drug resistance, 93
multinodular goiter, 138
multiple myeloma, 513
multiple sclerosis, 257
MUSE, 554
myalgia, 159
mycobacteria, 349
myelodysplasia, 109
myelodysplastic, 99

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

myelogenous leukemia, 332
myelopoiesis, 60
mylohyoid nerves, 433
myocardial infarction, 114, 126, 127, 451, 459
myocardial ischemia, 451
narcotics, 450
nasopharyngeal, 387
natural history, 46, 51, 182
natural killer cells, 7
nausea, 348
Nef, 142
neonate, 328, 329
nephroblastoma, 356
nephropathy, 221
nerve growth factor, 553
neuroblastoma, 376, 385, 400, 404, 415, 418
neuroendocrine, 160
neuromotor control, 470
neuropsychiatric, 33
neurosurgery, 458
neurosyphilis, 65
neutropenia, 200
neutrophil, 19, 330
nitrates, 119
nitric oxide, 149
no standard therapy, 86
nocturnal, 172
nocturnal enuresis, 543
nocturnal oxygenation, 245
nodal radiation, 364
node positive, 78, 79
noise, 472
non-compliance, 424
non-lymphoblastic, 362
non-ulcer dyspepsia, 177, 186
nonprotein calories, 279
nutrition, 279
nyctohemeral, 165
observation, 84, 85
obstructive lung disease, 240
ocular eye, 491
oligonucleotides, 220
oligospermia, 132
oncogenes, 109
oncology, 106, 282
oncology patients, 274

* Reference is to page numbers in Volume II.
oncology treatment, 399
optic pathway tumors, 371, 372
optimal dose, 102
oral diseases, 52
orchiectomy, 539
organizational model, 432
orofacial force control, 468
osteotomy, 511
osteitis, 39
osteoarthritis, 247
osteoc conducive potential, 519
osteogenic, 420
osteosarcoma, 357, 397
osteotomy, 504
outpatient, 441
ovarian, 292, 293, 294, 314, 317, 318, 320
ovarian carcinoma, 299, 307, 310
ovarian tumors, 308
ovary, 286, 302
over age 60, 73
oxandrolone, 343
oxygen consumption (VO2), 223
P-glycoprotein, 412
p53, 136, 546
p53 gene, 281
pain, 272, 425
pain relief, 513
pap, 280
para-aortic, 311
pathogenesis, 254
pathologic Stage C, 540
patient expectations, 187
patient satisfaction, 187
PCP, 64
pediatric, 385, 387
pediatric planovalgus, 514
pediatric tumors, 352
pelvic, 301, 306, 312
pelvic malignancies, 284, 285, 298
Pentostam, 206
peptic ulcer, 170
perceptions, 428
pericardial window, 121
perinatal HIV, 46
peripheral IV catheters, 273
pharmacodynamics, 425

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

pharmacoepidemiology, 42, 55
pharmacokinetics, 118, 124, 125
pharmacy, 42
phase, 482
Phase I, 87
Phase III, 316
phenotypic changes, 20
Philadelphia chromosome, 76, 104
photoreceptors, 265
physical medicine, 428
physis, 522
picornavirus, 128
pituitary, 324
pityriasis rosea, 128
placenta, 333
plasma, 201
platelet function, 464
plugs, 39
pneumatic dilation, 171
pneumococcal, 495
Pneumocystis carinii, 242
pneumoperitoneum, 448
POG, 361
pollen, 24
poly-ICLC, 258
polycaprolactone foam, 519
polycarbonate, 491
polymerase chain reaction, 128
polysaccharide, 495
polysomnography, 269
poor prognosis, 72
poor risk, 384
poor risk Hodgkin's, 71
post dural puncture, 452, 462
post-gastrectomy, 85
post-menarche, 527
post-op radiation, 72
post-remission, 90
posterior spinal fusion, 515
postmenopausal, 80, 131
postoperative, 239
postoperative spirometry, 234
potency, 3
potential, 286
pravastatin, 115
prediction equations, 236

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

predisposing factor, 117
preferred, 471
pregnancy, 275, 496
pregnancy attitudes, 270
pregnant women, 66, 348
preoperative, 241
preparations, 494
prescription, 424
prevalence, 351
prevention, 41
primary, 146
primitive neuroectodermal, 367
progressive adenopathy, 198
proliferation, 4, 222
prostacyclin, 212, 214, 215
prostaglandin, 350
prostaglandin E2, 338
prostate, 539, 541, 547, 548, 549, 550, 551, 552
prostate cancer, 194, 537, 540, 542, 544
prostatism, 553
protein, 142
proto-oncogenes, 438
Pseudomonas, 207, 230
psychiatric, 190
psychiatric diagnoses, 436
psychiatry, 188, 440
psychological import, 144
psychology, 275
psychometrics, 188
psychosocial adaptation, 69
Puerto Rican, 445
pulmonary, 241
pulmonary changes, 239
pulmonary disease, 231
pulmonary function test, 231
pulmonary nodule, 449
pupillary defects, 262
pupillary size, 265
PWB spine system, 497
quality of life, 277
rabbit, 511, 512, 525
rabbit ulna, 528
radiation, 88, 100, 296, 304, 305, 311, 315, 319, 355
radiation therapy, 82, 389, 407, 531
radiculopathy, 427, 430
radiofrequency ablation, 120

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

radiotherapy, 381
radiotherapy (XRT), 396
randomized, 293
rare tumors, 352
Ras gene, 109, 281
rat, 34, 453, 519
Raynaud's, 255
receptor, 150, 490
receptor positive, 78, 80
recognition, 146
recombinant GP160, 66
recurrent, 385, 421, 423
recurrent brain tumor, 402, 409
recurrent disease, 498
recurrent leukemia, 394
recurrent sarcoma, 390
red cell, 322
red cell antigens, 26
referral, 441
reflexes, 427, 469, 477
refractory, 98
refractory cancer, 193
refractory disease, 368
rehabilitation, 426
relapse, 403
relapsed, 98, 405
relaxation, 442
REM sleep, 269
renal cell, 93
renal tubular cells, 219
renal tumor, 356
repair, 532, 533
resolution, 480
respiration, 237
respiratory control, 224
response, 503
restenosis, 122
reticulocyte, 26, 28, 29
retrovirus, 254
rgp 120 Genentech, 45
rgp160, 53, 58
rh BMP-2 protein, 517
rhabdomyosarcoma, 361, 391, 392, 393
rheumatoid arthritis, 243, 246, 249
rigid, 534
rigidity, 264

* Reference is to page numbers in Volume II.

266
SUBJECT INDEX

RNA, 133
RSV, 328
saline lavage, 342
sarcoidosis, 228
sarcoma, 289, 290, 303, 420
schizophrenia, 438
schizophreniform, 439
sciatica, 463
scintigraphy, 179
scleral, 492
sclerosing, 173
screening, 183
seizure, 261
sequential chemotherapy, 273
sequential therapy, 90
serine, 346
serum antibiotic levels, 499
severity, 466
sex steroids, 335
sexual intercourse, 114
shock, 210
shockwaves, 503, 512, 522, 528, 529
short stature, 344
sickle cell disease, 327
SIL2R, 334
silent interval, 475
single-agent, 94
sinusitis, 13
skeletal, 534
skeletal muscle, 461
SLE, 251
sleep, 224, 245
sleep apnea, 38
smoking, 41
smooth muscle cell, 116
snoring, 38
soft tissue sarcoma, 412, 498
soldiers, 277
solid malignancy, 326, 414
solid tumor, 86, 87, 101, 102
Somalia, 42
somatization, 187
somatomedin C, 323
somatostatin, 338
spasticity, 264
spectral, 480

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

spectral contrast, 482
spectrum, 472
speech, 469, 470, 479
speech kinematics, 466
speech perception, 465, 467, 475, 476
speechreading, 476
spermatozoa, 166
spinal, 455
spinal cord, 263
spinal fusion, 497
spirometry, 236, 240
spondylolisthesis, 526
Sprotte needle, 452
SQ 32, 756 (BV-araU), 63
squamous, 321
squamous cell carcinoma, 300
stability, 18
Stage B2, 542
Stage II, 107
Stage IV breast cancer, 94
Staphylococcus aureus, 218
stem cells, 204, 205
stimulation, 455
stress hormone production, 456
stress testing, 119
stuttering, 466, 469, 477
suboptimal, 287
substance P, 429
substernal goiter, 138
subtalar stabilization, 514
subtotal nodal radiation, 71
sulfamethoxazole, 347
sulfasalazine, 169
suppressor, 6
supratentorial tumor, 389
suramin, 193
surfactant, 331
surfactant therapy, 342
surgery, 404, 488
surgical resection, 88
survey, 154
survival, 112
survivors, 69
susceptibility, 349
symptom distress, 270
symptom onset, 378

* Reference is to page numbers in Volume II.

268
subject index

symptoms, 190
syndenosis, 500
syphilis, 56
systemic sclerosis, 31, 252
T lymphocytes, 32
T-cell, 252, 360, 408
T-cell receptor, 105
T-lymphoblastic leukemia, 366
T-non-Hodgkin's lymphoma, 366
tamoxifen, 132
taxol, 101, 310, 314, 318, 320, 414, 421
Tc-99m-Sestamibi, 447
temporal nerves, 433
tendinitis, 248
tendon, 506
tendon repair, 521
terfenadine, 118, 124, 125
testicular cancer, 546
TGF-beta, 31
therapy, 65, 115, 228
thermometry, 339
thoracentesis, 232
thoracic bioimpedance, 487
thoracoplasty, 515
thrombocythemia, 199
thrombocytopenia, 202
thrombolytic therapy, 126
thrombosis, 253
thymosin alpha-1, 181
thyroid, 133, 136, 139, 154, 157, 163, 167
thyroid function, 156
thyroid hormone, 131, 209
thyrotropin, 142, 162
thyroxine, 145, 151
TIMP, 213
TIMP-1, 211
tissue, 317
TNF, 113, 324, 325
topotecan/cisplatin, 87
total joint arthroplasty, 499
total parenteral, 279
toxicity, 92, 418
toxin B, 35
transesophageal, 484
transfusion, 203
transmission, 180

* Reference is to page numbers in Volume II.
SUBJECT INDEX*

transplant, 365
transplantation, 166, 494
trauma, 431
traumatic brain injury, 259, 268
treatment, 56, 64, 137, 274
treatment complications, 353
Trendelenburg, 38
TRH, 135
trial period, 471
triamcinolone acetonide, 228
trimethoprim, 347
Trisomy 12, 91
tryptase, 14
TSH, 135, 165
tumors, 292, 352, 423
Turner's Syndrome, 343
TURP, 541
ulna, 525
ultra long, 453
ultradian rhythms, 434
unresectable, 95
untreated CML, 76
upper airway, 227
uptake, 156
urine cultures, 191
urine osmolality, 543
urushiol, 25
uterine, 303
uterus, 289
vaccination, 23
vaccine, 45, 218
vaccine therapy, 53, 58, 59, 62
valved allograft conduits, 535, 536
vasopressin, 160
VATS, 239
venom immunotherapy, 5
ventilation, 331
ventilatory control, 266
videostroboscopy, 530
vinblastine, 93
virus, 201
virus culture, 50, 57
vitamin D receptor, 148
vocational rehabilitation, 431
volume, 484
VP-16, 295

* Reference is to page numbers in Volume II.
vulva, 313
Walter Reed stage, 54
war, 426
war injuries, 524
war-time, 275
warfare, 501
Wilms' tumor, 353, 356, 375
withdrawal of care, 238
work of breathing, 223, 486
xylazine, 37
YAC, 141
zidovudine, 49

* Reference is to page numbers in Volume II.